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Summary  
Lung cancer is the leading cause of cancer-related death in the UK and worldwide. 
The development and metastasis of lung cancer is regarded as a complex process 
involving a number of mechanisms. Deep understanding of lung cancer metastasis 
is necessary to aid clinical diagnosis and management of the disease. SIPA1 (Signal 
Induced Proliferation Associated 1) is a mitogen induced GTPase activating protein 
(GAP). This protein may also hamper mitogen-induced cell cycle progression when 
abnormally or prematurely expressed. Some evidence suggests SIPA1 may be 
involved in the MET signalling pathway. There is also evidence showing that SIPA1 
may be involved in the regulation of tight junctions, which are key components in the 
prevention of metastasis. The role of SIPA1 in lung cancer remains largely unknown. 
This study aimed to evaluate the importance of SIPA1 in the development of and 
progression lung cancer, showing the cellular function of SIPA1 and the molecular 
mechanism/s involved.   
Expression of SIPA1 was found to be significantly higher in human lung cancer 
tissues compared to normal lung tissue. Lung cancer patients with higher SIPA1 
levels had a poorer prognosis compared to patients with low SIPA1 level, especially 
in lung adenocarcinoma. In vitro cell models showed knockdown SIPA1 in A549 cells 
and SK MES1 cells decreased the aggressive behaviour in invasion and proliferation, 
and the SIPA1 knockdown cells demonstrated leaky cell to cell barriers. SIPA1 related 
gene expression correlation assays using our own lung cancer patient cohort and 
TCGA cohort demonstrated that SIPA1 had high correlation with cell signalling by 
receptor tyrosine kinases (RTKs), especially HGF/MET signalling pathways and TJ 
components. KinexusTM protein kinase array analysis also revealed SIPA1 is involved 
in the regulation on the RTKs signalling and HGF/MET signalling. Co-culture of in 
vitro cell models with HGF showed that the regulation of HGF on cell barrier and 
invasion required the present of SIPA1. At the molecular level, knockdown of SIPA1 
decreased tight junction based barrier function by downregulating MET. Knockdown 
of SIPA1 reduced the protein expression level of MET but not the transcript level, and 
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regulation was attained through silencing of Grb2, SCOS, and PKCμ, reducing the 
internalization and recycling of MET.   
SIPA1 may act as a targeting molecule in cancer. Knockdown of SIPA1 reduced the 
growth and invasion potential of lung cancer cells in vitro. SIPA1 influences the tight 
junction proteins in cancer cell lines and further work may reveal the mechanism by 
which SIPA1 mediates the HGF influenced development and metastasis of tumours.  
In conclusion, SIPA1 plays an essential role in tumorigenesis and metastasis of lung 
cancer. SIPA1 could be used as a biomarker for diagnosis and prediction of patients’ 
prognosis. Moreover, the interaction of SIPA1 with MET showed SIPA1 can be a 
potential therapeutic target for patients with aberrant MET derived non-small cell lung 
cancer and drug resistance.   
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Chapter-1 Introduction 
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1.1 The lung and lung cancer 
1.1.1 The biology of the lung  
 Lung Anatomy  
The lung is the most important organ in the respiratory system, located in the thoracic 
cavity, above the diaphragm, on both sides of the mediastinum, divided into the left 
lung and the right lung. The surface of the lungs covers the visceral pleura, and many 
polygonal structures called pulmonary lobules are seen through the pleura. Infection 
localised in these structures is called lobular pneumonia. The normal lungs in the 
living state are light red, soft, spongy, and elastic. Generally, the weight of an adult 
lung is about 1/50 of the weight of the person, the average male lung weighs 1000-
1300 g, and the average female is 800-1000 g. Healthy adult males have an air 
capacity of approximately 5000-6500 ml in both lungs and females are smaller than 
males (Henry Gray, 2010).  
The shape of the two lungs is different, the right lung is wider and shorter, and the left 
lung is narrower and longer. The lungs are conical, including an apex, a base, three 
surfaces, and three borders. The apex of the lung is the superior end of the lung, 
which is obtusely rounded and protrudes into the base of the neck through the 
thoracic inlet, reaching 2-3 cm above the medial third of the clavicle. The base of the 
lung is the inferior or diaphragmatic surface of the lung, which is attached to the 
diaphragm, and is indented by the diaphragm to form a half-moon depression. The 
costal surface is the lateral side of the lung adjacent to the lateral, anterior and 
posterior thoracic walls. The mediastinal surface of the lung is the medial surface, 
adjacent to the mediastinum and has an elliptical depression in the centre called the 
hilum or the first hilum of the lung. The hilum of the lung is the portal for access to the 
bronchi, blood vessels, nerves, and lymphatic vessels, which are wrapped by 
connective tissue. Together these structures are called the root of the lung. The 
structures in the two roots from the anterior to the posterior are the superior 
pulmonary vein, the pulmonary artery and the main bronchus. While the structures in 
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the roots of the left and right lungs are different from superior to inferior. The 
structures in the left lung root are the left pulmonary artery, the left main bronchus 
and the left inferior pulmonary vein from superior to inferior, and the structures in the 
right lung root are right superior lobar bronchus, right pulmonary artery and right 
inferior pulmonary vein from superior to inferior. The anterior border is the junction of 
the anterior edges of the costal surface and mediastinal surface, which is a sharp 
well-defined border. There is a cardiac notch in the inferior part of the left lung anterior 
border, and below the notch there is a protrusion called the lingua of the left lung. The 
posterior border is the junction of the posterior edges of the costal surface and the 
mediastinal surface, located in the lung groove on either side of the spine. The inferior 
border is the junction of costal surface and diaphragmatic surface, the position of 
which varies with breathing (Henry Gray, 2010, Frank H. Netter, 2018).  
The lungs are divided into lobes by interlobular fissures. The interlobular fissure of 
the left lung is called the oblique fissure, which runs from posterior and superior to 
anterior and inferior of the hilum, and divides the left lung into a superior lobe and 
inferior lobe. In addition to an oblique fissure, the right lung has a horizontal fissure, 
which divides the right lung into the superior lobe, the middle lobe and the inferior 
lobe.  
There are impressions or grooves formed by the impression of adjacent organs on 
the surface of the lung. Cardiac impressions are located anterior and inferior to both 
the left and right hilum. There is a groove for the oesophagus posteriorly and a groove 
for the azygos vein in the superior part of the right hilum. There are impressions for 
the thoracic aorta and arch of aortic in the posterior and superior part of the left hilum 
(Henry Gray, 2010, Frank H. Netter, 2018).  
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Figure 1.1: Lung in situ: anterior view. Atlas of Human Anatomy, Seventh 
Edition, 2018. Frank H. Netter, MD (Frank H. Netter, 2018).  
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Figure 1.2: Lung: medial views. Atlas of Human Anatomy, Seventh Edition, 2018. 
Frank H. Netter, MD (Frank H. Netter, 2018).  
 
1.1.2 Lung histology  
The surface of the lung is covered with a smooth serosa (visceral pleura) and the 
connective tissue deep in the serosa penetrates into the lungs, dividing the lungs into 
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many pulmonary lobules. The lung tissue can be divided into two parts: pulmonary 
stroma and pulmonary parenchyma. The pulmonary stroma includes connective 
tissue and blood vessels, lymphatic vessels, and nerves. The pulmonary parenchyma 
comprises the branches of the intrapulmonary bronchus radiating out to a large 
number of alveoli peripherally. There are approximately 24 branches from the main 
bronchus (level 1) to the alveoli. The main bronchus enters the lung through the hilum, 
and the branches are divided successively into lobar bronchus, segmental bronchus, 
small bronchus, bronchioles, terminal bronchioles, respiratory bronchioles, alveolar 
ducts, alveolar sacs and alveoli. Because of the repeated divisions from the main 
bronchus peripherally, it is called the bronchial tree(Netter, 2014, Frank H. Netter, 
2018).  
From the lobar bronchus to the terminal bronchioles is the lung air conduction part. 
More distally is the lung respiratory part where alveolar cells appear in different 
degrees below the respiratory bronchioles(Netter, 2014, Frank H. Netter, 2018).  
Each bronchiole, along with its branches and alveoli, constitutes a pulmonary lobule. 
The pulmonary lobules are conical, with the tip facing the hilum, the base facing the 
lung surface, and connective tissue separating adjacent pulmonary lobules. The 
contour of the base of the pulmonary lobules is visible on the surface of the lungs and 
is 1-2.5 cm in diameter. There are 50-80 pulmonary lobules in each lobe, they are the 
basic structural and functional units of the lung (Netter, 2014, Frank H. Netter, 2018, 
Ovalle William K., 2007).   
A. Lung air conduction organisation 
a. Lobar bronchus to small bronchus  
The wall structure is similar to that of the main bronchus. The epithelium is a 
pseudostratified ciliated columnar epithelium, and the goblet cells, glands and 
cartilages are reduced. The smooth muscle fibres gradually increase more 
peripherally.  
b. Bronchioles and terminal bronchioles  
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The epithelium gradually changes from pseudostratified ciliated columnar epithelium 
to single layer columnar epithelium. Goblet cells, glands and cartilages gradually 
disappear. Ringed smooth muscle is more pronounced, forming a complete circular 
smooth muscle layer. The ciliated cells in the terminal bronchioles are reduced. The 
cells are mainly cilia-free Clara cells, which have smooth surfaced endoplasmic 
reticulum and detoxification function.  
 B. Lung respiratory organisation 
a. Respiratory bronchioles  
A small number of alveoli appear on the wall of the tube, the epithelium are simple 
cuboidal epithelia which transition to simple squamous epithelia at the opening of the 
alveoli.  
b. Alveolar ducts  
The structure of the alveolar ducts’ wall indistinct due to alveolus encroaching on the 
wall of the duct.  
c. Alveolar sacs  
Alveolar sacs are the common opening of several alveoli.  
d. Pulmonary alveolus  
The alveoli are semi-spherical small capsules with a diameter of about 200μm. They 
are open to the alveolar sac, alveolar duct or respiratory bronchioles. The alveoli are 
the part of the lung where gas is exchanged and constitute the main structure of the 
lung. The adult lung has 300-400 million alveoli, and the total surface area can reach 
140m2 while inhaling. The alveolar wall is very thin, and consists of a single layer of 
alveolar epithelium.   
• TypeⅠalveolar cells: are flat with a thickness of approximately 0.2μm, covering 
about 95% of the surface area of the alveoli. TypeⅠalveolar cells are the site for 
gas exchange and have no proliferative capacity. If the typeⅠalveolar cells is 
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damaged, then the typeⅡalveolar cells will differentiate to supplement.  
• TypeⅡalveolar cells: are cubic or round and scattered between typeⅠalveolar 
cells, covering 5% of the alveolar surface area. TypeⅡalveolar cells are rich in 
mitochondria, lysosomes, rough surfaced endoplasmic reticulum and Golgi 
bodies. They have many secretory granules constituting the lamellar body and 
secrete the contents of the lamellar body via the mechanism of exocytosis to 
produce surfactant on the surface of the alveolar cells, which could reduce the 
surface tension of the alveoli.    
e. Alveolar septum  
The connective tissue between adjacent alveoli is called the alveolar septum, which 
contains fibroblasts, pulmonary macrophages, capillary lymphatic vessels and nerve 
fibres.  
f. Pulmonary macrophage  
Pulmonary macrophages are differentiated from monocytes in the blood and are 
widely distributed in the pulmonary stroma. Pulmonary macrophages have an active 
phagocytic function and play an important role in immune defence. 
g. Alveolar pore  
The alveolar pores are small holes for gas communication between the alveoli.  
h. Blood-air barrier  
The blood-air barrier is a structure through which the gas exchange between the 
alveoli and blood occurs with a thickness of 0.2-0.5μm, consisting of the surfactant 
layer, typeⅠalveolar cell and its basement membrane, thin connective tissue, capillary 
basement membrane and continuous capillary endothelium (Ovalle William K., 2007).  
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Figure 1.3: Intrapulmonary airway: schema. Atlas of Human Anatomy, Sixth 
Edition, 2014. Frank H. Netter, MD (Netter, 2014).  
 
 Blood supply to the lungs  
The blood supply to the lungs comes from the pulmonary and bronchial arteries. The 
pulmonary arteries carry deoxygenated to the lungs whilst the bronchial arteries carry 
oxygenated blood to the lungs (Henry Gray, 2010).   
 
 Development of lung 
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At the fourth week of embryonic development lung buds appear. These are the 
primordial origins of the main bronchi and lungs. By the fifth week, the left and right 
lung buds are divided into two and three parts respectively, which would form the 
segmental bronchi of the left and right lungs. At the end of the second month, the 
lobar bronchi of the lungs form the segmental bronchus. At the end of the sixth month, 
terminal bronchus, respiratory bronchioles and a small number of alveoli appears. In 
the seventh month, the number of alveoli increases. A few weeks before birth, the 
lungs mature rapidly, the alveoli become larger, the alveolar wall becomes thinner, 
and alveolar surfactant is produced (Moore, 2011).   
 
1.1.3 Lung cancer  
 Epidemiology of lung cancer  
1.1.3.1.1 Incidence and mortality 
Lung cancer is the leading cause of both cancer incidence and mortality worldwide. 
In 2018, it was estimated that there are 2,093,876 new cases of lung cancer. This 
accounts for 11.6% of all cancers. Estimated age-standardized rate (ASR) of 
incidence for lung cancer in 2018 was 22.5 per 100,000 person-years, ranking third 
place among all cancers. In males, both the estimated number of cases (1,368,524) 
and ASR of incidence (31.5 per 100,000 person-years) were the highest, and in 
females the estimated number of cases for lung cancer (725,352) and ASR of 
incidence (14.6 per 100,000 person-years) ranked third, after female breast cancer 
and colorectal (Figure 1.4) (Bray et al., 2018).  
Regardless of the estimated number of deaths or ASR of mortality, lung cancer is the 
highest rate of cancer, both in the general population (1,761,007, 18.6 per 100,000 
person-years) particularly in males (1,184,947, 27.1 per 100,000 person-years). In 
female patients, the mortality rate of lung cancer is only lower than that of breast 
cancer, with the estimated number of deaths of 57,606 and ASR of mortality of 11.2 
per 100,000 person-years (Figure 1.5) (Bray et al., 2018).  
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In the UK, lung cancer is the 3rd most common cancer accounting for 13% in 2015. 
There were 46,700 newly diagnosed lung cancer patients every year from 2013 to 
2015. Both in males and females in the UK, lung cancer is the 2nd most common 
cancer with the number of new cases of 24,500 in male and 21,900 in female in the 
year of 2015. Around 35,600 people died of lung cancer in the UK each year between 
2014 and 2016; in 2016, 21% of cancer deaths were as a consequence of lung cancer. 
Lung cancer caused the most deaths in males (19,300) and females (16,300) in 2016 
(Bray et al., 2018, Smittenaar et al., 2016).  
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Figure 1.4: Pie Charts Present the Distribution of the number of Cases and 
Deaths for the 10 Most Common Cancers in 2018 for (A) Both Sexes, (B) Males, 
and (C) Females (Bray et al., 2018).  
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Figure 1.5: Incidence and mortality of lung cancer (Bray et al., 2018). (A) 
Estimated number of new cases and deaths in 2018 in both sexes. (B) Estimated 
ASR of new cases and deaths in 2018 in both sexes. (C) Estimated number of new 
cases and deaths in 2018 in male. (D) Estimated ASR of new cases and deaths in 
2018 in male. (E) Estimated number of new cases and deaths in 2018 in female. (F) 
Estimated ASR of new cases and deaths in 2018 in the female. 
 
1.1.3.1.2 Geographic Variation  
Generally, incidence and mortality are higher in developed regions such as North 
America and Europe, whereas relatively low incidence and mortality are found in 
Oceania and Asia. The top 5 countries with the highest age standardized incidence 
and mortality rates are Hungry (56.7 per 100,000 for incidence rate and 44.4 per 
100,000 for mortality rate, which is the highest in the world), Serbia, France New 
Caledonia, Greece and French Polynesia. Most of the countries with high incidence 
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and mortality rates are located in Europe and Oceania (Figure 1.6) (Bray et al., 2018).  
 
 
Figure 1.6: Geographic Variation of lung cancer in different countries (Bray et 
al., 2018). (A) Estimated ASR of new cases and deaths of lung cancer in 2018 in 
different continents. (B) Estimated top 10 ASR of new cases and deaths of lung 
cancer in 2018 in different countries. (C) Estimated bottom 10 ASR of new cases and 
deaths of lung cancer in 2018 in different countries. 
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Due to the large population base in Asian countries, especially in China, even though 
the incidence and mortality rates of lung cancer is not the highest in Asia compared 
to other continents, the number of new cases and deaths are the highest in the world. 
In 2018, the estimated number of new lung cancer cases in Asia was 1,225,029 and 
the number of deaths 1,068,862, accounting for 58.5% and 60.7% of the total number, 
exceedingly twice that of Europe (the number of new cases being 470,039 22.4%, 
deaths 387913 22%). The continents with the fewest number of new cases and 
deaths were Oceania and Africa; in Oceania there were only 16,937 reported new 
cases and 11,822 reported deaths (Figure 1.7) (Bray et al., 2018).   
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Figure 1.7: Geographic Variation of lung cancer in different continents (Bray et 
al., 2018). (A) Estimated numbers of new cases of lung cancer in 2018 in different 
continents. (B) Estimated numbers of deaths of lung cancer in 2018 in different 
continents. (C) Estimated number of new cases and deaths of lung cancer in 2018 in 
different continent.  
There seems no doubt that China has the highest number of new cases of and deaths 
from lung cancer in the world. The number of new cases in China was 774,323 and 
the number of deaths 690,567, accounting for 37% and 39.2%, these ratios 
exceeding the proportion of China’s population to the world’s population. The USA, 
Japan and India are the second to fourth countries with the highest newest cases of 
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and deaths from lung cancer. In addition, the incidence of and mortality from lung 
cancer are relatively high in Germany, Russia, UK and France. Almost all of the 
countries with the greatest numbers of lung cancer are located in Asia and Europe, 
whilst the countries with lesser cases of lung cancer are in Africa, such as Comoros, 
Vanuatu and Sao Tome and Principe (Figure 1.8) (Bray et al., 2018).  
 
 
Figure 1.8: Countries with the most new-cases and deaths of lung cancer (Bray 
et al., 2018). (A) Estimated number of countries with the most new-cases of lung 
cancer in 2018. (B) Estimated number of countries with the most deaths of lung 
cancer in 2018. (C) Estimated number of countries with the most new-cases and 
deaths of lung cancer in 2018. (D) Estimated number of countries with the fewest 
new cases and deaths of lung cancer in 2018.  
 
 Aetiology of lung cancer  
1.1.3.2.1 Tobacco smoke  
Tobacco smoking is the most common cause of lung cancer. In the UK, 72% of lung 
cancer patients are associated with smoking, where 71% are caused by active 
smoking and 1% are caused by environmental tobacco smoke (Bray et al., 2018, 
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Brown et al., 2018). It is estimated that 86% of lung cancer deaths in the UK are 
caused by smoking (Bray et al., 2018). People who smoke more than 400-600 
cigarettes a year have a significantly increased risk of lung cancer. Compared with 
people who never smoke, those who smoke more than 5500 cigarettes a year are 26 
times more likely to develop lung cancer (Bray et al., 2018, Doll et al., 2005, Darby et 
al., 2005). Smoking is strongly associated with the risk of small cell lung cancer and 
squamous cell carcinoma (SCC) as compared with other types of lung cancer 
(Khuder, 2001, Pesch et al., 2012).  
Smoking cessation has significant health benefits and can improve life expectancy 
compared to permanent smokers even for long-term smokers, older smokers and 
those people who quit smoking after lung cancer diagnosis, (Bray et al., 2018).  
1% of lung cancer cases in the UK are caused by environmental tobacco smoke (ETS, 
also known as second-hand smoke). It is estimated that 15% of lung cancer cases in 
the UK are developed by those who have never smoked are related to ETS (Bray et 
al., 2018, Brown et al., 2018). Studies have shown that non-smokers who are 
exposed to ETS have a 31% higher risk of lung cancer than those who have not been 
exposed to ETS (Bray et al., 2018, Kim et al., 2014). The risk of lung cancer among 
non-smokers has doubled in people with the highest levels of exposure to ETS in the 
workplace compared to those who do not (Bray et al., 2018, Stayner et al., 2007).  
The development of lung cancer requires decades of long-term smoking; the 
demographic effects of e-cigarettes may not show up until the middle of this century. 
Currently there is little evidence to determine whether the impact of e-cigarettes is 
less than that of combustible tobacco products in terms of promoting lung cancer 
(Gotts et al., 2019). 
 
1.1.3.2.2 Ionising radiation 
Ionising radiation can be either occupational or non-occupational; this exposure can 
be from ionising radiation from outside the body, as well as in vivo radiation caused 
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by inhalation of radioactive dust and gases. In the UK, ionising radiation causes 
approximately 5% of lung cancer cases (Bray et al., 2018, Brown et al., 2018). It is 
estimated that 9% of lung cancer deaths across Europe are associated with exposure 
to indoor radon (Bray et al., 2018, Darby et al., 2005).  
 
1.1.3.2.3 Air pollution 
a. Outdoor air pollution 
Industrial waste gas, vehicle exhaust and road asphalt in cities all have carcinogens. 
In the UK, 8% of lung cancer patients are caused by air pollution (Bray et al., 2018, 
Brown et al., 2018). Studies have shown that for every 10μg/m3 of PM 2.5 (fine 
particular matter, PM) air pollution, the risk of lung adenocarcinoma is 40% higher 
and the risk of lung adenocarcinoma is 29% higher per 10μg/m3 of PM 10 air pollution 
(Bray et al., 2018, Hamra et al., 2014).  
b. Indoor air pollution 
A meta-analysis primarily from China revealed that people who use coal for cooking 
or heating at home have double the risk of having lung cancer (Bray et al., 2018, 
Hosgood et al., 2011, Kurmi et al., 2012).  
 
1.1.3.2.4 Occupational carcinogens 
In the UK, 13% of lung cancer cases are related to workplace exposure (Bray et al., 
2018, Brown et al., 2018). Asbestos, silica, diesel engine exhaust, TCDD (2,3,7,8-
tetrachlorodibenzo-para-dioxin), radon, mineral oils, arsenic and inorganic arsenic 
compounds are all common occupational carcinogens associated with lung cancer 
and working as a painter or welder also carries an increased risk (Bray et al., 2018).  
 
1.1.3.2.5 Family history  
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A meta-analysis showed that lung cancer risk is 82% higher in people whose sibling 
has/had lung cancer and 25-37% higher in people whose parent has/had lung cancer 
(Bray et al., 2018, Cote et al., 2012).  
 
 Classification of lung cancer 
1.1.3.3.1 General classification 
According to the distribution of tumours in the lungs, lung cancer may be allocated to 
three main types: central type, peripheral type and diffuse type.  
• Central type lung cancer occurs in the main bronchus or lobar bronchus, forming 
a mass in the hilum. Central type cancer is the most common lung cancer, 
accounting for 60% -70% of the total numbers of lung cancer.  
• Peripheral lung cancer originates from the segmental bronchi or distal bronchi, 
forming nodular or spherical tumours in the peripheral part of the lung close to 
the lung membrane. The relationship with the bronchus is not obvious. It 
accounts for 30%-40% of the total number of lung cancers.  
• Diffuse lung cancer is rare, accounting for only 2% to 5% of lung cancers. It is 
easily confused with lung metastatic tumours (Travis, 2015).  
 
1.1.3.3.2 Histopathological classification  
The histopathological features of lung cancer are complex and diverse. Lung cancer 
can be divided into two major types: small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC). Any types of epithelial lung cancer other than SCLC belong to 
NSCLC, which accounts for more than 85% of all lung cancers. SCLC is less common 
bot more aggressive than NSCLC. SCLC is usually lacking early symptom, which 
means once symptoms do appear, it often indicates that the cancer has metastasized. 
Consequently, the prognosis of SCLC is worse than NSCLC (Herbst et al., 2018, 
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Jamal-Hanjani et al., 2017).  
According to the 2015 WHO classification of tumours of the lung, all the lung 
carcinoma can be subdivided into: adenocarcinoma, squamous cell carcinoma, 
neuroendocrine tumours, large cell carcinoma, adenosquamous carcinoma, 
sarcomatoid carcinoma, carcinosarcoma, pulmonary blastoma, papillomas, 
adenomas, et al. In addition to primary pulmonary carcinoma, tumours of the lung 
include mesenchymal tumours, lymphohistiocytic tumours, tumours of ectopic origin 
and metastatic tumours (Travis et al., 2015a, Travis et al., 2015b) (Table 1.1).  
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Table 1.1: WHO Classification of Tumours of the Lung, Pleura, Thymus and 
Heart. Fourth edition(Travis et al., 2015a).  
 
 
 Lung adenocarcinoma (LUAD)  
Adenocarcinomas have glandular differentiation, mucin production, or lung cell 
marker expression. LUAD Tumours usually have acinar, papillary, micropapillary, 
squamous, or solid growth, with mucin or lung cell marker expression such as TTF1 
and Napsin A (Travis et al., 2015b, Travis et al., 2015a).  
  
23 
 
a. Invasive mucinous adenocarcinoma. Invasive mucinous adenocarcinoma is one 
type of adenocarcinoma including formerly classified as mucinous bronchioloalveolar 
carcinoma. The tumour cells are goblet or columnar morphologically with much 
intracytoplasmic mucin. The growth pattern could be lepidi (most common), acinar, 
papillary, or micropapillary, except solid.  
b. Colloid adenocarcinoma. Colloid adenocarcinoma has abundant mucin pools 
intracellular covering air spaces.  
c. Foetal adenocarcinoma. Foetal adenocarcinoma is an adenocarcinoma which 
resembles foetal lung. The tumours of lower grade are purer but high-grade tumours 
usually have more than 50% foetal morphology.  
d. Enteric adenocarcinoma. Enteric adenocarcinoma is an adenocarcinoma that has 
some features resembling the adenocarcinomas arising in the colorectum.  
e. Minimally invasive adenocarcinoma. Minimally invasive adenocarcinoma (MIA) is 
a small (less than 3cm, and invasion dimension less than 5cm), solitary 
adenocarcinoma. MIA is predominantly lepidic in pattern, solitary and discrete, but 
rarely mucinous.   
f. Atypical adenomatous hyperplasia. Atypical adenomatous hyperplasia is a small 
(usually less than 0.5 cm in size) localized proliferation. Atypical adenomatous 
hyperplasia has atypical type II pneumocytes and/or Clara cells growing mildly to 
moderately lining the alveolar walls and sometimes respiratory bronchioles. 
g. Adenocarcinoma in situ. Adenocarcinoma in situ (AIS) is a small (usually less than 
3 cm in size), localized adenocarcinoma with pure lepidic growth limited to neoplastic 
cells along pre-existing alveolar structures. Generally, AIS lacks stroma, vascular or 
pleural invasion, meanwhile the acinar, papillary, solid or micropapillary invasion and 
intra-alveolar tumour cells are usually absent. AIS is mostly non-mucinous, but rare 
mucinous cases occur.  
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 Squamous cell carcinoma (LUSC)  
Squamous cell carcinoma has features of either keratinization and/or intercellular 
bridges, or is a morphologically undifferentiated NSCLC with squamous cell 
differentiation markers under immunohistochemical test (Travis et al., 2015b, Travis 
et al., 2015a).  
a. Basaloid squamous cell carcinoma. Basaloid squamous cell carcinoma is a poorly 
differentiated malignant epithelial tumour. Basaloid squamous cell carcinoma 
proliferates as small cells with lobular architecture and peripheral palisading, and 
normally lacking squamous morphology but expressing typical immunohistochemical 
squamous markers. Basaloid squamous cell carcinoma usually contains keratinizing 
or non-keratinizing squamous cell components. This type used to be considered as 
a variant of large cell carcinoma, but was recognized as a different type after the 2nd 
version WHO classifications in 1999 (Travis et al., 2015b, Travis et al., 2015a). 
b. Squamous cell carcinoma in situ. Squamous dysplasia is a precursor lesion of 
squamous cell carcinoma existing in the bronchial epithelium. Squamous dysplasia 
as well as the carcinoma in situ are continuous parts of recognizable histological 
changes in the large airways. Dysplasia can be found as single or multifocal lesions 
throughout the whole tracheobronchial tree (Travis et al., 2015b, Travis et al., 2015a).  
 
 Neuroendocrine tumours 
a. Small cell carcinoma (Small Cell Lung Cancer, SCLC). Small cell carcinoma is a 
poorly differentiated type of neuroendocrine lung cancer, which is a malignant 
epithelial tumour consisting of small cells with scant cytoplasm, ill-defined cell borders 
finely dispersed granular nuclear chromatin, and absent or inconspicuous nucleoli. 
Morphologically, the cells are round, oval, or spindle-shaped. Nuclear moulding is 
prominent. Extensive necrosis is typically found in SCLC, and the mitotic count is 
high. Most small cell carcinomas express neuroendocrine markers. Combined small 
cell carcinoma can have an additional component, which could be any of the 
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histological types of NSCLC, such as adenocarcinoma, squamous cell carcinoma, 
large cell carcinoma, or large cell neuroendocrine carcinoma, or less commonly 
spindle cell carcinoma or giant cell carcinoma (Travis et al., 2015b, Travis et al., 
2015a).   
b. Large cell neuroendocrine carcinoma (LCNEC). Large cell neuroendocrine 
carcinoma belongs to NSCLC with typical histological neuroendocrine morphology 
features like rosettes and peripheral palisading, and immunohistochemical 
neuroendocrine markers. Like SCLC, there also exists combined LCNEC with 
components of adenocarcinoma, squamous cell carcinoma, or spindle cell carcinoma, 
and/or giant cell carcinoma (Travis et al., 2015b, Travis et al., 2015a).  
c. Carcinoid tumour. Carcinoid tumours are neuroendocrine epithelial malignancies, 
which can be divided into two subtypes: typical and atypical carcinoids. typical 
carcinoids are tumours with less than 2 mitoses per 2 mm2, and lacking necrosis. The 
size usually measures more than 0.5 cm. Atypical carcinoids require tumours having 
2–10 mitoses per 2 mm2, and/or foci of necrosis (Travis et al., 2015b, Travis et al., 
2015a).  
 
 Large cell carcinoma 
Large cell carcinoma is an undifferentiated non-small cell lung cancer lacking the 
cytological, architectural, and immunohistochemical features of small cell carcinoma, 
adenocarcinoma, or squamous cell carcinoma. The diagnosis requires a thoroughly 
sampled resected tumour, and cannot be made on non-resection or cytology 
specimens such as free cancer cells (Travis et al., 2015b, Travis et al., 2015a). 
 
 Adenosquamous carcinoma 
Adenosquamous carcinoma is a carcinoma showing components of both LUSC and 
LUAD, with each component constituting at least 10% of the tumour. A resection 
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specimen is required for definitive diagnosis(Travis et al., 2015b, Travis et al., 2015a).  
 
1.1.3.3.3 Molecular classification and biomarkers 
With the successive identification of a series of cancer-driver genes for lung cancer, 
multiple studies have shown that targeted therapy and immunotherapy drugs have 
greatly improved prognosis and prolonged the survival of lung cancer patients 
carrying the corresponding driver genes. The classification of lung cancer is also 
further subdivided into molecular subtypes based on driver genes in addition to the 
previous simple histopathological classification (Table 1.2) (Herbst et al., 2018, Chen 
et al., 2014).  
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Table 1.2: Major genetic changes and molecular biomarkers work as check 
points for diagnosis and molecular classification in SCLC and two major type 
of NSCLC(Travis et al., 2015b).  
 
 
All NSCLC patients, regardless of their clinical characteristics (history of smoking, 
gender, race, etc), should be routinely tested for EGFR (epidermal growth factor 
receptor) mutations, ALK (anaplastic lymphoma kinase) fusions, and ROS1 (ROS 
proto-oncogene 1) fusions. EGFR mutation detection should cover EGFR 18, 19, 20, 
and 21 exons. Other gene mutations that can be used as therapeutic targets include 
KRAS (KRAS proto-oncogene) mutation, HER2 (human epidermal growth factor 
receptor 2) mutation, BRAF (B-Raf proto-oncogene) mutation, RET (RET proto-
oncogene) mutation, MET (MET proto-oncogene) mutation and amplification, etc. 
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(Figure 1.9)(Collisson et al., 2014, Hammerman et al., 2012, Sharma et al., 2007).  
 
 
Figure 1.9: Alterations in targetable oncogenic pathways in LUAD (pink) and 
LUSC (blue) (Herbst et al., 2018). The activated mutation (yellow box) in EGFR, 
KRAS, ALK, MET and inactivated mutation (purple box) in PTEN, CDKN2A and TP53 
are most common genetic changes in NSCLC.  
Programmed death 1 (PD-1) is a key immune-checkpoint receptor which is expressed 
by activated T cells, and mediates immunosuppression. PD-1 functions primarily in 
peripheral tissues, where T cells may encounter the immunosuppressive PD-1 
ligands PD-L1 and PD-L2, which are expressed by tumour cells. Inhibition of the 
interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and 
mediate preclinical antitumor activity. Immunotherapy checkpoints PD-1 and/or PD-
L1 have been shown to be useful for the treatment of local or metastatic NSCLC. The 
detection of immunotherapy checkpoints could provide useful information for 
treatment (Sacher and Gandhi, 2016).  
Tumour mutational burden (TMB) may predict the efficacy of immune checkpoint 
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inhibitors. It is feasible to estimate TMB using NGS (Next Generation Sequencing 
technology). When tissue specimens are insufficient, the use of cDNA (circulation 
DNA) to estimate TMB is a potentially feasible technique (Altorki et al., 2019, Herbst 
et al., 2018).  
 
 Staging of lung cancer  
Accurate staging is one of the most important factors influencing the choice of 
treatment and prognosis of lung cancer. At the 16th World Lung Cancer Congress in 
Denver, USA, in September 2015, the International Association for The Study of Lung 
Cancer (IASLC) announced the newly revised TNM staging system for lung cancer 
(Table 1.3, Table 1.4) (Rami-Porta et al., 2015, Asamura et al., 2015, Eberhardt et 
al., 2015, Rami-Porta et al., 2014).  
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Table 1.3: Proposed T, N, and M descriptors for the eighth edition of TNM 
classification for lung cancer (Goldstraw et al., 2016).  
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Table 1.4: Proposed stage groupings for the eighth edition of the TNM 
classification for lung cancer (Goldstraw et al., 2016). 
 
 
 Treatment of lung cancer 
1.1.3.5.1 Surgery 
In early stage lung cancer, surgery usually achieves an effective outcome. Indications 
for surgical treatment are for non-small cell lung cancers of stageⅠ,Ⅱand selected 
stageⅢa (e.g. T3N1M0) (NCCN.org, 2020a). In patients with mediastinal lymph node 
metastasis (N2), surgery may be considered after chemotherapy or 
chemoradiotherapy. In stageⅢb and stageⅣ lung cancer, surgery should not be 
classified as the main treatment (NCCN.org, 2020a). In addition to tumour factors, 
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vital organs such as the heart and lungs of the patient must have sufficient functional 
reserves to withstand surgery. Anatomical lobectomy and lymph node dissection are 
the preferred surgical methods for lung cancer (Rami-Porta et al., 2005, NCCN.org, 
2020a). Most small cell lung cancer has metastasis at the time of consultation, and 
surgical treatment is still controversial. Surgery should only be considered for patients 
with stageⅠ(T1N0 or T2N0) SCLC where it has been confirmed that there is no 
involvement with the mediastinal lymph nodes. While stage 1 patients accounted for 
only 5% of all patients. Evidence suggests that SCLC patients with clinical stages of 
disease over T2N0 cannot benefit from surgery (NCCN.org, 2020b).  
 
1.1.3.5.2 Chemotherapy  
Chemotherapy includes neoadjuvant chemotherapy (preoperative chemotherapy), 
adjuvant chemotherapy (postoperative chemotherapy), maintenance chemotherapy, 
and palliative chemotherapy. Commonly used chemotherapeutic drugs include the 
platinums (carboplatin, cisplatin), gemcitabine, pemetrexed, taxanes (paclitaxel, 
docetaxel), vinorelbine, etoposide and camptothecin analogues 
(Irinotecan)(NCCN.org, 2020b, NCCN.org, 2020a). Non-small cell lung cancer is not 
sensitive to chemotherapy. The recommended first-line regimen for chemotherapy is 
a combination of two drugs containing cisplatin (NCCN.org, 2020a). Small cell lung 
cancer is very sensitive to chemotherapy and chemotherapy is the basic treatment 
for all SCLC patients. Many single-agent chemotherapy and combination 
chemotherapy regimens are effective in treating SCLC. Etoposide and cisplatin (EP) 
are the most commonly used initial combination chemotherapy regimens (NCCN.org, 
2020b).  
 
1.1.3.5.3 Radiotherapy  
Radiation has a wide killing effect on cancer cells. Radiotherapy can be generally 
divided into radical radiotherapy and palliative radiotherapy. And the radical 
  
33 
 
radiotherapy contains adjuvant radiotherapy and neoadjuvant radiotherapy. 
Radiotherapy is usually combined with chemotherapy to treat lung cancer. Because 
of the differences in the stage of cancer and general condition for individual patients, 
the combined regimen can be concurrent chemoradiotherapy or sequential 
chemoradiotherapy. For NSCLC patients, all drugs can be used for sequential 
chemoradiotherapy regimes. However regimens for concurrent chemoradiotherapy 
may include cisplatin with etoposide or vinorelbine (NCCN.org, 2020a). For SCLC, 
combined chemoradiotherapy should comprise etoposide with cisplatin (NCCN.org, 
2020b). Small cell lung cancer is most sensitive to radiotherapy, followed by 
squamous cell carcinoma and adenocarcinoma. Therefore, the dose of radiotherapy 
for SCLC should be the smallest and that for adenocarcinoma should be the largest 
(NCCN.org, 2020b, NCCN.org, 2020a).  
 
1.1.3.5.4 Targeted therapy  
Cytotoxic chemotherapy works as the historical standard treatment for NSCLC, but it 
has now faced a therapeutic bottleneck recently (Schiller et al., 2002). Molecular 
targeted drugs that inhibit the abnormal activation of signalling pathways which 
promote tumorigenesis have a significant role in the treatment of NSCLC and 
improvement of the prognosis of patients, and have gradually become a research 
hotspot (Herbst et al., 2008, Herbst et al., 2018). Therefore, accumulated trails in 
NSCLC targeted therapy are focusing on the use of drugs that inhibit various targets, 
especially epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase 
(ALK).  
EGFR (epidermal growth factor receptor) gene mutation. EGFR belongs to the 
receptor tyrosine kinase (RTK) super-family on the surface of cells working as a 
mediators of extra-cellular signalling triggered by different growth factors (Sharma et 
al., 2007, Wu et al., 2017). The EGFR receptor consists of four domains in the 
extracellular region, a short extracellular juxtamembrane (eJM) region, a 
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transmembrane domain and a short intracellular juxtamembrane (iJM) region, 
following a tyrosine kinase domain with at least five tyrosine autophosphorylation 
sites, and a carboxy tail (Lemmon et al., 2014). EGFR binds to its activating ligands 
epidermal growth factor (EGF) and transforming growth factor-α (TGFα) leading to 
the dimerization of EGFR and trans-phosphorylation of the tyrosine residues in the 
carboxy tail, which could activate the downstream signalling pathways and correlates 
with malignant proliferation, survival, invasion, angiogenesis and metastasis of 
cancer (Hynes and Lane, 2005, Wheeler et al., 2010). Overexpression of EGFR was 
found in tumours of head and neck, ovary, cervix, bladder, oesophagus, stomach, 
brain, breast, colon and often associated with poor prognosis (Nicholson et al., 2001, 
Krause and Van Etten, 2005). In lung cancer, especially in NSCLC, retrospective 
analysis revealed EGFR overexpression was found in 40-85% of NSCLC cases and 
a high level of EGFR was associated with poor outcome (Fuster and Sandler, 2004, 
Nicholson et al., 2001, Ohsaki et al., 2000, Hirsch et al., 2003). In addition to 
amplification, various EGFR mutations also contribute to the development of NSCLCs 
which are seen in about 30-40% of Asian NSCLC patients and in about 10% of 
Caucasian NSCLC patients (Shigematsu et al., 2005). Heterozygous mutations in the 
tyrosine kinase domain clustering around the ATP binding pocket can activate EGFR 
and its downstream signalling independently, without the binding of the ligand. In 
NSCLC The most common mutations in EGFR are the exon 19 deletion (EGFR del19) 
and point missense mutations on exon 21 (EGFR L858R), which are also the target 
of EGFR inhibitors (EGFR tyrosine kinase inhibitors, TKI) (Sharma et al., 2007, 
Mitsudomi and Yatabe, 2007, Shi et al., 2014). Other mutations such as exon 19 
insertion are also sensitive to TKI. Exon 20 insertion and p.T790M predict resistance 
to TKI. Commonly used TKIs include the first generation of TKI gefitinib, erlotinib, 
erlotinib, second generation TKI afatinib and third generatjion TKI oxitinib (NCCN.org, 
2020a).  
ALK (anaplastic lymphoma kinase, ALK) gene rearrangements. ALK is a receptor 
tyrosine kinase in NSCLC, with the most common fusion partner with ALK being 
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echinoderm microtubule-associated protein-like 4 (EML4). ALK-TKIs such as 
crizotinib, ceritinib, alectinib and brigatinib can be used for ALK rearrangement 
positive NSCLC (NCCN.org, 2020a). 
Other mutations. ROS 1 (ROS proto-oncogene 1) gene rearrangements, BRAF(B-
Raf proto-oncogene) point mutation and KRAS(KRAS proto-oncogene) point 
mutation are also seen in NSCLC, TKIs such as crizotinib, ceritinib, trametinib, 
dabrafenib can be used as targeted therapy (NCCN.org, 2020a).  
 
1.1.3.5.5 Immunotherapy  
In NSCLC tumours with programmed death ligand  (PD-L1) positively expressed , 
an inhibitor such as pembrolizumab, nivolumab and atezolizumab can be used to 
block the binding of PD-1 and PD-L1 (NCCN.org, 2020a).  
 
1.2 Metastasis of cancer 
Tumour metastasis is a complex, multistage process in which cancer cells have to 
separate from the primary tumour, invade into adjacent tissue, migrate and travel 
through the circulatory system and then settle and proliferate in the distant tissue or 
organ forming the secondary disease (Cheung and Ewald, 2016, Talmadge and Fidler, 
2010, Massague and Obenauf, 2016). Once formed, tumours begin the process of 
metastasis in order that malignant cancer cells can enter the vasculature which may 
occur well before the tumour is diagnosed (Massague and Obenauf, 2016). This is a 
major important cause of the high mortality in patients with cancer (Valastyan and 
Weinberg, 2011).  
 
1.2.1 The invasion-metastasis cascade  
The process of cancer metastasis consists of a succession of complex cellular 
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biological events collectively termed the metastatic cascade (Figure 1.10) (Valastyan 
and Weinberg, 2011):  
 
 
Figure 1.10. The main steps in the formation of metastatic cascade (Massague 
and Obenauf, 2016). The primary tumour cancer cells invade into the local ECM, 
promote angiogenesis; then invade into the blood vessels and c circulate throughout 
the blood. Once the circulating tumour cells extravasate the blood vessel and settle 
at a distant organ, the cancer cells proliferate and survival in the new site to form 
micrometastases.     
 
1.2.2 Local invasion through extracellular matrix (ECM) and stromal cells.  
Local invasiveness refers to the entry of cancer cells from primary tumour into the 
surrounding stroma and thereafter into the adjacent normal tissue (Valastyan and 
Weinberg, 2011). To achieve this cancer cells must enter the basement membrane 
(BM), a specialized extracellular membrane. The tight junction (TJ) in epithelial cells 
works as an intrinsic wall to separate the epithelial and stromal compartments and is 
the first barrier to prevent cancer invasion (Bissell and Hines, 2011, Tsukita et al., 
2001). To overcome the epithelial tissue barrier, including TJs and E-cadherin 
mediated intercellular adherens junctions (AJs) and desmosomes (Cavallaro and 
  
37 
 
Christofori, 2004, Tsukita et al., 2001), cancer cells have to conduct a cell-biological 
program known as epithelial mesenchymal transition (EMT) (Valastyan and Weinberg, 
2011, Ye and Weinberg, 2015, Thiery et al., 2009), which is managed by a group of 
transcription factors (EMT-TFs) including Slug, Snail, Twist, E47, KLF8 and Zeb 
family (Thiery et al., 2009). The ECM also contains growth factor molecules that can 
be liberated by carcinoma-secreted proteases such as the matrix-degrading 
metalloproteinases (MMPs) family and cathepsins. (Valastyan and Weinberg, 2011, 
Kessenbrock et al., 2010) Moreover the BM is also involved in signal transduction 
with cancer cells via integrin signalling pathways initiating alterations in cell polarity, 
proliferation, invasion and apoptosis (Hood and Cheresh, 2002).  
Once invading cancer cells have dissolved the BM, they enter the stroma, 
consequently encountering fibroblasts, myofibroblasts, endothelial cells, adipocytes, 
mesenchymal stem cells, as well as immune cells such as macrophages (Quail and 
Joyce, 2013). These stromal cells can enhance the aggressive behaviours of cancer 
cells through various signalling pathways. For instance, interleukin-6 (IL6) secreted 
by adipocytes can stimulate breast cancer cells (Dirat et al., 2011); and CD4+ T cells 
can stimulate tumour associated macrophages (TAMs) to activate epidermal growth 
factor receptor (EGFR) signalling in the breast cancer cells (DeNardo et al., 2009).  
 
1.2.3 Intravasation into the lumina of blood vessels.  
Intravasation involves cancer cells entering into the lumina of lymphatic or blood 
vessels after locally invasion (Gupta and Massague, 2006, Valastyan and Weinberg, 
2011). The spread of cancer cells in lymphatic tissue is an important prognostic 
marker for disease progression, and metastatic carcinoma cells in hematogenous 
circulation represents a major mechanism of cancer spread (Gupta and Massague, 
2006). Microvessel walls formed by endothelial cell can be invaded by cancer cells 
with various molecular changes such as activating of the Notch signalling pathway 
(Sonoshita et al., 2011, Meurette and Mehlen, 2018) and the cytokine-transforming 
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growth factor-β (TGFβ) signalling pathway (Giampieri et al., 2009, Seoane and Gomis, 
2017), epidermal growth factor (EGF) (Wyckoff et al., 2007, Lemmon and 
Schlessinger, 2010b) and colony-stimulating factor 1 (CSF-1) (Wyckoff et al., 2007). 
Intravasation is largely influenced by the structural features of tumour-associated 
blood vessels, so that cancer cells can stimulate the formation of new blood vessels 
within their local microenvironment via a variety of mechanisms such as the activation 
of vascular endothelial growth factors (VEGFs). This process is termed 
neoangiogenesis (Carmeliet and Jain, 2011).  
 
1.2.4 Survival and transport within the circulatory system.  
Once cancer cells have intravasated into the lumen of the vasculature, they can 
disseminate widely throughout the body. In recent years, advanced technologies 
have been developed to aid in the detection of circulating tumour cells (CTCs) in the 
circulatory system of cancer patients (Nagrath et al., 2007). 
 
1.2.5 Extravasation and arrest at a distant site to form a secondary focus.   
In the circulation system, CTCs have to arrest and settle at a distant organ site, and 
brain, liver, lung and bone are some of the most common sites for metastasis.  
(Valastyan and Weinberg, 2011). Once lodged in the microvasculature of distant 
organs, the CTCs can initiate intraluminal growth to form a microcolony followed by 
breaking through or extravasation of the walls of surrounding vessels. Thereby 
cancer cells directly contact with stromal tissue cells. In order to overcome the 
barriers preventing extravasation in tissues with low microvessel permeability, cancer 
cells are able to secrete factors which can induce vascular hyperpermeability, 
including the protein Fascin-1 and other components of invading protrusions known 
as invadopodia, along with autocrine enhancers of cancer-cell motility such as 
epiregulin and WNT ligands (Minn et al., 2005, Massague and Obenauf, 2016). For 
example, the secreted protein angiopoietin-like-4 (Angptl4), as well as the 
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pleiotropically acting factors EREG, COX-2, MMP1 and MMP2 dissolve the 
pulmonary vascular endothelial cell junctions during the extravasation of breast 
cancer cells in lung metastases (Gupta et al., 2007, Minn et al., 2005). Similarly 
angiopoietin2 (Angpt2), MMP3, MMP10, placental growth factor, and VEGF secreted 
by various types of primary tumours are also capable of inducing pulmonary 
hyperpermeability to welcome the arrival of carcinoma cells in the lungs leading to 
the extravasation of CTCs (Weis et al., 2004). Platelets associated with CTCs can 
stimulate extravasation by activating TGF-β signalling triggered EMT in cancer cells 
(Labelle et al., 2011).  
 
1.2.6 Formation of micrometastases.  
In order to form micrometastases, extravasated cancer cells have to survive in the 
foreign microenvironment in the distant organ (Massague and Obenauf, 2016). 
Primary tumours can release systemic signals such as lysyl oxidase (LOX) (Erler et 
al., 2009) which changes the distant microenvironments into more hospitable sites 
for disseminated cancer cells to form micrometastases (Valastyan and Weinberg, 
2011). At the same time, extravasated cancer cells must adapt to foreign tissues. For 
instance, during the development of lung and bone metastasis, the extravasated 
breast cancer cells survival and metastatic colonization are achieve through the 
activating the Src-dependent CXCL12 activation of Akt signalling (Zhang et al., 2009).  
 
1.2.7 Proliferation at secondary foci - metastatic colonization.  
Disseminated cancer cells are still not guaranteed to form a macroscopic metastasis 
even when the extravasated cancer cells have survived their initial encounter with the 
microenvironment of a foreign organ tissue. In breast cancer metastases, the 
disseminated cancer cells may stay in quiescence for a considerable time, which is 
related to an inability to trigger the focal adhesion kinase (FAK), integrin b1, and Src 
pathways (Barkan et al., 2008). When considering the “seed-and-soil” hypothesis, 
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specific organ microenvironments are more or less hospitable for the proliferation and 
survival of certain types of cancer cells  (Massague and Obenauf, 2016, Fidler, 
2003).  
 
1.3 SIPA1 and metastasis of cancer  
1.3.1 SIPA1 (Signal Induced Proliferation Associated 1) 
Since Dr. Stephen Paget proposed the "seed and soil" theory of metastasis in 1889 
(Paget, 1889), research regarding the mechanism of cancer metastasis has been a 
keen area of interest for over 100 years (Fidler, 2003). People gradually recognized 
that cancer metastasis is a complex process involving multiple factors including 
sustaining proliferative signalling and evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis recurrence, activating 
invasion/migration and drug resistance (Hanahan and Weinberg, 2011, Valastyan 
and Weinberg, 2011). All these factors lead to a poor prognosis. Increasing numbers 
of oncogenes, such as ErbB2, PI3KCA, MYC, CCND1 and tumour suppressor genes, 
such as p53, and Rb were identified as being related to tumour metastasis (Lee and 
Muller, 2010). Additionally, many more signalling pathways were found to play an 
essential role in the development and progress of cancer including TGF-β (Seoane 
and Gomis, 2017), MAPK (Dhillon et al., 2007), Wnt (Logan and Nusse, 2004), 
NOTCH (Ranganathan et al., 2011), FAK (Sulzmaier et al., 2014), PI3K/Akt 
(Vanhaesebroeck et al., 2010, Goncalves et al., 2018) etc. In this project, we focus 
on signal-induced proliferation-associated protein 1 (SIPA1), which has been found 
to participate in the metastasis process of malignant tumours and to play an important 
role in the metastatic process.  
 
1.3.2 Cloning and identifications of the gene of SIPA1  
The gene SIPA1, also called as SPA1 (suppressor of phyA-105), was first cloned from 
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a murine lymphoid cell line, LFD 14, after IL-2 stimulation in 1995 by M. Hattori 
(Hattori et al., 1995). SIPA1 in mice was originally described as 3518 bp long with a 
long open reading frame (ORF) (from position 1199 to 3280) and several short ORFs 
in the 5’-end (Hattori et al., 1995). In 1997, the same research team cloned the human 
SIPA1 cDNA from human peripheral blood lymphocytes (PBL) after stimulation with 
phytohemagglutinin and TPA (Kurachi et al., 1997). The human SIPA1 gene was 
mapped to chromosome 11q13.1, spanning 12.8 kb. The human SIPA1 gene is highly 
homologous to the murine gene, containing 16 exons, amongst which exon 1, 91 bp 
of exon 2 (considered as 5’-UTR) and the 3'-region 205 bp of exon 16 are 
untranslated (Hattori, 2011). The human SIPA1 genome contains a much longer ORF 
of 1042 residues (from position 297 to 3425) (Kurachi et al., 1997). In the 5’ terminal 
region of SIPA1 gene, residues from position 192 to 539 (containing part of the exon 
5, exon 6, 7 and part of exon 8 in human) were found to be highly homologous to 
human Rap1-GAP (Gap related domain, GRD), both in human and murine. Upstream 
of the GRD encoded a proline-rich domain with the potential ability to bind SH3 and 
downstream of GRD there is the PDZ domain which consists of part of exon 9. In the 
3’ region, part of exon 14, exon 15 and translated part of exon 16 encoded a leucine 
zipper (LZ)-like domain, which were also found to be conserved in both humans and 
mice (Figure 1.11) (Kurachi et al., 1997, Hattori, 2011).  
 
1.3.3 The structure and expression of SIPA1 protein  
In mice, the SIPA1 gene encodes a 68-KDa protein (P68) with 693 amino acids, 
mostly located in the nuclei (Hattori et al., 1995), whilst the human SIPA1 protein 
contains 1042 amino acids with a molecular mass 130-KDa (Kurachi et al., 1997). 
Three domains were identified in the SIPA1 protein: a RapGTPase-activating protein 
(GAP) related domain (GRD) (350-539), a PSD-95/discs-large/ZO-1 Homology (PDZ) 
domain (685-759) and a leucine zipper like (LZ) domain (964-1042) which is similar 
to myosin tail (Hattori, 2011). There was a proline-rich domain including possibly 
SH3-binding motifs located in the N terminal to the GRD and upstream the LZ domain 
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had a probable PEST (P, Pro; E, Glu; S, Ser; T, Thr) sequence (Figure 1.11) (Kurachi 
et al., 1997). The GRD domains are key catalytic functional regions of those large 
proteins, involving in variety of interactions with other proteins, lipids, and regulatory 
molecules (Bos et al., 2007). The PDZ domain is more commonly known as the 
protein binding domain, especially for proteins with scaffold functions (Manjunath et 
al., 2018). Ligand selection and ligand interactions are relatively complex and 
conservative. The PDZ domain can resist the effects of mutations to maintain its 
unique structure (Alber, 1992). The leucine zipper (LZ) mediates dimerization, 
juxtaposing two basic regions to form the DNA-binding site. Lastly PEST sequences 
are regarded as target sites for phosphorylation and/or degradation (Ghose et al., 
2001).  
Expression levels and localization of SIPA1 protein vary in different human tissues 
and cells. SIPA1 protein is most highly expressed in a lymphohematopoietic system 
such as the spleen, bone marrow and thymus and SIPA1 may be located in the 
cytoskeleton, plasma membranes and possibly nuclei resting with the type of cell and 
interaction with other proteins (Hattori, 2011).  
 
 
Figure 1.11. The structure of human SIPA1 gene and protein. (A) Schematic 
representation of the SIPA1 gene structure. (B) 16 exons of SIPA1 gene. (C) 
Schematic representation of the SIPA1 protein structure.  
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1.3.4 Germline polymorphisms in SIPA1  
There exist thousands of single-nucleotide polymorphisms in the SIPA1 gene, in 
which seven SNPs located in the promoter region or encoding region of SIPA1 have 
been identified as being associated with tumorigenesis, metastasis and prognosis in 
previous research (Roberts et al., 2013, Crawford et al., 2006, Gaudet et al., 2009, 
Hsieh et al., 2009a, Brooks et al., 2010). Amongst them, most research has focused 
on three SNPs: G>A SNP rs931127 located in the promoter region; rs3741378 a C>T 
or C>G SNP that encodes for the replacement of a serine (Ser) to phenylalanine (Phe) 
amino acid in exon 3; and rs746429, a G>A SNP that encodes for a synonymous 
amino acid (Alanine, Ala) transformation in exon14. These three SNPs are 
considered to be related to the development, metastasis and prognosis of breast, 
lung and cervical cancer (Pei et al., 2013, Roberts et al., 2013, Ugenskiene et al., 
2016, Hsieh et al., 2009a, Gaudet et al., 2009, Crawford et al., 2006, Brooks et al., 
2010, Hsieh et al., 2009b, Gdowicz-Klosok et al., 2015, Xie et al., 2013). Other SNPs 
were shown to be involved in breast cancer: rs2306364, a G>A SNP rs2448490, a 
G>A, G>C or G>T SNP, both of which encode for a synonymous amino acid (Alanine, 
Ala) transformation (Roberts et al., 2013, Hsieh et al., 2009a, Xie et al., 2013) In 
addition, rs75894763, a G>A SNP also encoding for a synonymous amino acid 
(Valine, Val) transformation (Roberts et al., 2013) and rs75894763 are also related 
to lung cancer (Xie et al., 2013). The G>T SNP, rs3741379, encoding for the 
replacement of an Ala to Ser amino acid have been indicated to be involved in the 
process of lung cancer metastasis (Xie et al., 2013).  
 
1.3.5 SIPA1 family and Rap1-GTPase activating proteins  
The initial function of SIPA1 was believed to be specific GAP activity for Ras-related 
mediating proteins, Rap1, Rap2, Rsr1 and nuclear Ran (Kurachi et al., 1997). 
Although recent research suggested that SIPA1 cannot work as a GAP for Ran or 
other small GTPases (Kurachi et al., 1997). SIPA1 overexpression induced rounding 
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and eventual detachment of inherently adherent cells from extracellular matrix by 
inhibiting endogenous Rap1 activation, indicating that Rap1 signals are involved in 
the regulation of cell adhesion and SIPA1 functions as a negative regulator of cell 
adhesion (Hattori et al., 1995).  
Human RapGTPase activating protein mainly consists of two subfamilies: SIPA1 
family and rapGAP family. In addition, the SIPA1 family also has SIPA1-like1 (SIPAL1, 
also called E6TP1 or SPAR), SIPAL2, and SIPAL3 except SIPA1 and the rapGAP 
family contains rapGAP1 and rapGAP2 (Hattori, 2011). All the RapGAPs share 
homologous catalytic GRD domain in addition to an analogous PDZ domain (Kurachi 
et al., 1997, Hattori, 2011).  
 
1.3.6 SIPA1 interacting molecules (Figure 1.12)  
 Nuclear SIPA1 and integrin β1  
Nuclear SIPA1 have been shown to interact with and activate the integrin β1 promoter 
in breast cancer cells (Zhang et al., 2015). After SIPA1 knock down in MDA-MB-231 
cell, mRNA levels of SIPA1 were significantly downregulated. Chromatin 
immunoprecipitation experiments revealed nuclear SIPA1 could interact with the 
ITGB1 promoter and increase its transcription activity, causing further 
phosphorylation changes in the integrin-mediated FAK/Akt signalling pathway, 
thereby affecting the adhesion and invasion capability of cancer cells (Zhang et al., 
2015).  
 
 Association of SIPA1 and AF6  
Co-immunoprecipitation experiments demonstrated that SIPA1 bonded specifically 
with AF6 (afadin) n 293T cells transfected with both SIPA1 and AF6, with further 
studies revealing that binding occurred between the GRD domain of SIPA1 and the 
PDZ domain of AF6. AF6 was reported to localize at the cell adhesion sites and have 
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an association with the tight junction (TJ) protein ZO1 (Zonula Occludens 1). SIPA1 
also co-localized with AF6 in the similar cell to cell adhesion site, so it was suggested 
that SIPA1 may also regulate TJs via AF6, although evidence remained fragmentary 
(Su et al., 2003).  
 
 SIPA1 colocalizes with AQP2 in renal collecting ducts  
Studies in renal collecting ducts have shown that SIPA1 directly binds to aquaporin 
2 (AQP2) and is involved in the regulation of trafficking AQP2 to the apical membrane. 
AQP2 has the ability to bind to molecules containing a PDZ domain, so SIPA1 with a 
PDZ domain can combine with AQP2 and play a role in the intracellular transport of 
AQP2. Studies also demonstrated that the Rap1 signalling pathway was involved in 
the AQP2 intracellular transport system. As a regulation factor of Rap1, SIPA1 can 
control the transport process by inhibiting Rap1. Therefore, the interaction between 
SIPA1 and AQP2 may be both direct and indirect (Noda et al., 2004).  
 
 Brd4 interacts with SIPA1  
In HeLa cells, the bromodomain protein Brd4 was found to bind to the GRD domain 
of SIPA1 directly and this interaction is mainly located in the cell nucleus, especially 
near or at the inner face of the nuclear membrane, and enhances the RapGTPase 
activity of SIPA1 for Rap1 and Rap2 (Alsarraj et al., 2013, Farina et al., 2004). The 
combination of SIPA1 and Brd4 promotes the cell cycle through M to G1 phases, 
which may also regulate cancer development (Farina et al., 2004). 
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Figure 1.12: Schematic diagram of the SIPA1 interacting molecules. SIPA1 is in 
the centre of the interaction. SIPA1 can regulate the transcription of ITGB1, and then 
control the MMP family. Also, the inhibition of Rap1 could modulate the MMP through 
Akt signalling by contraries. AF6 showed in the red is the key molecule which SIPA1 
could affect directly and adjust the tight junction proteins, further maintain the cell-to 
cell barrier function. 
 
1.3.7 Multiple roles of SIPA1 in cancer and the mechanisms thereof  
 Breast cancer  
The role of SIPA1 in cancer and cancer metastasis has mostly been studied in breast 
cancer. Immunohistochemical staining has shown that in breast cancer patients, 
SIPA1 is localized to the nuclear region, where the expression level might be a 
predictive factor for lymph node metastatic status. Similarly, in breast cancer cells, 
SIPA1 is mainly localized to the nucleus in the aggressive breast cancer cell line 
MDA-MB-231 cells after transgenic overexpression of SIPA1 (Zhang et al., 2015). In 
vitro cell function experiments demonstrated that knock down of SIPA1 reduced the 
potential of for adhesion, migration and invasion in the MDA-MB-231 cell line, but 
promoted cells to proliferate (Zhang et al., 2015). These changes may be due to the 
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fact that nuclear SIPA1 interacts with the integrin β1 promoter (ITGB1) and activated 
it, thereby regulating the adhesion and invasion of breast cancer cells. Knock down 
of SIPA1 in the MDA-MB-231 cell line suppressed the integrin mediated FAK/Akt-
MMP9 signal pathway by markedly decreasing the phosphorylation levels of FAK and 
Akt and extracellular secretion of MMP9 (Zhang et al., 2015). Thus the mechanism 
of SIPA1 promoting breast cancer cell adhesion, invasion and metastasis may occur 
by regulating the integrin β1/FAK/Akt-MMP9 signalling pathway.  
 
 Prostate cancer 
In human prostate cancer (CaP) patients, high expression of SIPA1 was associated 
with poor disease prognosis and tumour metastasis (Shimizu et al., 2011). Similarly 
in the human CaP cell lines, LNCaP with low metastatic capacity inoculated into SCID 
mice was accompanied with undetectable levels of SIPA1, while PC3 cells with high 
metastatic capacity in SCID mice was accompanied with by high levels of SIPA1 
expression (Shimizu et al., 2011). After transduction of SIPA1, the low metastatic 
LNCaP cells inoculated into the testis of SCID mice exhibited a high metastatic 
capacity to the abdominal lymph nodes. Following knock down of SIPA1, the highly 
metastatic PC3 cells exhibited reduced metastatic capacity and there was no 
significant change in the size of primary tumour in both groups (Shimizu et al., 2011). 
Thus, the effect of SIPA1 on prostate metastasis is greater than the effect on 
proliferation. In vitro, after transduction of SIPA1 in LNCaP cells, expression of SIPA1 
resulted in decreased adhesion of CaP cells to the extracellular matrix (ECM). 
Nuclear Brd4 and ECM-related gene expression were down-regulated, which was 
regulated by Rap1 activation (Shimizu et al., 2011). A meta-analysis of human gene 
expression data (Oncomine website: https://www.oncomine.org/resource/login.html) 
from prostate, lung and a variety of solid tumours showed overexpression of SIPA1 
in human primary prostate cancer tissues which was related to cancer metastatic 
progress.  
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 Oral squamous cell carcinoma 
Expression of SIPA1 in both human oral squamous cell carcinoma (OSCC) and 
OSCC cells is higher than in normal tissue and is related to regional lymph node 
metastasis in OSCC patients. In the OSCC cell line HSC-3 and HSC-4, knockdown 
of SIPA1 reduced the ability of cells to invade and migrate, but increased the 
adhesion of cells and had no significant effect on proliferation compared with the 
control group. In the same cell line, knockdown of SIPA1 down-regulated the cytosolic 
expression of BRD4, but abundant BRD4 protein was still expressed in the nucleus 
(Takahara et al., 2017). The interaction between SIPA1 and BRD4 may promote 
OSCC metastasis. The expression of ITGB1, an integrin which is known to be an 
important marker of cell invasion and adhesion, was significantly higher in SIPA1 
knock down cells than control cells. However, the expression of MMP7 (membrane 
metalloproteinase 7) which has an essential role in tumour invasion, growth and 
metastasis, was markedly reduced after knock down of SIPA1 (Takahara et al., 2017). 
Therefore, SIPA1 and its interaction with BRD4 may impact the development and 
metastatic progression of OSCCs by regulating ITGB1 and MMP7.   
 
 Colorectal cancer 
In human colorectal adenocarcinoma patients, there was increased expression of 
SIPA1 in tumour, especially in the well-differentiated and moderately differentiated 
tumours as compared to poorly-differentiated tumours. Those patients with a higher 
expression level of SIPA1 were associated with poor prognosis. In vitro experiments 
demonstrated that after knock down of SIPA1 in HT115 and Caco-2 colorectal cancer 
cell lines, the potential of cancer cells to invade, adhere and migrate was increased 
compared to the control group, while the ability to proliferate was decreased (Ji et al., 
2012). This suggested SIPA1 may have an active role during progression of 
colorectal adenocarcinoma.   
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 Cervical cancer 
Two SNPs in SIPA1 (rs931127, 313G>A and rs746429, 2760G>A) were potentially 
related to an increased risk of nodal metastasis in cervical cancer. The G allele at 
both rs931127 and rs746429 in SIPA1 was associated with nodal disease in overall 
cases and controls. In terms of the tumour size, patients with smaller stage ⅠB1 
tumours having the G allele showed an increased risk of nodal metastases at SIPA1 
rs746429 and at rs931127. However, the correlation between polymorphisms in 
SIPA1 and nodal metastasis was not significant inⅠB2 tumours (which are larger 
lesions). The G allele in SIPA1 at both rs746429 and rs931127 was significantly 
related to nodal disease in patients without lymph vascular space invasion (LVSI), 
which was considered as an independent poor prognostic factor for cervical cancer 
patients. The GG genotype was associated with a markedly higher risk of nodal 
disease in both SNPs of SIPA1 in patients without LVSI. Histologically, SNPs in 
SIPA1 rs746429 and rs931127 were not related to histology types (adenocarcinoma 
or squamous cancer). Moreover, SNPs of SIPA1 made no difference to the survival 
of cervical cancer patients (Brooks et al., 2010).  
 
 Lung Cancer 
Previous studies focused on polymorphisms in SIPA1 in lung cancer development 
and metastasis. Three SNPs were found to be involved in lung cancer, rs931127 A>G, 
rs2448490 G>A and rs3741379 G>T (Gdowicz-Klosok et al., 2015, Xie et al., 2013). 
In a previous study, researchers genotyped these SNPs in the southern Chinese 
population. High frequency of the G allele at rs931127 was significantly correlated 
with the risk of lung cancer, but no significant connection was observed in the other 
two SNPs. From the perspective of tumour staging and grading, the fusion of the G 
allele in rs931127 was also associated with poor clinical stages, nodal metastasis 
and distal metastasis. The SNP rs931127 A>G in the promoter of SIPA1 was highly 
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associated with tumour genesis and metastasis of lung cancer (Xie et al., 2013). 
Another study suggested that G allele fusion in SNP rs931127 A>G was significantly 
correlated with more serious progression free survival (PFS) in patients with non-
small cell lung cancer (NSCLC) (Gdowicz-Klosok et al., 2015). Therefore the SIPA1 
SNP rs931127 A>G may be identified as an independent prognostic predictive factor 
for PFS in NSCLC patients (Gdowicz-Klosok et al., 2015, Xie et al., 2013).  
 
 Gastric cancer 
There is scant previous research regarding the role of SIPA1 in gastric cancer. A 
single study demonstrated both mRNA level (detect by qPCR) and protein expression 
(detect by western blotting) of SIPA1 in gastric tumour tissues was lower than tumour-
adjacent normal tissues On the contrary, IHC of gastric tumour tissues revealed that 
positive staining of SIPA1 was significantly higher than in tumour adjacent normal 
tissue (Li et al., 2017) . Positive staining of SIPA1 in the tumour from gastric cancer 
patients tumour tissue was markedly associated with the degree of differentiation, 
lymph node metastases and clinical grading (Li et al., 2017). The expression and 
function of SIPA1 in gastric cancer and its mechanism remains to be explored.  
 
 Melanoma  
There is little known regarding the role of SIPA1 in melanoma and limited research 
conducted previously. One study indicated that in fast-growing melanoma there was 
significant overexpression of the SIPA1, resulting in the inactivation of Rap1 and 
aggressive melanoma cell models. When knockdown of SIPA1 in these melanoma 
models was carried out, adhesion capability was enhanced but chlorogenic potential 
and migration ability were reduced (Mathieu et al., 2012). These data suggested that 
SIPA1 interacted with Rap1 and may have a complex role in the regulation of 
melanoma development and metastasis.  
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1.3.8 Summary of SIPA1 in cancer  
Although it has been nearly 30 years since the discovery of SIPA1, there has been a 
scarcity of research carried out as regards to the role of SIPA1 in cancer. However, 
the mechanism of SIPA1’s role in human cancer and cancer metastasis warrants 
further exploration. Clinical data showed SIPA1 is upregulated in tumour tissue 
compared with normal tissue. In addition, studies of SIPA1 in different cancers 
demonstrated that SIPA1 promotes cancer cell invasion, migration and proliferation. 
In almost all types of cancers, SIPA1 was associated with lymph node metastasis, 
which suggests that SIPA1 might be a judgment indicator of cancer metastasis and 
patients’ prognosis. Interaction of SIPA1 with molecules and signalling pathways 
such as ITGB1, MMP, AF6, AQP2, Brd4, FAK/Akt may be involved in cancer 
development and metastasis. moreover, the classical function of SIPA1 in Rap1 
signalling pathway may also be closely related to cancer and cancer metastasis. 
Meanwhile SIPA1’s direct or indirect interaction with various types of molecules may 
also be involved in development and metastasis of cancer, the importance of which 
is yet to be revealed.   
 
1.4 HGF/MET signalling pathway  
1.4.1 Hepatocyte growth factor  
Hepatocyte growth factor (HGF), also called scatter factor (SF), is a paracrine cellular 
growth factor, with both motility and morphogenic effects (Weidner et al., 1991, 
Gherardi and Stoker, 1990). HGF is synthesized and secreted by mesenchymal cells 
as a single-chain precursor and activated by HGFAC (Hepatocyte Growth Factor 
Activator, HGFA or HGFAC) in the extracellular stroma, forming an active α- and β-
chain heterodimer and targeting epithelial cells and endothelial cells. HGF contains 
six domains, an amino-terminal hairpin loop (HL), four kringle domains (K1–K4) and 
a serine protease homology (SPH) domain lacking proteolytic activity (Figure 1.13) 
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(Trusolino et al., 2010). HGF-induced cell scatter may increase the motility and 
invasiveness of the cells, which is essential for embryonic development but may also 
result in the metastasis of cancer (Wen-Sheng Wu, 2010, Martin et al., 2004, Martin 
et al., 2001, Jiang et al., 1999).  
 
 
Figure 1.13: The schematic diagram of domain structures of HGF and MET-RTK 
(Trusolino et al., 2010). (A) The schematic diagram of the HGF structure. HGF 
consists of six domains: one hairpin loop (HL), four kringle domains (K1–K4) and a 
serine protease homology (SPH) domain. (B) The schematic diagram of the MET 
structure. MET consists of a transmembrane β chain and an extracellular α chain. 
The Sema domain, PSI domain with a transmembrane helix and four IPT domains, 
the juxtamembrane domain, catalytic domain, C-terminal docking site are shown in 
the figure.   
1.4.2 The HGF/MET pathway and receptor tyrosine kinase (RTK) families 
The receptor of HGF is the tyrosine-protein kinase receptor MET, also called 
hepatocyte growth factor receptor (HGFR), was first identified in the 1980s as an 
  
53 
 
oncogene (Bottaro et al., 1991, Cooper et al., 1984, Birchmeier et al., 2003a). MET 
belongs to the receptor tyrosine kinase (RTK) family. All RTKs have conservative 
molecular structure, with extracellular ligand binding domains, transmembrane 
domain, and cytoplasmic region that contains the protein tyrosine kinase (TK) domain, 
additional carboxyterminal and juxtamembrane regulatory regions (Figure 1.13) 
(Lemmon and Schlessinger, 2010a). Similarly, the MET receptor consists of a 140kDa 
transmembrane β chain and a 50kDa extracellular α chain. These two subunits are 
disulfide-bonded to form a heterodimeric complex of 185kDa. The extracellular 
amino- terminal (N-terminal) portion of MET binds to the ligand. The extracellular β 
subunit contains the Sema domain (whole α chain plus part of β chain), PSI domain 
which contains a transmembrane helix and four IPT (immunoglobulin-like fold shared 
by plexins and transcriptional factors) domains. The intracellular segment has three 
regions: a juxtamembrane domain, a catalytic domain, and a carboxy-terminal (C-
terminal) multifunctional docking site (Figure 1.14) (Cooper et al., 1984, Trusolino et 
al., 2010).  
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Figure 1.14: Introduction of the Human receptor tyrosine kinases (RTKs) Family 
Members. Human RTKs contain 20 subfamilies, each subfamily together with their 
members names was shown under the receptors’ schematic diagram. The 
extracellular and intracellular domains of the RTK family are noted respectively 
(Lemmon and Schlessinger, 2010a). 
 
Binding to HGF/SF triggers autophosphorylation of the cytoplasmic domain of MET. 
Phosphorylation of two tyrosine residues Y1234 and Y1235 in the catalytic region is 
important for the activation of MET to work as a tyrosine kinase, while phosphorylating 
the Y1349 and Y1356 tyrosine residues in the C-terminal docking site is crucial for 
adaptor protein recruiting. The adaptor proteins always contain a Src homologous 2 
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(Sh2) domain, which can interact with MET and a Src homologous 3 (Sh3) domain 
which is used for binding to downstream signal molecules (Gao and Vande Woude, 
2005, Ferracini et al., 1991). Many adaptor proteins such as Shc, Src, Grb2, p85 
regulatory subunit of PI3K and Gab1 could bind with the met receptor directly or 
indirectly (Wen-Sheng Wu, 2010, Birchmeier et al., 2003a). Numerous downstream 
signalling pathways can be triggered by HGF/MET, such as Raf-ERK/MAPK 
signalling pathway, PI3K/MAPK signalling pathway, Jun amino-terminal kinase (JNK) 
signalling pathway, signal transducer and activator of transcription-3 (STAT3)  
signalling pathway, nuclear factor κB (NF-κB) signalling pathway and the β-catenin 
signalling pathway (Figure 1.15, 1.16) (Birchmeier et al., 2003a, Cavallaro and 
Christofori, 2004, Meurette and Mehlen, 2018, Goncalves et al., 2018, Pylayeva-
Gupta et al., 2011, Morikawa et al., 2016).  
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Figure 1.15: Schematic diagram of the major MET downstream signalling 
pathways and the regulation of cellular function (Trusolino et al., 2010). Cell 
proliferation is regulated by MET signalling via control the Ras/ERK, PI3K/Akt, STAT3 
and NF-kB signalling pathway. MET could also modulate the apoptosis, differentiation 
and transformation via ERK, MEK, PI3K/Akt and STAT3 signalling pathway.  
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Figure 1.16: Schematic diagram of intracellular downstream signalling 
pathways activated by HGF/MET RTK(Graveel et al., 2013). The activation of MET 
recruits of scaffolding proteins like Gab1 and Grb2, then downstreaming activates 
Ras-ERK-MAPK. Activated Ras leading the activation of Rac1/CDC42-α/β-cat to 
regulate the cell adhesion junction. And Gab2-Rap1-FAK activation also regulates 
cytoskeletal and cell adhesion via integrins. Gab1-PI3K-Akt activation controls cell 
survival and DNA transcription through NF-kB and mTOR. 
 
1.4.3 The regulation of MET  
Like many RTKs, the regulation of MET is a very complex process which never stops 
during the whole process from production to final degradation of the MET receptor 
(Figure 1.17). MET expression is modulated by DNA methylation and histone 
acetylation/methylation, which are catalysed by DNA methyltransferases (DNMT) and 
histone acetylases (HATs) respectively. Various transcription factors could modulate 
MET gene expression at the transcript level. After transcription, alternative splicing of 
MET mRNA precursors into mature mRNAs of various lengths takes place. The 
mature mRNA is recognized and regulated by micro-RNAs in the cytoplasm leading 
to inhibition of MET mRNA translation. MET mRNA translation is also regulated by 
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multiple modifiers such as glycosylation in the Golgi apparatus and ligand binding 
dependent kinases phosphorylation or auto-phosphorylation. Internalization leading 
to degradation and recycling regulates the activity of MET signalling (Zhang and 
Babic, 2016).  
 
 
Figure 1.17: Simplified scheme of regulation of MET (Zhang and Babic, 2016). 
The regulation of MET is multifaceted and in several different levels, which occurs in 
the DNA, mRNA, and protein levels, and involves multiple processes including 
transcription, translation, modification, splicing, internalization, and degradation, etc.  
 
1.4.4 Internalization and recycling of MET 
The Cbl E3 ubiquitin ligase mediates ubiquitination of MET, providing a signal for MET 
internalization, which has been shown to be clathrin- or caveolin- dependent. 
Internalization can be enhanced by Grb2, CIN85, SNX2, CD44 and PTP1B. Once 
internalized, the MET receptor can be delivered to lysosomes to be degraded or it 
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can be recycled back to the plasma membrane through the endosomal compartments. 
PKCε is important for e delivery towards the endosomes, from which the c-Met 
receptor can signal to specific signalling routes, including STAT3. Recycling back to 
the plasma membrane has been shown to be dependent on RCP, GGA3 and/or TSN4  
(Figure 1.18) (Viticchiè and Muller, 2015).  
 
 
Figure 1.18: Simplified scheme of the internalization and recycling of MET 
(Viticchiè and Muller, 2015). The internalization and recycling are initiated by 
ubiquitination MET mediated by Cbl E3 ubiquitin ligase. Grb2, CIN85, SNX2, CD44v6 
and PTP1B could all enhance the internalization and recycling. And the PKC is 
required for the endosome delivery and RCP, GGA3 and/or TSN4 is important for the 
recycling of MET back to the membrane.   
 
1.4.5 HGF/MET activation in cancer. 
HGF/SF is produced by surrounding mesenchymal cells and interacts with MET 
which is expressed in epithelial cells (Martin et al., 2004, Martin et al., 2001). This 
ligand/receptor-mediated association between the stroma and epithelium is essential 
for normal physiological processes such as organogenesis during embryonic 
  
60 
 
development and hepatocyte repair after injury and is tightly regulated (Gao and 
Vande Woude, 2005, Wen-Sheng Wu, 2010). However, HGF/MET activation is also 
observed in cancer and many tumours constitutively express HGF and/or MET 
(Birchmeier et al., 2003a, Wen-Sheng Wu, 2010, Martin et al., 2002). In many 
tumours, high expression of MET has been shown to be necessary to maintain 
tumour growth and survival  (Shinomiya et al., 2004). In tumour cells, MET can also 
be overexpressed or mutated, thereby activating the downstream pathway without 
the need for a ligand (Figure 1.19) (Birchmeier et al., 1997, Duplaquet et al., 2018). 
MET gene amplification was found in gastric cancer and NSCLC, which is regarded 
as the driving factors for tumorigenesis and an essential resistance mechanism 
(Duplaquet et al., 2018). MET mutations in the tyrosine kinase domain have been 
found in both sporadic and hereditary forms of human papillary renal carcinomas 
(Schmidt et al., 1997). In both gastric (Lee et al., 2000) and small cell lung cancer 
(Ma et al., 2003), exon 14 skipping mutation encoding the juxtamembrane domain of 
MET were found. Mutations in this domain can continuously activate the MET 
signalling pathway (Peschard et al., 2001, Duplaquet et al., 2018).  
 
 
Figure 1.19: Schematic diagram of different molecular mechanisms activating  
MET in cancer (Duplaquet et al., 2018). Figure shows the MET gene amplification, 
HGF autocrine loop, MET mutations, and generation of MET fusion proteins through 
chromosomal rearrangement.  
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1.4.6 HGF/MET in NSCLC  
High expression of MET can be observed in 61% of NSCLC patients and is closely 
related to poor prognosis (Ma et al., 2005).  
a. In NSCLC, MET may be a driver of tumorigenesis, but not commonly (Wu et al., 
2017). MET exon 14-skipping mutations could be found in only about 3% of NSCLCs 
and MET inhibitor monotherapy has a significant effect on such tumours(Frampton et 
al., 2015). Amplification of MET may be a 1-7% carcinogenic driver of NSCLC, and 
similarly this tumour may be inhibited by MET inhibitor monotherapy (Collisson et al., 
2014).  
b. MET may be the cause for drug resistance to other therapies (Wu et al., 2017). 
The largest group of NSCLC patients likely to benefit most from MET inhibitor therapy 
(in combination with an EGFR TKI) are patients with abnormal MET activity and 
resistance to EGFR-TKI. Combination of MET inhibitor with EGFR inhibitor may 
restore sensitivity to EGFR-TKIs (Raghav et al., 2012). Abnormal MET activity may 
be the second most common cause of acquired/secondary resistance to EFGR-TKI 
treatment, after EGFR T790M mutation. Previous research has revealed that in 
NSCLC, MET amplification occurs in 5-22% cases of acquired/secondary resistance 
to EGFR-KI therapy (Wu et al., 2017).  
 
1.5 Tight junctions 
1.5.1 The Tight Junction (TJ) structure and function 
In addition to connective tissue in human and multicellular animals, cells in other 
tissues are arranged and interconnected via various structures on the surface of 
adjacent cell membranes. These connections function to strengthen the mechanical 
connection between cells, maintain the integrity of tissue structure and coordinate the 
function of the cells. These structures are called cell junctions. Cell junctions, together 
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with cell adhesions, are the basic structural forms in which tissue remain intact and 
functionally distinct and which regulate multiple functional activities of cells such as 
growth, proliferation, differentiation and migration (Tracey A. Martin, 2013).  
Cell junctions are divided into three groups based on difference in structure and 
function: tight junction (TJ), anchoring junctions and communicating junctions. Tight 
junctions are the areas between the cell membranes of adjacent cells, which can 
completely occlude the space between cells and isolate the extracellular space, 
thereby creating an intercellular barrier (Tracey A. Martin, 2013, Martin and Jiang, 
2009). TJs maintain the permeability of epithelial cells and endothelial cells. 
Molecules and inflammatory cells can pass through the barrier of TJs in endothelial 
cells, whereas in epithelial cells, TJ acts in an adhesive manner and prevents cell 
dissociation (Martin and Jiang, 2009).  
 
1.5.2 The structure of tight junctions 
Tight junctions have a characteristic structure. They are located on the apical side of 
the epithelium and endothelial cells close to the external surface. Under electron 
microscopy, the TJ can be seen to be intermittently fused between the outer plasma 
membrane of adjacent cells and the cell gap disappeared at the fusion site. There 
remains a cell gap of 10-15nm in the non-fusion site (Tracey A. Martin, 2013, Martin, 
2014). TJs appear as continuous intramembrane particle strands in the protoplasmic 
side, which completely circumscribe the apices of the cells as a network. The TJ 
structure is representative of the conglomerate of molecules that constitute, associate 
with or regulate TJs (Martin, 2014).  
 
1.5.3 The tight junction proteins 
In short, the TJ proteins consist of three major components (Martin, 2014, Tracey A. 
Martin, 2013):  
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• Integral transmembrane proteins  
• Peripheral or plaque anchoring proteins  
• TJ associated or regulatory proteins 
The integral transmembrane protein includes the TAMP (transmembrane adhesion 
membrane proteins) such as Occludin, Tricellulin (also called Marvel D2), Marvel D3, 
the Claudin family, junctional adhesion molecules (JAMs), Nectins and other CTX 
(Cholera toxin) family members. Most peripheral or plaque anchoring proteins contain 
PDZ motifs which participate in protein-protein interactions, such as the Zonula 
Occludens (ZO) family ZO1, ZO2 and ZO3, MAGI-1 (membrane-associated 
guanylate kinase1), s-afadin, Par3 and Par6. The TJ associated or regulatory 
proteins include α-catenin, Cingulin and Rho-GTPases (Table1.5) (Martin, 2014, 
Tracey A. Martin, 2013, Martin and Jiang, 2009).  
 
Table 1.5: Proteins involved in TJ structure, function and regulation.  
Integral 
transmembrane 
proteins 
Peripheral or plaque 
anchoring proteins 
TJ-associated/regulatory 
proteins. 
the TAMP proteins:  
Tricellulin (Marvel D2) 
Marvel D3 
Occludin  
ZO family:  
ZO1  
ZO2 
ZO3 
Cingulin, 7H6,  
Symplekin, ZONAB,  
Rab-13, 19B1, ponsin,  
Rab 3B, PKC, l-afadin,  
c-src, Gαi-2, Gαi-12,  
α-catenin, Pals, PATJ,  
PKA, JEAP, Pilt, PTEN,  
ZAK, SCRIB, ITCH,  
Rho-GTPases, WNK4,  
vinculin 
Claudin family  MAGI-1, -2, -3 
JAMs  s-afadin/AF6 
Nectins Par3/ASIP 
CTX family:  
Coxsackie adenovirus 
receptor (CAR) 
Par6 
MUPP-1 
CAROM 
 CASK   
 
1.5.4 The function of tight junctions  
The four main functions of the epithelial/endothelial TJs are (Martin, 2014, Martin and 
Jiang, 2009):  
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a. The TJ seals the intercellular space and the separation of apical and basolateral 
fluid compartments of epithelia and endothelia. The TJ works as a diffusion barrier to 
plasma membrane lipids and proteins, and those polarized epithelial and endothelial 
cells require TJs to define apical and basolateral membrane domains. Therefore in 
the epithelium, the TJ is essential to maintain the chemical and electrical gradients 
across the cell monolayer, which is requisite for vectorial transport processes such 
as absorption and secretion.  
b. TJ molecules are intermediates and transducers of cell signalling that play a role 
in polarity, cell differentiation, cell growth and proliferation.  
c. TJs mediate cell to cell adhesion between adjacent cells.  
d. The TJ is a barrier to cell migration and motility.  
Scientists have a better understanding of the barrier function of TJs, but as a complex 
multi-protein structure, understanding of the role of TJs in cell processes, proliferation, 
differentiation, as well as the development and metastasis of tumours is limited 
(Martin, 2014). It has become increasingly obvious that human cancer is frequently 
associated with the failure of epithelial cells to form TJ and to establish correct 
apicobasal polarity (Martin and Jiang, 2009). Changes in the expression and/or 
distribution of the TJ protein may result in complete loss of the TJ structure due to 
cancer cell invasion and ultimately cancer cell evaluation. Therefore, TJs could be an 
important factor in the progression of tumours (Martin, 2014).  
 
1.5.5 Tight junctions are barriers to cancer metastasis  
It is clear that the interaction and penetration of tumour cells with the endothelium is 
a critical step in tumour metastasis. Early studies demonstrated that TJ molecule 
reduction is associated with tumour development and it has become evident that TJs 
are the structure that cancer cells must overcome in order to metastasize successfully 
(Satoh et al., 1996, Ren et al., 1990, Hoevel et al., 2002, Martin, 2014). Gradually, it 
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has been discovered that both up- regulation and down-regulation of TJ proteins can 
lead to loss of cell-cell binding, inhibition of cell contact, uncontrolled growth and loss 
of adhesion to basement membrane, eventually lead to tumourigenesis (Martin, 
2014). Meanwhile, it is not only the change of cancer cell TJs, but the change of TJs 
in endothelial cells that is also very important for cancer metastasis (Martin, 2014). 
TJs occur between cancer cells and endothelial cells and may be the primary 
structure that hinders the transfer of cancer cells successfully (Martin and Jiang, 
2009). TJs in vascular endothelial cell acts as a barrier between blood and tissue 
against metastatic cancer cells (Martin et al., 2002). Consequently, cancer cells must 
destroy the TJ structure in order to penetrate the endothelium. The regulation and 
functional changes of TJs form a vicious cycle in cancer progression, where changes 
in TJ function/structure are not only the consequence but also the cause of cancer 
progression. TJs are also critical to cancer development and sustainability, which 
ultimately leads to metastasis and secondary disease (Martin, 2014). Thus, studying 
the role of TJs in cancer is critical to understanding cancer metastasis and creating 
new diagnostic and therapeutic methods.  
 
1.5.6 Changes in TJs in lung cancer  
Previously is has been shownthat a statistically significant association exists between 
tumours and Claudin1 or Claudin5 in lung cancer patients (Paschoud et al., 2007). 
Squamous cell carcinoma and normal bronchial basal cells are Claudin1 positive, 
Claudin5 negative, while adenocarcinoma, normal columnar epithelium and alveolar 
cells are Claudin5 positive, Claudin1 negative, suggesting different progression of 
lung cancer development. Claudin4 and ZO1 were positive in both lung squamous 
cell carcinoma and adenocarcinoma, whereas Cingulin was not detected in 
squamous cell carcinoma. In squamous cell carcinoma, the transcription level of 
JAM1, Occludin, Claudin3, Claudin4, Claudin7, Cingulin, ZO2 and ZO3 was 
significantly decreased, but Claudin1 was increased. In adenocarcinoma, the 
transcription levels of Claudin1, Claudin3, Claudin4, Claudin7, ZO2 and ZO3 were 
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also found to be significantly reduced compared to normal bronchial cells (Paschoud 
et al., 2007). Quantitative real-time reverse transcription PCR analysis revealed 
differential expression of Claudin1 occurs in 82.1% of tumours in small cell lung 
cancer (Liu et al., 2007). An early study of 68 lung cancers and adjacent normal lung 
tissue showed that Occludin stained strongly in normal lung tissue. IHC found 
Occludin is strongly stained in spots and short lines at the apex of bronchial epithelial 
cells and bronchial gland cells, and strongly stained continuously in the membrane of 
the alveolar epithelium (Tobioka et al., 2004). In all adenocarcinomas, regardless of 
typing and staging, Occludin exhibits similar staining in the luminal cancer cells as 
the normal tissue mentioned above. However, Occludin staining was not obvious in 
squamous cell carcinoma, large cell carcinoma, small cell carcinoma or 
neuroendocrine cancer (Tobioka et al., 2004). Therefore, it has been suggested that 
Occludin can be used as a molecular marker for determining the histological 
classification of lung cancer (Martin and Jiang, 2009, Tobioka et al., 2004).  
1.6 Hypothesis and aims of this study  
SIPA1 has been considered to play a positive role in the invasion and migration of 
breast cancer (Zhang et al., 2015). Previous work from the host laboratory showed 
that SIPA1 was involved in the regulation of HGF on TJs in breast cancer cell lines 
(unpublished data). However, there are limited studies investigating the function of 
SIPA1 in lung cancer (Gdowicz-Klosok et al., 2015, Xie et al., 2013) and the 
mechanism of SIPA1 in cancer development and metastasis still remains largely 
unknown especially the mediation of SIPA1 in regulating the TJs and reacting to HGF 
signalling pathway in lung cancer cells.  
This thesis will test the hypothesis that SIPA1 plays a role as an important tumour 
promoter and a key modulator of the regulation of HGF in TJs in human lung cancer, 
and that it is linked to poor disease progression in the patients with lung cancer. 
The aims of the study were as follows:  
a. To determine the expression of SIPA1 in human lung cancer tissue and its 
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implications in cancer development and metastasis and disease progression.  
b. To generate cell models from human lung cancer cell lines with various expression 
of SIPA1.  
c. To assess the impact of differentially expressed SIPA1 on human lung cancer cell 
lines.  
d. To investigate the underlying mechanism of SIPA1 in regulating tight junctions in 
human lung cancer cell lines.  
e. To investigate the underlying mechanism of SIPA1 involved in the HGF/MET 
signalling pathway on the regulation of tight junctions in human lung cancer cell lines.  
f. To investigate the underlying mechanism of SIPA1 in the regulation of human lung 
cancer cell behaviours including growth, invasion, migration and adhesion.  
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Chapter-2 Materials and methods 
  
69 
 
2.1 General materials 
 Cell lines  
The cell lines used throughout the study were three lung cancer cell lines: A549, SK-
MES-1 and COR-L23. A549 and SK-MES-1 cell lines were purchased from the 
American Type Culture Collection (ATCC) (LGC standard, Salisbury, England) and 
COR-L23 was purchased from the European Collection of Animal Cell Cultures 
(ECACC) through ECACC Salisbury, England. All cell lines were verified at the source 
for identity and were at low passage throughout the study. Further detailed 
information of these cell lines is listed in Table 2.1.  
 
Table 2.1: Details of lung cancer cell lines used in this study  
Cell line A549  SK-MES-1 COR-L23 
Species  Homo-sapiens, 
Human 
Homo-sapiens, Human Homo-sapiens, 
Human 
Tissue  
 
Lung Lung; Derived from 
Metastatic Site: pleural 
effusion 
Lung 
Disease  Adenocarcinoma Squamous cell carcinoma Large cell 
carcinoma 
Gender  Male Male Male 
Age  58 years 65 years 62 years 
Morphology Epithelial-like Epithelial Epithelial 
Growth 
properties   
Adherent Adherent Adherent 
Country UK UK UK 
 
 Collection of human cancer tissues  
A clinical cohort consisting of lung tumours (n=148) together with adjacent 
background tissues (n=148) was obtained immediately after surgery and stored in a 
freezer at -80°C until used. The cohort was the result of two consecutive collections, 
of which the protocol of collection, the procedure for tissue storage and processing 
including materials used to process the tissues was identical. Informed, written 
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consent was obtained from the patients at Peking University Cancer Hospital. All 
protocol and procedures were approved by the Peking University Cancer Hospital 
Research Ethics Committee (Appendix). The frozen tissues were sectioned using a 
Leica CM1900 Cryostat (Leica Microsystems Ltd, Bristol, UK) at 8-10μm thickness. 
These sections (n>50) were aliquoted into three portions. Firstly, some of the sections 
were mounted on glass slides immediately and fixed for routine histology assessment. 
Secondly, part of the sections were mounted on slides and fixed using 
Superfrost®Plus microscopic slides and stored at -20 ℃  for further 
immunohistochemical analysis. Thirdly the remaining sections were merged together 
and homogenized to extract RNA for genetic analysis. 
 
 General compounds 
Chemicals material and reagents used throughout the study together with their 
suppliers are shown in Table 2.2.  
 
 General plastic consumables, hardware and software  
General plastic consumables, the instruments, various hardware and software used 
throughout the study together with their suppliers are listed in Table 2.3.  
 
Table 2.2: Chemicals and reagents 
Material/Reagent  Supplier  
10% Foetal calf serum (FCS)  Sigma-Aldrich, Pooled, Dorset, UK  
A/G protein agarose beads  Insight Biotechnology, Wembley, UK  
Acetic acid  Fisher Scientific, Leicestershire, UK  
Acrylamide mix (30%)  Sigma-Aldrich, Poole, Dorset, UK  
Agarose  Melford Laboratories Ltd, Suffolk, UK  
Ammonium persulphate (APS)  Sigma-Aldrich, Poole, Dorset, UK  
Amphotericin B  Sigma-Aldrich, Poole, Dorset, UK  
Ampicillin  Sigma-Aldrich, Poole, Dorset, UK  
Bio-Rad DC™ Protein Assay  Bio-Rad Laboratories, Watford, London, 
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UK  
Blasticidin S Melford Laboratores Ltd., Suffolk, UK 
Boric acid  Melford Laboratories Ltd, Suffolk, UK 
Bovine serum albumin (BSA)  Sigma-Aldrich, Poole, Dorset, UK  
Bromophenol Blue  Sigma-Aldrich, Poole, Dorset, UK  
Calcium chloride (CaCl2)  Sigma-Aldrich, Poole, Dorset, UK  
Chloroform  Sigma-Aldrich, Poole, Dorset, UK  
Coomassie Blue  Sigma-Aldrich, Poole, Dorset, UK  
Crystal violet  Sigma-Aldrich, Poole, Dorset, UK  
Diethylpyrocarbonate (DEPC)  Sigma-Aldrich, Poole, Dorset, UK  
Dimethylsulphoxide (DMSO)  Sigma-Aldrich, Poole, Dorset, UK  
Disodium phosphate (Na2HPO4)  BDH Chemicals Ltd, Poole, Dorset, UK  
Dithiothreitol  Sigma-Aldrich, Poole, Dorset, UK  
Dulbecco’s Modified Eagles’ Medium 
(DMEM)/Nutrient mixture F-12 Ham’s 
Sigma-Aldrich, Poole, Dorset, UK  
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich, Pooled, Dorset, UK  
Ethanol  Fisher Scientific, Leicestershire, UK  
Formalin  Sigma-Aldrich, Poole, Dorset, UK  
Glycine Melford Laboratories Ltd, Suffolk, UK 
GoTaq® Green Master Mix  Promega (Southampton, UK) 
Hydrochloric acid (HCl)  Sigma-Aldrich, Poole, Dorset, UK  
Isopropanol  Sigma-Aldrich, Poole, Dorset, UK  
Matrigel®  Corning Incorporated, Flintshire, UK  
Methanol  Fisher Scientific, Loughborough, UK  
PVDF membrane  EMD Millipore Corporation, Watford, 
London. UK  
Penicillin  Sigma-Aldrich, Poole, Dorset, UK  
Ponceau S Stain  Sigma-Aldrich, Poole, Dorset, UK  
Precision qScript™ RT PCR kit  Primerdesign Ltd, Southampton, UK  
Potassium chloride (KCl)  Fisons Scientific Equipment, 
Loughborough, UK  
GI-1640 Sigma-Aldrich, Poole, Dorset, UK  
Sodium azide (NaN3)  Sigma-Aldrich, Poole, Dorset, UK  
Sodium chloride (NaCl)  Sigma-Aldrich, Poole, Dorset, UK  
Sodium dodecyl sulphate (SDS)  Melford Laboratories Ltd, Suffolk, UK  
Sodium fluoride (NaF) Sigma-Aldrich, Poole, Dorset, UK  
Sodium hydroxide (NaOH)  Sigma-Aldrich, Poole, Dorset, UK  
Sodium nitrate (NaNO3) Sigma-Aldrich, Poole, Dorset, UK  
Sodium orthovanadate (Na3VO4)  Sigma-Aldrich, Poole, Dorset, UK  
Sodium pyrophosphate (Na4P2O7) Sigma-Aldrich, Poole, Dorset, UK  
Streptomycin  Sigma-Aldrich, Poole, Dorset, UK  
Sucrose  Fisons Scientific Equipment, 
Loughborough, UK  
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SYBR®Safe DNA gel stain  Invitrogen, Paisley, UK  
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, Poole, Dorset, UK  
TRI Reagent  Sigma-Aldrich, Poole, Dorset, UK  
Tris-Cl  Melford Laboratories Ltd, Suffolk, UK  
Triton X-100  Sigma-Aldrich, Poole, Dorset, UK  
Trypsin  Sigma-Aldrich, Poole, Dorset, UK  
Tween 20  Melford Laboratories Ltd, Suffolk, UK  
Vectastain Universal ABC kit  Vector Laboratories Inc, Peterborough, 
UKA  
Zinc chloride (ZnCl)  Sigma-Aldrich, Poole, Dorset, UK  
 
Table 2.3 Instruments, hardware and software  
Hardware/Software  Supplier  
0.4 μm and 8 .0 μm cell culture inserts  EMD Millipore Corporation, Watford, 
London. UK 
25 cm2 and 75 cm2 cell culture flasks  CELLSTAR, Greiner bio-one, 
Stonehouse, Gloucester, UK  
6 well, 24 well, 48 well, 96 well cell 
culture plate.  
CELLSTAR, Greiner bio-one, 
Stonehouse, Gloucester, UK 
8-well glass chamber slide (for 
immunofluorescence) 
EMD Millipore Corporation, Watford, 
London. UK 
Neubauer haemocytometer counting 
chamber  
Mod-Fuchs Rosenthal, Hawksley, UK  
Lecia DM IRB microscope  Lecia GmbH, Bristol, UK  
ACCUsPIN Micro 17R  Thermo Fisher Scientific, Germany  
EVOS FL Auto 2 imaging system  Thermo Fisher Scientific, Waltham, MA 
USA  
Electrical Cell-Substrate Impedance 
Sensing (ECIS) 
Applied BioPhysics Inc, Troy, New York, 
USA 
ECIS array plate 96W1E+ Ibidi Mannheim, Germany 
Image J  Public Domain  
GraphPad Prism  
Microsoft Excel  Microsoft In., Redmond, WA, USA  
UV light chamber  Germix, UK  
Class II laminar flow cabinet  Wolflabs, York, UK  
 
 Primers  
All primers used in this study were designed using the Beacon Design Programme 
(Biosoft International, Palo Alto, California, USA) and were synthesized by either 
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Invitrogen (Paisley, UK) or Sigma (Poole, Dorset, UK). Details of the primers used for 
conventional RT-PCR and real time quantitative PCR (QPCR) are provided in Table 
2.4.  
 
Table 2.4 Primers for conventional RT-PCR, QPCR and ribozyme synthesis  
PRIMER 
NAME  
PRIMER SEQUENCE(5’-3’) 
GAPDHF8  GGCTGCTTTTAACTCTGGTA  
GAPDHR8  GACTGTGGTCATGAGTCCTT  
GAPDHF1 AAGGTCATCCATGACAACTT 
GAPDHZR1 ACTGAACCTGACCGTACAGCCATCCACAGTCTTCTG 
SIPA1F1 AGAACTCGCTGTCACCAC 
SIPA1ZR ACTGAACCTGACCGTACATACTGATGGCTTGGCTGT 
CLDN1F GAAGTGTATGAAGTGCTTGG 
CLDN1ZR ACTGAACCTGACCGTACAGACCTGCAAGAAGAAATA 
CLDN2F1  AAGTCTTTGACTCCTTGCTG 
CLDN2ZR ACTGAACCTGACCGTACAGCCACAAAGATTGCTATCAC 
CLDN3F1 ACTGCCACAGGACCTTCA 
CLDN3ZR ACTGAACCTGACCGTACAATGGTGATCTTGGCCTTG 
CLDN4F1 GCAGCAACATTGTCACCT 
CLDN4ZR ACTGAACCTGACCGTACAGTACACCTTGCACTGCATC 
CLDN 5F1 TTCCTGGACCACAACATC 
CLDN5ZR1 ACTGAACCTGACCGTACACACCGAGTCGTACACTTTGC 
CLDN5F2 TTCCTGGACCACAACATC 
CLDN5ZR2 ACTGAACCTGACCGTACACACCGAGTCGTACACTTTGC 
CLDN6F1 ACGTGCCCTCTGTGTCAT 
CLDN6ZR ACTGAACCTGACCGTACACTCCACACAGGTGGTACACT 
CLDN7F1 ATAACCCTTTGATCCCTACC 
CLDN7ZR ACTGAACCTGACCGTACAACAGGAACAGGAGAGCAGT 
CLDN8F1 GCTTGGAGAAGCTCTCTACTT 
CLDN8ZR ACTGAACCTGACCGTACAAGCTACTGCTCTTTTCGTTG 
CLDN9F1 GTGCCCTCTGTGTCATTG 
CLDN9ZR ACTGAACCTGACCGTACATCCACACACGTGGTACACT 
CLDN10F1 GTCTCCAACTGCAAGGACT 
CLDN10ZR ACTGAACCTGACCGTACAGCAAATATGGAACCAAAGAA 
CLDN11F1 CCGGTGTGGCTAAGTACA 
CLDN11ZR ACTGAACCTGACCGTACACACACAGGGAACCAGATG 
CLDN12F1 CTCTGCCTGATTGGAATG 
CLDN12ZR ACTGAACCTGACCGTACAACCTGCACTATTGACCAGAC 
CLDN14F1 CACCCTACAGGCCCTACC 
CLDN14ZR ACTGAACCTGACCGTACAGTCTTTGTAGGCAGCTGGT 
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CLDN15F1 CCTGGGCGTCTACAACTG 
CLDN15ZR ACTGAACCTGACCGTACAATAGACATCAGCCGGACA 
CLDN17F1 CTGCTTATTGGCATCTGTG 
CLDN17ZR ACTGAACCTGACCGTACATGAAGTTCCCAGAAGGTATG 
CLDN18F1 GGATCATGTTCATTGTCTCA 
CLDN18ZR ACTGAACCTGACCGTACACATCCAGAAGTTAGTCACCAG 
CLDN19F1 GGAGCCCTCTTCATCCTG 
CLDN19ZR ACTGAACCTGACCGTACAGTGCTTGGGTTGAAGAACT 
CLDN20F1 AGCAAACTTTCTGGATCTGA 
CLDN20ZR ACTGAACCTGACCGTACACAGAAAATCATGCCAGAGAT 
CLDN22F1 CAGGCTCTTGTAACCTCAAC 
CLDN22ZR ACTGAACCTGACCGTACATTGGATGACACAGGTTTG 
CLDN23F1 CCGCCATCAAGTACTACAG 
CLDN23ZR1 ACTGAACCTGACCGTACACCACCGAGTTGGTGTAGG 
CLDN24F1 GTGGACGCACATGACTGT 
CLDN24ZR ACTGAACCTGACCGTACACAGGAGGAAGGTGAGCTG 
JAM1F2 AACAAGATCACAGCTTCCTA 
JAM1ZR ACTGAACCTGACCGTACAACAAGTGTATGTCCCAGTGT 
JAM2F1 CTGATAGGGGCTGTAAATCT 
JAM2ZR ACTGAACCTGACCGTACATAATGATGCAAGACAGTTCC 
JAM3F1 TTGATGAGATTGTGATCGAG 
JAM3ZR ACTGAACCTGACCGTACAATCTTGCCTACTGGTACAGC 
ZO1ZF2 TGGGTATGACACACATGGTA 
ZO1ZR2 ACTGAACCTGACCGTACAGGTGGTACTTGCTCGTAA 
ZO2F1 CAAAAGAGGATTTGGAATTG 
ZO2ZR1 ACTGAACCTGACCGTACAGAGCACATCAGAAATGACAA 
ZO3F1 CTGACATGGAGGAGCTGA 
ZO3ZR1 ACTGAACCTGACCGTACAGCTTAGCTTCCCTTCTGACT 
AF6F ATCATCCACCACTGGAAC 
AF6ZR  ACTGAACCTGACCGTACATCATCACTCCATGGAACTC  
OCLNZF G AATTCAAACCGAATCATTG 
OCLNZR ACTGAACCTGACCGTACATGAAGAATTTCATCTTCTGG 
Z sequence ‘ACTGAACCTGACCGTACA’ highlighted in blue. Z-sequence presents 
on the specific primers containing a 5’ hairpin structure labelled with a fluorophore 
(FAM). 
 
 Antibodies  
 Primary antibodies  
Full detailed information of primary antibodies used in the current study are supplied 
in Table 2.5. 
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 Secondary antibodies  
The secondary antibodies used for western blotting were horseradish peroxidase 
(HRP) conjugated anti-goat IgG, goat anti-rabbit IgG, and rabbit anti-mouse IgG 
antibodies, all these antibodies are purchased from Sigma (Table 2.5) (Poole, Dorset, 
UK).  
 
Table 2.5 Primary and secondary antibodies used in this study 
Antibodies  Molecular 
weight 
(kDa)  
Supplier  Product code  
Mouse anti SIPA1  112  Abcam  ab219085 
Mouse anti GAPDH  37 Insight Biotechnology  sc-32233 
Mouse anti AF6 200 Insight Biotechnology sc-74433 
Rabbit anti ZO1 220 Thermo Fisher 
Scientific 
61-7300 
Goat anti ZO2 160 Insight Biotechnology sc-12386 
Goat anti ZO3 80-160 Insight Biotechnology sc-11475 
Goat anti Claudin1 22 Insight Biotechnology sc-17658 
Rabbit anti Claudin5 23 Insight Biotechnology sc-28670 
Goat anti Claudin7 24 Insight Biotechnology sc-17670 
Goat anti Claudin9 23 Insight Biotechnology sc-17672 
Rabbit anti Claudin10 23/19  Insight Biotechnology sc-25710 
Rabbit anti Claudin11 20 Insight Biotechnology sc-25711 
Goat anti Claudin15 23 Insight Biotechnology sc-17683 
Rabbit anti Claudin19 22 Insight Biotechnology sc-134618 
Rabbit anti Claudin20 23.5 Novusbio H00049861-D01P 
Goat anti Claudin23 32 Insight Biotechnology sc-87047 
Mouse anti JAM1  36 Insight Biotechnology sc-53623 
Goat anti JAM2 54 Insight Biotechnology sc-23002 
Goat anti JAM3 38 Insight Biotechnology sc-23006 
Goat anti Occludin 60-82 Insight Biotechnology sc-8145 
    
Rabbit anti-mouse  
(whole molecule)  
IgG peroxidise  
conjugate  
Dependent 
on primary  
Sigma-Aldrich  A5278  
Goat anti-rabbit  Dependent Sigma-Aldrich  A0545  
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(whole molecule)  
IgG peroxidise  
conjugate  
on primary  
Rabbit anti-goat  
(whole molecule)  
IgG peroxidise  
conjugate  
Dependent 
on primary  
Sigma-Aldrich  A5420  
 
 Preparation of Reagents, Buffers and Standard solutions  
 Solutions for molecular biology experiments 
• Tris-Boric-Acid (TBE) electrophoresis buffer  
TBE buffer 10X concentrate (T4415) was purchased from Sigma-Aldrich (Poole, 
Dorset, UK), and diluted with distilled water into 1X stock and stored at room 
temperature for further use.  
 
• Diethylpyrocarbonate (DEPC) water 
500μl of diethyl pyrocarbonate (DEPC) (Sigma-Aldrich, Poole, Dorset, UK) was 
dissolved in 9,500μl distilled water to make the stock solution of DEPC water and 
autoclaved before use.  
 
• Loading buffer (used for DNA electrophoresis) 
25mg bromophenol blue (Sigma-Aldrich, Poole, Dorset, UK) and 4g sucrose (Fisons 
Scientific Equipment, Loughborough, UK) was dissolved in 10ml of H2O to prepare 
the loading buffer and stored at 4°C until use.  
 
Solutions for use in cell culture  
• Preparation of Complete Cell Culture Medium 
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A549, SK-MES-1 lung cancer cells were cultured in Dulbecco’s Modified Eagle’s 
medium supplemented with 50ml heat inactivated foetal calf serum (FCS) (Sigma-
Aldrich, Pooled, Dorset, UK) and 5ml of an antibiotic cocktail comprising penicillin, 
streptomycin and amphotericin B (Sigma-Aldrich, Pooled, Dorset, UK). COR-L23 
lung cancer cells were cultured in GI 1640 containing 2mM glutamine with 50ml of 
heat inactivated FCS and 5ml of an antibiotic cocktail comprising penicillin, 
streptomycin and amphotericin B. The prepared medium was stored at 4°C for no 
more than one month.  
 
• Preparation of 0.05M EDTA 
The buffer was prepared by dissolving 40g NaCl, 1g KCl, 5.72g Na2HPO4 (BDH 
Chemical Ltd., Poole, England, UK), 1g KH2PO4 (BDH Chemical Ltd., Poole, England, 
UK) and 1.4g EDTA (Sigma-Aldrich, Pooled, Dorset, UK) in 5 litres of dH2O to prepare 
the stock solution. The pH was adjusted to 7.4 using Sodium hydroxide (NaOH) and 
was autoclaved before use.  
 
• Trypsin (25mg/ml) 
Dissolving 500mg trypsin in 20ml 0.05M EDTA to prepare the 25mg/ml stock solution. 
The solution was filtered through a 0.2μm Minisart filter Sigma-Aldrich (Pooled, 
Dorset, UK) and stored at -20°C. The working solution was prepared by further 
dissolving 250μl of the stock trypsin/EDTA solution in 10ml of 0.05M EDTA to detach 
cells, and was stored at 4°C until use.  
 
• Phosphate buffered saline (PBS) 
PBS buffer 10X concentrate was purchased from Sigma-Aldrich (Poole, Dorset, UK), 
and diluted with distilled water into 1X stock and stored at room temperature for 
further use.  
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• Antibiotics 
Antibiotic Antimycotic Solution (100X) was purchased from Sigma-Aldrich (Poole, 
Dorset, UK). 5ml of the antibiotic solution was added to a 500ml DMEM to obtain a 
final 1X concentration.  
 
 Solutions for use in cloning 
• Luria Bertani (LB) broth  
LB broth buffered capsules were purchased from Melford Laboratories Ltd (Bildeston 
Road, Chelsworth, Ipswich, Suffolk). The pH value was adjusted to 7.2 at 20°C and 
then the broth was sterilized by autoclaving and stored at room temperature until use.  
 
• LB agar  
LB agar was prepared by the addition of 25 LB broth capsules and 15g agar dissolved 
in 1L of distilled water at 37°C. The pH value was adjusted to 7.2 at 20°C and then 
the broth was sterilized by autoclaving and stored at room temperature until use. LB 
agar was melted in a microwave to make a LB agar dish. Adding appropriate antibiotic 
when the agar solution was cooled down to about 65°C. The agar solution was then 
poured into 10 cm2 Petri dishes. The LB agar dishes were stored at 4°C.  
 
 Solutions for use in protein work 
• Lysis Buffer 
Lysis buffer was prepared by dissolving NaCl 150mM (8.76g), Tris 50mM (6.05g), 
sodium azide 0.02% (200mg), sodium deoxycholate 0.5% (5g), Triton X-100 1.5% 
(15ml), Aprotinin 1μg/ml (1mg), Na3VO4 5mM (919.5mg) and Leupeptin 1μg/ml (1mg) 
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in 1 litre of dH2O, and was stored at 4°C until use.  
 
• Tris Buffered Saline (TBS) 
Tris Buffered Saline 10X solution (T5912), 1L, was purchased from (Sigma-Aldrich, 
Poole, Dorset, UK) and diluted in 9L of distilled water. The pH was adjusted to 7.4 
using HCl and stored at room temperature until use.  
 
• Ammonium persulphate (APS), 10% 
The solution was prepared by dissolving 1g APS in 10ml dH2O and then stored at 
4°C for future use. 
 
• Running buffer 
Tris-Glycine-SDS Buffer 10X concentrate (T7777), 1L, (Sigma-Aldrich, Poole, Dorset, 
UK) was diluted in 9L of distilled water and stored at room temperature for further use. 
 
• Transfer buffer  
Tris-Glycine Buffer 10X concentrate (T4904) (Sigma-Aldrich, Poole, Dorset, UK) , 1L, 
was diluted in 9L of distilled water containing 2L methanol (Fisher Scientific, 
Loughborough, UK) and stored at room temperature for further use. 
 
2.2 Cell Culture 
 Cell Culture, maintenance and Storage 
A549, SK-MES-1 and COR-L23 lung cancer cell lines were cultured in Dulbecco’s 
Modified Eagle’s Medium/Nutrient F-12 Ham (DMEM-F12, Sigma-Aldrich, Poole, 
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Dorset, UK). This medium contains 2mM L-glutamine and 4.5mM NaHCO3 and 
supplemented with 10% heat inactivated Foetal Bovine Serum (Sigma-Aldrich, Poole, 
Dorset, England, UK) and antibiotics in PH 7.3. 
All cell lines were cultured in 25 cm2 and 75 cm2 flasks (Greiner Bio-One Ltd, 
Gloucester, UK) depending on the required application with a loose cap in an 
incubator at 37℃, 95% humidification and 5% CO2.  
Confluency and viability of cells were visually assessed with an inverted phase 
contrast microscope. The confluency of cells was estimated based on the percentage 
of cells covering the surface of the tissue culture flasks. Cells were left to grow until 
they reached sub-confluency (80-95%) for experiments. All handing of cells was 
carried out using a Class II laminar flow cabinet with autoclaved and sterile equipment. 
Cells were passaged when they reached 80%-90% confluency.  
 
 Trypsinization and Counting of cell lines 
The tissue culture flask was taken out from the incubator and the waste medium was 
aspirated using a glass pipette. Following this, the flask was briefly washed with 
sterile 5ml EDTA BSS buffer to remove remaining serum which would inhibit the 
action of trypsin. 
Approximately 1-2ml of trypsin/EDTA solution (Trypsin 0.01% (w/v) and EDTA 0.05% 
(w/v) in BSS buffer) was added to the tissue culture flask. The adherent cells were 
detached after the flask was returned to the incubator for 5-10 minutes at 37°C. 
Flasks were inspected visually under the light microscope to make sure the cells were 
detached completely.  
Once detached, 5ml DMEM containing 10% FCS was added to the flask to neutralise 
the trypsin and the detached cells were washed from the surface of the flask. The cell 
mixture was then transferred to a 30ml universal container (Greiner Bio-One Ltd, 
Gloucestershire, UK) and centrifuged at 1,800g for 10 minutes. 
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The supernatant was aspirated and the cell pellet was re-suspended in medium for 
re-culturing or used in experimental work immediately. 
Cell counting was carried out using a Neubauer haemocytometer counting chamber 
under a light microscope using the x10 objective lens. The haemocytometer 
calculated the number of cells in a predetermined volume of fluid in order to obtain 
the quantity of cells per millilitre. The haemocytometer chamber was divided into 9 
squares with dimensions of 1mm x 1mm x 0.2mm. For consistency of cell density and 
error reduction, four corners of 9 squared areas were counted. The number of cells 
was calculated using the following equation: 
 
Cell number/ml = (the sum of the number of cells in four corners/8) x (1x104) 
 
 Storage of cell lines in liquid nitrogen and cell resuscitation 
Cells were detached with trypsin from the flask as described in section 2.3.2. After 
centrifugation, the cells were re-suspended in medium with 10% dimethyl sulfoxide 
(DMSO) at a density of 1x106 cells/ml. 
The cell suspension was transferred into 1ml pre-labelled CRYO.STM tubes (Greiner 
Bio-One, Germany) wrapped in protective tissue paper and then frozen down to -
80°C. For longer term storage, the cells were transferred and stored at -196°C in a 
liquid nitrogen tank. 
In order to resuscitate the frozen cells, the CRYO.STM tube was taken from the liquid 
nitrogen and thawed in a 37°C water bath rapidly. The cell suspension was then 
transferred into a 30ml universal container containing 5ml of pre-warmed medium 
and then centrifuged at 1,800g for 5 minutes. The medium was removed by aspiration. 
The cells were then resuspended in 5ml medium. The cells were incubated at 37°C, 
95% humidification, and 5% CO2 for further experiment.  
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2.3 Methods for RNA detection 
 RNA extraction 
There are three main types of Ribonucleic acid (RNA) within the cytoplasm of all living 
eukaryotic cells:  
• ribosomal RNA (rRNA) 
• transfer RNA (tRNA) 
• messenger RNA (mRNA) 
Cellular mRNA was used in this study based on its important role of carrying genetic 
information and encoding corresponding protein products. At the transcript level, the 
presence of specific mRNA can indicate which proteins are likely to be produced by 
the cell. RNA isolation was performed using the Tri Reagent (Sigma-Aldrich, Poole, 
Dorset, UK) as outlined below. 
After cells were cultured in a monolayer to a confluence of approximately 90% (5-
10x105 cells), the medium was removed and replaced with RNA reagent (1ml per 5-
10x105 cells) to produce cell lysate. The homogenous lysate was then transferred 
into a sterile microfuge tube, and left at room temperature for 5 min. 
Chloroform was added to the homogenate at 0.2ml per 1ml of RNA reagent (Sigma-
Aldrich, Poole, Dorset, UK) and the tube capped and shaken vigorously for 15 
seconds. The resulting homogenate was then centrifuged at 12000g for 15 minutes 
at 4°C (Boece, Wolf laboratories, York, UK). Centrifugation resulted in separation of 
the lysate into three phases in the acidic environment - a red organic phase 
containing protein, an interphase containing DNA and a colourless upper aqueous 
phase containing RNA. 
The upper aqueous phase containing RNA was carefully transferred to a fresh 
microfuge tube. Following this, 500 μl of 2-propanol (per 1ml TRI Reagent®) was 
added to the sample, shaken and incubated on ice for 10 minutes before 
centrifugation, for pelleting precipitated RNA, at 12,000 x g for 10 minutes at 4°C. 
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Subsequently, an RNA pellet was observed at the bottom of the microfuge tube.  
The supernatant was discarded and the RNA pellet was washed with 1ml 75% 
ethanol (made with DEPC water) twice with vortexing and centrifuging at 7,500g for 
5 minutes at 4°C. 
The RNA pellet was briefly dried at 55°C for 5-10 min in a Techne, Hybridiser HB-1D 
drying oven (Wolf laboratories, York, UK), in order to remove any remaining ethanol. 
Finally, the RNA pellet was dissolved in 50-100μl (depending on RNA pellet size) of 
DEPC water by vortexing. DEPC is used as a histidine specific alkylating agent to 
inhibit the hydrolysis of RNA by RNAases. 
 
 RNA Quantification  
Once RNA isolation was completed, the concentration and purity of the resulting 
single stranded RNA were quantified by measuring its absorbance at a wavelength 
of 260nm using a UV 1101 Biotech spectrophotometer (WPA, Cambridge, UK). The 
RNA samples were measured with a Starna glass cuvette (Optiglass limited, Essex, 
UK). The A260nm/ A280nm ratio was used to estimate the purity of RNA sample by 
measuring the different absorbance between the RNA sample and DEPC water (as 
a blank control). The concentration of RNA samples was then standardised using 
DEPC water for reverse transcription (RT) or stored at -80°C for future use. 
 
 Reverse Transcription of RNA for production of cDNA 
To determine transcript expression, an mRNA template was used to generate 
complementary DNA (cDNA) using reverse transcription (RT). Transcripts of a 
particular gene were then determined using RT-PCR and QPCR. 
RT was performed by converting 500 ng of RNA into cDNA using the GoScriptTM 
Reverse Transcription System kit (Promega, Southampton, UK) Based on the 
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instruction provided by the manufacture, each reaction was set up in 200μl PCR tubes 
as follows in Table 2.6:  
 
Table 2.6: The system of RT-PCR.  
Component Volume  Each reaction  
GoScriptTM 5X Reaction Buffer  4μl  
MgCl2  1.2μl  
PCR Nucleotide Mix  1μl  
Recombinant RNasin Ribonuclease Inhibitor  0.5μl  
GoScriptTM Reverse Transcriptase  1μl  
RNA template (0.5μg/μl)  1μl  
Nuclease-Free Water  7.3μl  
 
The reaction was carried out in a 2720 Thermal Cycler (Applied Biosystems, Paisley, 
UK). The reaction condition is listed as following in Table 2.7:  
 
Table 2.7: The reaction condition of RT-PCR 
Time  Temperature  
5 minutes  25°C  
60 minutes  42°C  
15 minutes  70°C  
 
After the reaction completed, the cDNA was diluted by 1:4 with PCR water as a 
template for PCR or store at -20°C for future use.  
 
 Polymerase chain reaction  
Polymerase chain reaction (PCR) was first devised by Kary Mullis in 1983. It is a 
simple technique that is used to detect and amplify a single target DNA and produce 
thousands or millions of copies of the DNA sequence (Bartlett and Stirling, 2003). In 
this reaction, two short DNA sequences (oligonucleotides- i.e. forward and reverse 
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primers), which bind to the template DNA by base pairing, are required and are 
complementary to a defined sequence on each of the two stands of the DNA. These 
primers are aligned with the 3’ ends facing each other. 
The components of a PCR reaction include a DNA template containing the target 
DNA that is to be amplified, a heat resistant DNA polymerase such as Taq polymerase 
which synthesises DNA from nucleotides, short DNA fragments called primers which 
contain complementary sequences to the 3’ ends of the sense and anti-sense strand 
of the target DNA and which act as a starting point for DNA formation by the DNA 
polymerase, deoxynucleotide triphosphates (dNTPs) from which the polymerase can 
synthesise new DNA strands and a thermal cycler, which provides repeated cycles of 
heating and cooling to provide the required temperatures for each step of the reaction. 
The DNA produced by PCR acts as a further template for replication resulting in a 
chain reaction and the exponential amplification of DNA. 
In the current study, target genes were amplified using the GoTaq Green master mix 
(Promega, Southampton, UK). The reaction in aliquots of 16μl was set up in PCR 
tubes as described in Table 2.8:  
 
Table 2.8: The system of PCR. 
Component  Volume  
cDNA template  2μl  
Forward primer (working concentration of 1μM)  1μl  
Reverse primer (working concentration of 1μM)  1μl  
2X GoTaq Green master mix  8μl  
PCR H2O  4μl  
 
A test sample containing PCR water instead of cDNA template was run alongside to 
detect any contamination of the reaction.  
The PCR samples were briefly mixed and placed in a 2720 Thermo Cycler 
(ThermoFisher Scientific, Altrincham, UK). The condition of reaction was set as 
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described in Table 2.9:  
 
Table 2.9: The reaction condition of PCR. 
Step  Temperature  Time  Cycles  
Initialisation  94°C  5min  1  
Denaturation  94°C  20sec  32 cycles  
Annealing  55°C  20 sec  
Extension  72°C  30 sec  
Final extension  72°C  10min  1  
Final hold  4°C  ∞  1  
 
 Agarose gel electrophoresis and DNA visualization 
Agarose gel electrophoresis is the most common method to separate and analyse 
DNA fragments. It works by using electrical current to separate negatively charged 
DNA to a positive electrode through an agarose gel matrix, with the speed of 
migration depending on the size of DNA fragments. Agarose gels containing either 
0.8% (1-10kb DNA fragments) or 1-2% (smaller fragments less than 1kb) agarose 
were prepared for running DNA samples. 
The required amount of agarose powder (Melford Chemicals, Suffolk, UK) was added 
to 100ml (1X) TBE buffer and heated in a microwave oven until the agarose was 
completely dissolved. After cooling down for 5 minutes, the solution was stained with 
SYBR®Safe DNA gel stain (Invitrogen, Paisley, UK) and poured into electrophoresis 
cassettes (Scie-Plas Ltd, Cambridge, UK). Well forming combs were gently inserted 
and the gel was left to set at room temperature for 30-40 minutes until completely 
solidified.  
Once the gel had set, the well forming combs were removed after 1xTBE was poured 
over and exceed 5mm of the gel surface. 8μL DNA ladder (GenScript®, Piscataway, 
USA) was loaded into the first lane of the gel and then 8-10μL of DNA samples were 
loaded into additional wells of the gel by placing the gel loading tips just over the well. 
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The gel was run with an electrophoresis power supply (Gibco BRL, Life Technologies 
Inc.) at 120V, 100mA and 50W for approximately 30-50 minutes. When the visible 
dye line had moved the desired distance required for the product size, the electrodes 
were disconnected. 
The gel was then removed, and the DNA fragments visualised using Syngene U: 
Genius3 fluorescence UV transilluminator (Synoptics Ltd, Cambridge, UK). Images 
were saved electronically and printed using a thermal printer. 
 
 Quantitative RT-PCR (QPCR)  
Real-time (or quantitative) PCR is a sensitive technique for gene analysis. It 
measures PCR amplification in real-time as the reaction proceeds instead of at the 
end of the reaction in comparison with conventional PCR. This method works by 
detecting a fluorescent reporter probe which is increased during PCR amplification 
(PCR product is proportional to the level of fluorescence detected). The fluorescence 
level is continuously recorded by a sensitive camera attached to the system.  
In this study, the Ampliflour™ Uniprimer™ Universal system (Intergen company®, 
New York, USA) was used to quantify transcript copy number. The ampliflour probe 
consists of a 3’ region specific to the Z-sequence (ACTGAACCTGACCGTACA) 
present on the target specific primers and a 5’ hairpin structure labelled with a 
fluorophore (FAM). In this hairpin structure, the fluorophore is linked to an acceptor 
moiety (DABSYL) which acts to quench the fluorescence emitted by the fluorophore, 
preventing any signal from being detected. 
During PCR, the probe becomes incorporated and acts as a template for DNA 
polymerisation in which DNA polymerase uses its 5’-3’ exonuclease activity to 
degrade and unfold the hairpin structure, thereby disrupting the energy transfer 
between fluorophore and quencher, allowing sufficient fluorescence to be emitted and 
hence detected. The fluorescent signal emitted during each PCR cycle can then be 
directly correlated to the amount of DNA that has been amplified. This process is 
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illustrated in Figure 2.1. Each reaction to be amplified was set up as described in 
Table 2.10: 
 
 
Figure 2.1: Real time quantitative PCR using the fluorescent labelled Uniprimer. 
During the QPCR, primers containing the Z-sequence could recognise and bind to 
the specific 3’ region in step 1. Then in step 2, the Z-sequence could be recognized 
by Uniprimer. Subsequently in the next cycle the Uniprimer was open to show the 
fluorescent signal for detection.   
 
Table 2.10: The system of real time quantitative PCR. 
Component  Volume  
2x iQ™ Supermix  5μL  
Forward primer (10pmol/μL)  0.3μL  
Reverse primer (1pmol/μL)  0.3μL  
Amplifluor™ probe (10pmol/μL)  0.3μL  
cDNA  1μL  
PCR H20  3μL  
Total volume per reaction  10μL  
 
  
89 
 
Each sample was loaded into a 96 well plate (Applied Biosystems™, Life 
Technologies Ltd, Paisley, UK), covered with MicroAmp® Optical Adhesive film 
(ThermoFisher Scientific, Life Technologies Ltd, Paisley, UK) and run alongside a 
podoplanin (PDPL) standard of a known transcript number (ranging from 108 to 10). 
PDPL is a lymphangiogenesis marker, which is employed as a reference control gene 
for a standard curve to ensure any differences observed were not due to technical 
errors and allowed normalization of results. It is also used to calculate relative copy 
numbers of target genes. The 96 well plate was placed in an iCycler Thermal Cycler 
which uses a light source to excite the fluorescent molecules in the wells and an 
image intensifier and a 350,000-pixel charge-coupled device (CCD) detector to image 
all 96 wells every second and detect fluorescent light at the annealing stage. The 
conditions used for QPCR are shown as described in Table 2.11:  
 
Table 2.11: The reaction condition of real time quantitative PCR. 
Step  Temperature  
(°C)  
Time  
(minutes:seconds)  
Number of cycles  
Initial denaturation  94  05:00  1 
Denaturation  94  00:10  100 cycles  
Annealing  55  00:35  
Extension  72  00:20  
 
The fluorescent signal is detected at the annealing stage by a camera where its 
geometric increase directly correlates with the exponential increase of product. This 
is then used to determine a threshold for quantification of genes amplified in each 
reaction. Copy number of a target transcript is determined using the cycle number of 
a reaction when its fluorescence signal reaches the threshold. 
The degree of fluorescence emitted by a range of standards with a known copy 
number of a reference gene (PDPL) are used to compare the amount of fluorescence 
emitted by each sample, allowing for the transcript copy number of a target gene in 
each sample to be accurately calculated. 
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Furthermore, the transcript copy number of each sample was normalized against the 
detection of GAPDH copy numbers. The procedure was repeated at least three times, 
and representative data is demonstrated.  
How transcript levels are quantified is shown in Figure 2.2.  
 
 
Figure 2.2: Diagram of standard curve generation. (A) Reaction curves for serial 
diluted standard samples (108 to 10 copy number) using Step One plus Real-Time 
PCR System; (B) The standard curve generated based on the threshold cycle and 
copy number of the serial diluted standard samples. Red line indicates the standard 
curve generated and blue dots stand for different standard samples with known copy 
number. 
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2.4 Methods for protein detection 
 Protein extraction and preparation of cell lysates  
When cells reached sufficient confluence, the medium was removed and the cell 
monolayer was washed twice with PBS buffer. 5ml PBS was then added to the flask 
and the cells were scraped with a sterile cell scraper from the flask surface and 
transferred to a universal tube. 
The cell suspension was centrifuged at 1,800g for 10 minutes to obtain a cell pellet. 
After removal of the supernatant with a vacuum aspirator, 200-300μl (depending on 
pellet size) of lysis buffer was added to the universal tube and the cell suspension 
was transferred to a 1.5ml microfuge tube. In order to extract protein from cell lysate, 
the sample was incubated at 4°C for 1 hour with continuous rotation on a Labinoco 
rotating wheel (Wolf laboratories, York, UK) (25g and 4°C). After 1 hour, the resulting 
lysate was centrifuged at 13,000g for 15 minutes. The supernatant containing 
proteins was then transferred to a fresh tube. The pellet containing insoluble and any 
unwanted cell debris was discarded.  The protein sample was then either quantified 
for western blot or stored at -20°C until further use. 
 
 Protein quantification and preparation of samples for SDS-PAGE 
In order to standardize their concentration before they were analysed using sodium 
dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, the 
protein samples were quantified using the Bio-Rad DC Protein Assay kit (Bio-Rad 
Laboratories, Hemel-Hempstead, UK). The kit utilised a colorimetric assay based on 
the reaction of protein with an alkaline copper tartrate solution (Reagent A) and Folin 
reagent (Reagent B), which is used for the determination of protein concentration 
following detergent solubilisation. The protein reacts with copper in the alkaline 
medium resulting in the subsequent reduction of the Folin reagent and the production 
of a characteristic blue colour (with an absorbance between 405-750nm). Bovine 
serum albumin (BSA) was used as a standard for this protein quantification. 
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In a 96 well plate, 50mg/ml BSA standard (Sigma-Aldrich, Poole, Dorset, UK) was 
diluted in lysis buffer to produce a concentration gradient from 0.78mg/ml to 50 mg/ml. 
These were used to generate a standard curve for determining concentration of the 
protein samples.  Either protein samples or standards (5 µl) were added into each 
well on a 96-well plate and 25μl of Reagent A’ (prepared by adding 20μl of reagent S 
to every 1ml of reagent A) was added to each well followed by 200μl of Reagent B.  
After the sample was mixed, the plate was left at room temperature for 30-45 minutes 
for the colorimetric reaction to occur. The absorbance for each well was then 
measured at a wavelength of 630nm using the ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf Laboratories, York, UK).  
The standard curve was set up using the absorbance of the standards. Protein 
concentration of the test samples was determined according to the standard curve. 
Appropriate amounts of lysis buffer was used to standardise the protein samples to a 
final concentration of 1-2mg/ml depending on the lowest concentration of the same 
collection.  
This sample was finally diluted 1:1 with 2x Lamelli sample buffer concentrate (Sigma-
Aldrich, Poole, Dorset, UK) and then denatured by boiling at 100°C for 5-10 minutes. 
The boiled samples were either used immediately for SDS-PAGE or stored at -20°C 
until further use.  
 
 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
Four glass plates were prepared and assembled in two gel cassettes on a casting 
stand. Once assembled, ethanol was used to fill the space between the glass plates 
to test for leakages. 
The system used to conduct SDS-PAGE in this study was an OmniPAGE VS10 
vertical electrophoresis system (Cleaver Scientific Ltd., Rugby, Warwickshire, UK). 
  
93 
 
The required percentage of resolving gel was dependant on the protein size. A 
mixture of 15ml (enough for 2 gels) was prepared by adding all the constituents listed 
in Table 2.12:  
 
Table 2.12: Component of the 10% resolving gel 
Component of 10% Resolving gel   
Distilled water  5.9ml  
30% acrylamide mix (Sigma-Aldrich, Poole, Dorset, UK)  5.0ml  
1.5 M Tris (pH8.8)  3.8ml  
10% SDS  0.15ml  
10% Ammonium persulphate  0.15ml  
TEMED (Sigma-Aldrich, Poole, Dorset, UK)  0.006ml  
 
The resolving mixture was then added into space between the two glass plates 
carefully until it reaches a level about 1cm below the comb. In order to prevent gel 
oxidation, 1ml 2-propanol was added to cover the top of resolving gel. 
The gels were then left to polymerise at room temperature for about 30 minutes, or 
until set completely. The excess 2-propanol was poured off before a sufficient amount 
of stacking gel was added. The ingredients for staking gel are listed in Table 2.13.   
 
Table 2.13: Component of the stacking gel 
Component of Stacking gel  
Distilled water  3.4ml  
30% acrylamide mix (Sigma-Aldrich, Poole, Dorset, UK)  0.83ml  
1.0M Tris (PH 6.8)  0.63ml  
10% SDS  0.05ml  
10% Ammonium persulphate  0.05ml  
TEMED (Sigma-Aldrich, Poole, Dorset, UK)  0.005ml  
 
A well forming Teflon comb was inserted immediately after adding the stacking gel, 
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and the gel was left at room temperature for around 20 minutes for polymerisation to 
occur. 
After the gel was set, the loading cassette was transferred into an electrophoresis 
tank and covered with 1X running buffer before the well comb was removed. 10μl of 
Broad range markers (Santa Cruz Biotechnology, UK) were loaded into the first well 
of the gel, followed by 10-15μl of the required protein samples. 
The proteins were then separated at 80-120V, 50mA, and 50W for a period up to 3 
hours depending on the degree of separation required for target proteins according 
to their molecular weight.  
 
 Western blotting: transferring proteins from gel to nitrocellulose 
membrane  
After SDS-PAGE, the gel containing protein samples was electrically transferred onto 
a PVDF membrane. Following SDS-PAGE separation, the electrophoresis cassettes 
were disassembled and the gels were taken out. The stacking gel on each gel was 
cut off and discarded. The resolving gel was then placed on the lower graphite base 
electrode in a SD20 SemiDry Maxi System blotting unit (SemiDRY, Wolf Laboratories, 
York, UK) on top of 3 pieces of 1X transfer buffer pre-soaked filter paper (Whatman 
International Ltd., Maidstone, UK), and 1 sheet of PVDF membrane.  
An additional 3 sheets of pre-soaked filter paper were placed on top of the gel to form 
a sandwich arrangement in the order of filter papers, gel, membrane, filter papers 
(from cathode to anode) (Figure 2.3). Electroblotting was then conducted at 15V, 
500mA, and 8W for 40-90 minutes according to protein size. Once the proteins had 
been transferred sufficiently, the membranes were blocked with 5% milk solution (5% 
milk skimmed powder and 0.1% polyoxyethylene (20) sorbitan monolaurate (Tween 
20) in TBS for at least one hour at room temperature. This step aims to reduce 
background, i.e. non-specific binding to the membrane before subsequent probing 
with antibodies.  
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Figure 2.3: Diagram of the electrophoresis equipment transferring proteins 
from gel to membrane. The ‘sandwich’ structure from upper to lower: electrode (-) 
→ filter paper → acrylamide gel → PVDF membrane → filter paper → electrode 
(+). To make sure the negatively charged protein move towards the positive electrode.  
 
 Protein detection using specific Immuno-probing  
Once the blocking was completed, the membrane was transferred into 50ml falcon 
tubes (Nunc, Fisher-Scientific, Leicestershire, UK) with the membrane surface facing 
upwards. Then the membrane was incubated overnight at 4oC in 10ml 1% milk 
solution (1% milk powder, 0.1% Tween 20 in TBS) with primary antibody diluted 1:500. 
After probing with the primary antibody, the membrane was washed with 5ml TBST 
(TBS with 0.1% Tween 20) for three times (10 mins each) to remove remaining 
unbound antibodies. The membrane was subsequently incubated for one hour with 
continuous rotation with 5ml of 1:1000 horseradish peroxidase (HRP) conjugated 
secondary antibody diluted in 3% milk. The membrane was subsequently washed 
three times (10 mins each) with 5ml TBST before undertaking chemiluminescent 
detection.  
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 Chemiluminescent protein detection 
Chemiluminescent protein detection was carried out using a luminol/peroxide based 
enhanced chemiluminescence (EZ-ECL) kit (Biological Industries Israel Beit Haemek 
Ltd., Israel). This solution consists of a highly sensitive chemiluminescent substrate 
and is used to detect HRP for visualising the probed protein bands under X ray film 
or imaging system. The protocol was undertaken as follows: 100 µ L of ECL reagent 
was required per cm2 of membrane area with a 5-minute incubation at room 
temperature. The chemiluminescent signal was detected using G: Box (Syngene, 
Cambridge, UK) which contains both an illuminator and a camera linked to a 
computer. The exposure time was adjusted as necessary until the protein bands were 
sufficiently visible and the image was captured and analysed (ImageJ) for the protein 
band quantification. 
In this study, GAPDH was used as a loading control and run alongside when detecting 
any other proteins for additional normalisation of the sample. GAPDH was used 
because of its high abundance and conserved nature within eukaryotic cells and is 
one of the most widely employed and accepted internal controls in determining mRNA 
and protein expression. 
 
 Immunohistochemical staining 
This was based on paraffin embedded sections in the form of tissue microarray. After 
dewaxing and rehydration in each solution for 5 minutes sequentially: 100% xylene, 
50% ethanol with 50% xylene, 100% ethanol, 90% ethanol, 70% ethanol, 50% 
ethanol, the tissue section was treated with 3％ H2O2 for 15 mins to inactivate 
endogenous enzymes was . Antigens on the tissue section were repaired by heating 
the tissue section in the microwave for 20 mins. Horse serum (1-2 drops) was added 
into 5ml of 1× OptiMax Wash Buffer (BioGenex, San Ramon, USA) to prepare the 
blocking solution, and the tissue section was blocked in the blocking solution for 30 
minutes at room temperature. After blocking, the slide was washed three times with 
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wash buffer, and then incubated overnight in 4°C with primary antibody (diluted to a 
concentration of 10μg/ml in blocking solution). Any unbound antibody was 
subsequently removed after washing in buffer for 10 mins repeated three times. The 
corresponding secondary antibody diluted 1:1000 in blocking solution was added and 
incubated for 30 minutes in room temperature. After three washes with wash buffer, 
the sections were incubated with 200μl of VECTASTAIN® Universal ABC complex 
(Vector Laboratories Inc., Burlingame, USA) for 30 minutes. The ABC complex must 
be prepared ready at least 30 minutes before using by mixing 4 drops of the supplied 
reagent A, with 4 drops of regent B. The ABC solution was removed by washing three 
times with wash buffer, then 3,3’-Diaminobenzidine (DAB) chromogen (Vector 
Laboratories Inc., Burlingame, USA) were added on the tissue section and incubated 
for 5 minutes in the dark. The DAB was made up as a mixture of 2 drops of the 
provided buffer (pH 7.5), 4 drops of DAB, and 2 drops of hydrogen peroxide in 5ml of 
distilled water. A brown colouration showed the presence of the target protein and 
then the DAB was washed off using distilled water and the sections were co-stained 
with Mayer’s haemotoxylin for approximately 5 minutes. The tissue section was then 
washed with distilled water three times, and the tissue section slide was dehydrated 
for 5 minutes in each solution sequentially: 50% ethanol, 70% ethanol, 90% ethanol, 
100% ethanol, 50% ethanol with 50% xylene, 100% xylene. After dehydration, slides 
were mounted with DPX mount and left to dry.   
 
 Protein for KinexusTM microarrays 
 Sample preparation 
Before protein extraction, each cell type was cultured in two T75 flasks until 
approximately 80% confluent. Cells were left in serum free medium for 24 hours and 
treated with/without HGF (hepatocyte growth factor) (50ng/ml) for one hour. Cells 
were washed with PBS in 4°C twice and scraped from the flask in 5ml sterile PBS. 
The cell suspension was centrifuged at 2,500g for 10 minutes to pellet the cells. The 
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pellet of cells was lysed in 500μl lysis buffer and placed on a Labinoco rotating wheel 
(Wolf laboratories, York, UK) (25g and 4°C) for 60 minutes to make a sufficient extract. 
Then after centrifugation at 13000g for 15 minutes, the protein lysate was used for 
protein quantification described as before. Following this, 350μl of the solution was 
prepared and stored at -20°C until sending to KinexusTM microarray analysis 
(Kinexus Bioinformatics, Vancouver, British Columbia, Canada).  
 
 Antibody microarrays 
This study employed a recent protein kinase array, namely KAM1325. The array has 
1325 antibody spots (Kinexus Bioinformatics Ltd, Vancouver, Canada). A 
representative image for each of the antibody is as follows:  
 
 
Figure 2.4: Antibody layout on a typical KAM1325 protein array, image supplied 
by Kinexus Inc. Using the protein microarray to compare the difference in these key 
signalling molecules between the control cells and SIPA1 knockdown cells. The 
different sites in the figure show different colours (red and green) because different 
antibodies are recognized and stained with different colour dyes, and black means 
the stain intensity is very low.   
 
 Key information derived from KAM1325. 
The following are the key parameters collected and used for the data analyses: 
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Globally Normalized Signal Intensity - Background corrected intensity values are 
globally normalized. The Globally Normalized Signal Intensity is then calculated by 
summing the intensities of all the net signal median values for a sample.  
 
Flag - An indication of the quality of the spot, based on its morphology and 
background. The flagging codes used in the reports are as follows: 
0: acceptable spots 
1: spots manually flagged for reasons and may not be very reliable 
3: poor spots defined by various parameters 
%CFC (change from control) - The percent change of the treated sample in 
Normalized Intensity from the specified control. 
Calculation = (Globally Normalized Treated – Globally Normalized Control)/Globally 
Normalized Control) * 100  
% Error Range - A parameter to show how tightly the “Globally Normalized Net Signal 
Intensity” for adjacent duplicate spots of the same protein in the sample compare to 
each other. 
Calculation = ABS (Globally Normalized Spot 1 - Globally Normalized Spot 
2)/Globally Normalized Spot 2*100 
Log2 (Intensity Corrected) - Spot intensity corrected for background is log 
transformed with the base of 2. 
Calculation = LOG (Average Net Signal Median, 2) 
Z Scores - Z score transformation corrects data internally within a single sample.  
Z Score Difference - The difference between the observed protein Z scores in 
samples in comparison. 
Z Ratios - Divide the Z Score Differences by the SD of all the differences for the 
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comparison. 
 
 Antibody array analysis of SIPA1 interacting proteins 
The immunoprecipitates from normal and tumour tissues from the same patient was 
applied to the same slide, to reduce the inter-assay variance. The proteins samples 
were labelled, applied to the microarray, and image subsequently scanned using 
Perkin-Elmer Scan Array Reader laser array scanner, according to manufacturer's 
instructions. Analysis was carried out using the ImaGene 9.0 from BioDiscovery (El 
Segundo, CA). 
Here our analyses focused on the Globally Normalized Signal Intensity, %CFC and 
the Z-scores.  
 
 Immunofluorescence staining.  
Cells were seeded into 8 or 16 well glass chamber slides and allowed to reach about 
90% confluency in an overnight culture. After brief washing, the cells were exposed 
to 2% FCS media for 2 hours, before treatments were given. At the conclusion of the 
treatment, cells were fixed with 5% formaldehyde prepared in a neutral buffer for long 
than 2 hours. Following washing with PBS buffer, the cells were treated with a 
permeabilisation buffer (PBS with 0.1% Triton X100) for 5 minutes, before additional 
washing. Block the cells with horse serum. The primary antibody or antibodies (in the 
case of dual staining), diluted to the pre-determined concentration in PBS with 1% 
BSA, were added to each well, followed by incubation for overnight at 4oC in dark (by 
wrapping in kitchen foil). After 5 extensive washings with the same buffer, secondary 
antibodies tagged with either FITC (fluorescein isothiocyanate) or TRITC 
(tetramethylrhodamine isothiocyanate) were added to the wells and allowed for a 
further 2 hours.  After brief washing, DAPI (4’,6-diamidino-2-phenylindole, for 
nucleus staining) was added to the well for 30 minutes, followed by extensive washing. 
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After carefully removing silicon sealant surrounding the wells, Fluosavetm was added 
to the slides and coverslips were carefully laid over the slides. The procedures were 
carried out in dark and slides always stored in dark at 4oC. The slides were 
subsequently examined under a fluorescent microscope and images photographs 
using a Hamamatsu Orca digital camera.  
 
 
Figure 2.5: Olympus Fluorescence Microscope equipped with a Hamamatsu 
digital camera. 
 
2.5 Targeting SIPA1 gene expression 
 Knock down of SIPA1 using Ribozyme Transgenes 
Hammerhead ribozyme transgenes were used to knockdown the expression of 
SIPA1 by specifically targeting and cleaving the SIPA1 transcript. Hammerhead 
ribozymes targeting SIPA1 were designed based on the secondary structure of 
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SIPA1 mRNA (Figure 2.6).  
 
 
Figure 2.6 A: Schematic diagram of the secondary structure of hammerhead 
ribozyme. Helix I and helix III are the binding site, which could recognize and bind to 
the specific sequence, then the cleavage site is able to cut the mRNA to knock down 
the gene expression in transcripot level.  
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Figure 2.6 B: Schematic diagram of the secondary structure of SIPA1 mRNA. 
Generated from The mfold Web Server:  
http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form. The loop region in the 
mRNA was chosen to be the site of action of the ribozyme (typical examples are 
marked in red).  
 
The transgenes were synthesised using touchdown PCR and the products were then 
  
104 
 
run on a 2% agarose gel to verify their presence and size before being cloned into 
the pEF6/His plasmid vector (Figure 2.7). Subsequently, the ribozymes obtained 
from the above procedure were cloned into the pEF6/V5-His-TOPO vector, and this 
was followed by transferring the reaction mixture to a vial of TOP10 chemically 
competent Escherichia Coli (E. coli). After 30 minutes on ice, the bacteria were 
subject to heat shock at 42℃ for 30 seconds, before being placed on ice for 2 
minutes. The bacterial mixture was added to S.O.C. medium (Super broth with 
Catabolite repression, a rich culture media used for E. coli) and placed on an orbital 
shaker for 1 hour, at a speed of 200g. The bacterial solution was plated on agar plates 
containing 100μg/ml ampicillin and allowed to grow overnight. As the pEF plasmid 
has antibiotic resistance genes to ampicillin and blasticidin, only the cells containing 
the plasmid were able to grow on the agar. Colonies of transformed E. coli, 
transgenes of SIPA1 cloned into pEF6/V5-His-TOPO plasmids (Invitrogen Inc., 
Paisley, UK) were analysed using RT-PCR with the T7F primer coupled either with 
RbBMR and RbTPF primers. After amplifying the correct colonies, the plasmids were 
extracted using the Promega Plasmid MidiPrep Kit. Control plasmid and the plasmid 
containing the ribozyme transgene were used to transfect A549, SKMES1 and 
CORL23 cell lines respectively. The transfected cells were cultured in selection 
medium containing 5-10μg/ml blasticidin for around 1-2 weeks so that only those cells 
containing the plasmid would survive. Following selection, the cells were transferred 
into maintenance medium containing 0.5μg/ml blasticidin. To verify the knockdown of 
SIPA1, RT-PCR, QPCR and western blot procedures were carried out as previously 
described.  
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Figure 2.7: Schematic of the pEF6 plasmid (From pEF6/V5-His TOPO TA 
Expression Kit protocol).  
 
2.6 In vitro Function assay 
 In vitro cell growth assay 
Medium (200µl) containing 3,000 cells was seeded into 96 well plates. These plates 
were incubated at 37℃, with 5% CO2, for periods of 24, 48, 72, and 120 hours 
respectively. 
After incubation, the medium was aspirated, and the cells were fixed with 4% 
formaldehyde for 10-20 minutes before being stained with 0.5% crystal violet for 10 
minutes. The plate was then rinsed with tap water and left to air dry. 
The crystal violet was then solubilised using 200μl of 10% acetic acid and the amount 
of cells was assessed by measuring the absorbance of the resulting solution at 
540nm using a spectrophotometer (BIO-TEK, ELx800, UK). The growth rate was 
calculated as a percentage, using the absorbance from the corresponding plate 
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collected at 24 hours as a baseline.  
 
 In vitro thiazolyl blue tetrazolium bromide (MTT) cell growth assay 
MTT (3-(4,5-dimetheylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium has 
been widely adopted in a variety of cell functional assays, especially cell viability 
assay. MTT can be converted into a purple coloured formazan product with 
absorbance near 570nm by viable cells with active metabolism. Such formazan 
product, soluble in DMSO, accumulates as precipitate and distributes inside the cell 
as well as the culture medium near the cell surface. The amount of formazan product 
corresponds to the number of viable cells following linearity. Thus, the absorbance of 
formazan solution is comparable to the number of viable cells. MTT stock solution 
(5.5mg/ml) was made by adding 110mg thiazolyl blue tetrazolium bromide powder 
(MTT) (Sigma-Aldrich, Inc., Dorset, UK) in 20ml PBS into a foil wrapped 30ml 
universal container, and the tube was then placed on a roller mixer (Stuart, Wolf-
Laboratories, York, UK) until the powder was dissolved thoroughly. Once the powder 
was dissolved completely, the solution was filtered through a 0.2μm filter on top of a 
fresh foil wrapped sterile universal tube in a biosafety cabinet and stored at 4°C in a 
fridge for further use. 
Once 90% confluency was obtained, cells were trypsinised, centrifuged and re-
suspended with normal medium. Cell number was then counted manually and an 
appropriate amount and cell density of cell solution was prepared for cell seeding. 
200μl of the cell suspension (2000 cells/200μl) was then pipetted into three 96-well 
plates in six replicates followed by incubation for 24 (1 day), 72 (3 days) and 120 
hours (5 days) at 37.0°C, 5% CO2 and 95% humidity respectively. 20μl of sterile MTT 
stock solution was added at 24, 72 and 120 hours after cell seeding (working 
concentration of 0.5mg/ml MTT) and the plates were incubated at 37°C, 5% CO2 and 
95% humidity for 4 hours. The MTT medium solution was then aspirated gently, using 
a glass aspirator, followed by the addition of 200μl of DMSO. After 10 minutes 
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incubation at 37.0°C, 5% CO2 and 95% humidity, the plate was taken out and tapped 
gently to thoroughly mix the DMSO solution.  
The absorbance of each well was read at 540nm using an ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). Experiments were 
repeated for a minimum of three times. The cell number in each well was determined 
by the absorbance and a percentage increase at each time point was calculated as 
follows: 
Percentage increase = [(day 3 or day 5 absorbance - day 1 absorbance)/(day 1 
absorbance-background absorbance)] x 100%  
 
 In vitro transwell cell invasion assay 
8μm pore transwell inserts (Millicell, Merck KGaA, Darmstadt, Germany) were placed 
into wells of a 24 well plate, using sterile forceps in order to prevent contamination. 
Each insert was coated with 100μl of serum free medium containing 50μg Matrigel® 
Basement Membrane Matrix (Corning Incorporated, Flintshire, UK, stock 
concentration 0.5μg /μl) and left to dry for 2 hours at 55℃. The Matrigel was then 
rehydrated with 200μl serum free medium at room temperature for 45 minutes. After 
the water was carefully discarded, 20,000-40,000 cells in 200μl medium were seeded 
into each insert. Medium (600μl) was then added to the bottom chamber of each well. 
The cells were incubated for 72 hours, with 5% CO2 at 37℃ (Figure 2.8). 
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Figure 2.8: Schematic diagram of in vitro invasion assay showing double 
chamber arrangement that is separated by a semi-permeable membrane (8.0 μm 
pore size). 
 
After 72 hours incubation, the Matrigel layer and the non-invasive cells were then 
removed from the insert using a cotton bud. Both the Matrigel layer and the non-
invasive cells were thoroughly removed as they can also be stained with crystal violet, 
impacting quantification of invasive cells that had invaded the Matrigel and porous 
membrane and established on the underside of the insert. The invasive cells were 
then fixed with 4% formalin for 10-20 minutes and stained with 0.5% crystal violet for 
10 minutes. The crystal violet was then washed off and the plate was left for air dry. 
The stained cells were subsequently counted and photographed under the 
microscope.  
 
 In vitro cell adhesion assay 
Serum free medium (100μl) containing 5μg Matrigel (Matrigel® Basement Membrane 
Matrix (Corning Incorporated, Flintshire, UK)) was added to a 96-well plate. The  
Matrigel was then left to dry for 2 hours at 55℃. Following this, 200μl of sterile water 
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was added to each well and left for at least 45 minutes at room temperature to 
rehydrate the Matrigel. The medium was aspirated and 20,000 cells, diluted in 200μl 
medium, were seeded into each well and left to adhere at 37℃, with 5% CO2 for 40 
minutes. 
After incubation, the medium was discarded and the cells were washed with BSS to 
remove any non-adherent cells. The remained adhered cells were then fixed with 4% 
formalin for 10-20 minutes, and then stained with 0.5% crystal violet for 10 minutes. 
Following substantial washes, the plates were left to dry before counting adherent 
cells and capturing images under the microscope. Due to the fluid dynamics within 
the small size wells of 96 well plate, the unevenly set Matrigel can lead to the cell 
aggregation around the edges of the well. In order to avoid this issue, only the cells 
that adhered to the central area of the well were counted.  
 
 In vitro MTT cell adhesion assay 
Cell adhesion assays were used to examine cell initial adhesive ability to Matrigel 
matrix. Matrigel was diluted with serum free medium (SFM) to 50μg/ml and 5μg of 
Matrigel was added to the wells of 96-well plate under sterile conditions followed by 
dehydration at 55°C for 1 to 2 hours. The Matrigel matrix coated wells were 
rehydrated by gently pipetting 100μl SFM and incubating at room temperature for at 
least 30 minutes before aspirating the SFM. Cells (40,000 cells in 200μl normal 
medium) were seeded on the rehydrated Matrigel matrix in six replicates and the 
plate was incubated for 45 minutes. Subsequently, the medium was gently aspirated 
by glass aspirator and 100μl of PBS was used to gently wash the wells twice. MTT in 
200μl normal medium (0.5mg/ml working concentration) was added to each well and 
the plate was incubated at 37.0°C, 5% CO2 and 95% humidity for 4 hours. The 
medium containing MTT was then aspirated followed by the addition of 200μl DMSO. 
After 10 minutes of incubation in DMSO at 37.0°C, 5% CO2 and 95% humidity, the 
plate was taken out and tapped gently to let the DMSO solution mix thoroughly. 
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The absorbance of each well was detected at 540nm using ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). Initially attached cell 
numbers in each well was determined by the absorbance. Experiments were 
repeated a minimum of three times. 
 
 In vitro cell transwell migration assay 
Transwell inserts (Millicell®, pore size 8.0μm, 24 well format, Greiner Bio one, 
Germany) were placed into wells of a 24 well plate (NUNC™, Greiner Bio one, 
Stonehouse, Glos, UK), using sterile forceps in order to prevent contamination. 
20,000 cells, in 200μl medium, were seeded into each insert. 600μl medium was then 
added to the bottom chamber of each well (Figure 2.9). The cells were incubated for 
72 hours, with 5% CO2 at 37℃. After 24 hours incubation, non-invasive cells were 
then removed from the insert using a cotton bud. Cells which had migrated through 
the insert were then fixed with 4% formalin for 10-20 minutes and then stained with 
0.5% crystal violet for 10 minutes. The crystal violet was then washed off and the 
plate was left to air dry. The stained cells were subsequently counted and 
photographed under the microscope. 
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Figure 2.9: Schematic diagram of in vitro transwell migration assay showing 
double chamber arrangement allowing the passage of cells through the 8.0um pores 
in the semi-permeable membrane. 
 
 In vitro cell migration assay (wound healing assay) 
An EVOS® FL2 Auto Imaging System (Life technologies, CA, USA) equipped with 
EVOS® Onstage Incubator (Life technologies, CA, USA) were used the in vitro cell 
migration assay. Such a system was used to capture images at certain time intervals 
at the same location in each monitored well and continuously maintain culture 
conditions for the cells being investigated. 
Cells in 1ml of normal medium were pre-seeded with appropriate density of 400,000- 
600,000 cells/well in a 24-well plate and incubated until the formation of a monolayer 
on the next day. The cell monolayer was scraped by a 200μl pipette tip producing an 
approximately straight wound. The medium was aspirated by glass aspirator and the 
well was washed by pipetting and aspirating PBS twice to remove the detached cell 
debris. 2ml of normal medium was then gently pipetted into the well followed by 10 
minutes of incubation at 37°C, 5% CO2 and 95% humidity for cell recovery. The 24-
well plate was then placed in an EVOS® Onstage Incubator (Life technologies, CA, 
USA) equipped in an EVOS® FL2 Auto Imaging System (Life technologies, CA, USA) 
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(Figure 2.10). Integrated EVOS® FL2 Auto Imaging System Software was used to 
set up and adjust the chamber environment condition at 37°C, 5% CO2. Views on 
each wound were set up to be captured in every 60 minutes interval until the 24th 
hour. The distance between two wound edges was measured using Image J v1.50c 
in pixels, and the distance change at every time interval was calculated by wound 
edge distance at minute zero subtracting wound edge distance at each time point. 
The mean and standard deviation was calculated using the three measurements per 
each wound and was plotted on a scatter line chart. Experiments were repeated a 
minimum of three times. 
 
 
Figure 2.10: EVOS® FL2 Auto Imaging System with EVOS® Onstage Incubator, 
which provide the environment condition at 37°C, 5% CO2 for cells, and record the 
cells via the various zoon of microscope.   
 
 Electric cell-substrate impedance sensing (ECIS)  
Electric cell-substrate impedance sensing (ECIS) instruments (Applied Biophysics 
Inc., NJ, USA) were applied to investigate cell behaviour based on the impedance 
parameter detected from gold electrodes coated on the bottom of a 96-well plate 
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(Applied Biophysics Inc., NJ, USA) (Figure 2.11). ECIS is an in vitro assay used to 
quantify cell behaviour through detection of impedance variation based upon the 
current flow change on the electrode that is cultured with cells. Such a technique 
enables the measurement of impedance over a range of frequencies to study different 
functional and structural cell properties, based on cell-cell junctional contacts and 
cell-substrate interactions, during the same period of time. Moreover, there are two 
parameters, resistance and capacitance, derived from impedance measurements. 
Resistance, consisting para- and trans-cellular current flow (Figure 2.12), is more 
likely to represent the quality and function of the cell barrier, whereas capacitance 
stands for the overall coverage of the electrodes. In this project, resistance measured 
in 1,000-4000Hz were chosen to analyse cell resistance referring to the function of 
tight junctions.  
 
 
Figure 2.11: Electric cell-substrate impedance sensing (ECIS). A. Electric cell-
substrate impedance sensing (ECIS) instruments (Applied Biophysics Inc., NJ, USA). 
B. ECIS 96-channel array station. C. 96W1E+ electrode array with two electrodes on 
the bottom of the well (available from: http://www.biophysics.com/cultureware.php).  
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Figure 2.12: Diagram of current flow following cell attachment to the gold 
electrode (available from: http://www.biophysics.com). A. At high frequencies 
(e.g. 40,000Hz), most current flows capacitively through the cell membranes. B. At 
lower frequencies (e.g. 2000Hz), the membrane impedance increases, and more 
current finds an easier route going under and between the cells.  
 
The 96-channel array station was connected to the ECIS instruments pre-warmed at 
37°C, 5% CO2 and 95% humidity in an incubator. 200μl of serum free medium was 
pipetted into each well of the 96-well ECIS plate, and the 96-well ECIS plate was 
connected to the 96-channel array station followed by connection check and 
stabilisation using Applied BioPhysics-ECIS Software V1.2.135 (Applied Biophysics 
Inc., NJ, USA). 
During the time required to complete stabilisation, the cell suspension solution with 
appropriate cell density was prepared based on the cell type. Once the array 
stabilisation was completed, the 96-well ECIS plate was removed from the array 
station and transferred into the biosafety hood where the medium was aspirated using 
a glass aspirator and replaced with 200μl of prepared cell suspension solution with 
the cells at an appropriate density. Each sample was seeded in at least six replicates. 
After the cell seeding, the 96-well ECIS plate was connected to ECIS station in the 
incubator. 
Following inoculation at time zero, resistance increases as the cells attach to the 
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electrode and begin spreading and the resistance will continue to increase until the 
cells reach confluence. For the initial functional analysis of our cells, the resistance 
was measured at multiple frequencies, and the first four hours of data, obtained at 
4,000Hz was taken to analyse the initial adhesion. 
A lethal electroporation (electrical wounding) was applied to the cells covering the 
gold electrodes for 30 seconds at the conditions of 3000μA and 60,000Hz to generate 
a uniform lesion (250 μm diameter). The resistance was measured following electrical 
wounding and used to analyse cell migratory function over a four-hour period 
following wounding. The electrical wounding and the subsequent measurements 
were repeated twice. The resistance obtained for each hour was used to subtract the 
initial value at hour zero to display the resistance change which represents the cell 
re-coverage of the electrodes from the starting point. Experiments were repeated for 
at least three times.  
 
 Transepithelial Resistance (TER)  
Transwell inserts (Millicell, MerkMillipore, Watford, UK) with 0.4 μm pores were 
placed into wells of a 24 well plate, using sterile forceps in order to prevent 
contamination. 5X104 cells were seeded into inserts in 500 μl medium with 1ml 
medium in the well outside of the insert (Figure 2.13). Cells were incubated at 37 °C, 
5 % CO2 for 24-48 hours until confluent. Medium was then replaced and resistance 
across the membrane was then measured in triplicate immediately afterwards using 
the EVOM² Epithelial Volt/Ohm Meter (World Precision Instruments, Hitchin, 
Hertfordshire, UK) (Figure 2.14). Various treatments were carried out and resistance 
was also measured every hour after the initial measurement for 12 hours. Change of 
the resistance was used as the measurement of the change of the TJ function of the 
cells.  
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Figure 2.13: Schematic diagram of transepithelial resistance assay showing 
double chamber arrangement preventing the passage of cells through the 0.4 um 
pores in the semi-permeable membrane.  
 
 
Figure 2.14: EVOM² Epithelial Volt/Ohm Meter with chopstick electrode for 
measuring the resistance between the two electrodes (World Precision 
Instruments, Hitchin, Hertfordshire, UK).  
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Chapter-3 Expression of SIPA1 in 
lung cancer and its clinical 
relevance  
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3.1 Introduction 
Over the past two decades, there have been limited literature reports, indicating that 
SIPA1 participates in the metastasis process of cancer. The initial function of SIPA1 
was thought to be that of having a specific GAP activity for Ras-related mediating 
proteins, Rap1, Rap2, Rsr1 and nuclear Ran (Kurachi et al., 1997). SIPA1 
overexpression induced rounding and eventual detachment of inherently adherent 
cells from the extracellular matrix by inhibiting endogenous Rap1 activation, 
indicating that Rap1 signals are involved in the regulation of cell adhesion and that 
SIPA1 functions as a negative regulator of cell adhesion (Kurachi et al., 1997, Hattori, 
2011). In addition to the functions originally discovered, SIPA1 was also found to 
have the ability to bind with a few molecules such as AQP2, BRD4, AF6, by so doing, 
play different roles in a variety of tumour types (Alsarraj et al., 2013, Brooks et al., 
2010, Noda et al., 2004, Su et al., 2003, Ugenskiene et al., 2016, Zhang et al., 2015).  
Our previous work has found that the invasive human breast cancer cell line MDA-
MB-231 and the PC-3 human prostate cancer cell line exhibited significantly reduced 
response to HGF during both transepithelial resistance (TER) and paracellular 
permeability (PCP) assays, as well as cell adhesion, after knockdown of SIPA1 
(p<0.001) (Jiang, 2013, Jiang, 2006).  
Studies on SIPA1 in human lung cancer are very sparse. There has been one report 
on the function of SIPA1 SNP polymorphism, in which it was shown that G allele at 
rs931127 was significantly correlated with the risk of lung cancer, as well as with poor 
clinical staging (Xie et al., 2013). G allele fusion in SNP rs931127 A>G was 
associated with worse progression free survival (PFS) in the patients with NSCLC 
(Gdowicz-Klosok et al., 2015). The role of SIPA1 in cancer is most focused on breast 
cancer. There is a very well-designed study showing the mechanism of SIPA1 in 
breast cancer carried out by Zhang et al. (Zhang et al., 2015). It revealed that nuclear 
SIPA1 affects ITGβ1 (integrin beta1) in breast cancer cells and activates the Alk 
signalling pathway, leading to a more invasive phenotype of breast cancer. There are 
also a few studies on the role of SIPA1 in prostate cancer. High expression of SIPA1 
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was associated with poor disease prognosis and metastases in human prostate 
cancer patients (Shimizu et al., 2011). SIPA1 increases the invasion and metastasis 
potential of prostate cancer cells both in vitro and in vivo in mice (Shimizu et al., 2011). 
SIPA1’s expression in both human oral squamous cell carcinoma (OSCC) and OCSS 
cells are higher than normal tissue, which is linked with metastasis to regional lymph 
nodes in OSCC patients (Takahara et al., 2017).  
In the light of the limited information about SIPA1 in human lung cancers and the 
potential link between SIPA1 and the clinical outcome of patients with cancer, this 
current chapter of the study aimed to establish the pattern of expression of SIPA1 in 
human non-small cell lung cancer (NSCLC), at both messenger RNA and protein 
levels, using QPCR and immunohistochemistry (IHC) and to determine the 
relationship, if any between SIPA1 expression and the clinical pathological features 
of these patients.  
 
3.2 Materials and methods  
3.2.1 Lung cancer tissues 
Lung tumours (n=148) together with adjacent normal tissue (n=148) were collected 
immediately after surgery and stored at -80°C until use, with written consent from the 
patients at Peking University Cancer Hospital. All protocols and procedures were 
approved by Peking University Cancer Hospital Research Ethics Committee 
(Appendix 1). RNA was extracted and converted to complementary DNA (cDNA) for 
subsequent quantification using real time quantitative PCR (QPCR).  
 
3.2.2 Primers and antibody 
All the primers used were synthesised and provided by Invitrogen (Paisley, UK). 
Primer sequences are shown in Table 2.3, 2.4. Mouse anti-SIPA1 antibody 
(ab219085) was obtained from ABCAM (Cambridge, UK). The name, molecular 
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weight, supplier, and the product code of the primary and secondary antibodies used 
in this chapter is shown in Table 2.5. 
 
3.2.3 RNA extraction, reverse transcription, PCR and QPCR 
Total RNA was isolated using TRI Reagent (Sigma-Aldrich, Poole, Dorset, UK), first 
strand cDNA was then synthesis using the GoScriptTM Reverse Transcription System 
kit (Thermo Fisher Scientific, Life Technologies Ltd, Paisley, UK). And QPCR was 
carried out as described in section 2.4.   
 
3.2.4 Immunohistochemistry (IHC) for lung tissue microarray 
Immunohistochemical staining was carried out on a lung disease spectrum tissue 
microarray (TMA) (LC1201, Biomax, Maryland, US). Staining intensity and positive 
percentage of SIPA1 staining was determined independently by three researchers 
(CL, YXC and YZC). The IHC scoring was calculated based on both staining intensity 
and positive percentage of SIPA1. IHC score = staining intensity (0-3) + positive 
percentage (0-3).  
 
3.2.5 Statistical analysis 
One-way ANOVA test, Two-way ANOVA test, t-test, paired t-test, Mann-Whitney test 
and chi-square tests were performed, where appropriate, to analysis the expression 
level of SIPA1 in tumours. SPSS was used to carry out the survival analysis. 
Differences were considered to be statistically significant when p<0.05.  
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3.3 Result  
3.3.1 Transcript level of SIPA1 in lung cancer  
Expression of SIPA1 in lung cancer was determined by evaluating the transcript 
levels of SIPA1 in two clinical cohorts, collected sequentially at the Peking University 
Cancer Hospital, using QPCR. Patients’ clinical and pathological features, as well as 
the levels of expression of the SIPA1 transcript are summarized in Table 3.1 A. 
Median levels of SIPA1 transcript levels in tumour and normal tissue are shown in 
Table 3.1 B, Figure 3.1 and Figure 3.2. Data was analysed using the Mann-Whitney 
test. It can be observed that SIPA1 was significantly upregulated in lung tumour 
tissues compared with adjacent normal lung tissues (p=0.0141). The same rise was 
also found when paired tissues were analysed (p=0.0358) (Figure 3.1, 3.2).  
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Table 3.1 A: Clinical and pathological demographics of the cohort and the level 
of expression of SIPA1 transcripts. We compared the SIPA1 transcript level 
between lung tumour tissue and normal tissue, also we look through the different 
expression of SIPA1 in each sub-group respectively like histology type, degree of 
differentiation, T Staging, nodal staging, TNM staging, TNM substaging and smoking 
history.  
Parameters 
Sample 
number 
Medi
an 
Interquartile 
range 
Q1 Q3 
Entire cohort 
Tumour 148 25 12 74 
Normal 148 19 7 45 
Histology type 
Squamous Cell 
Carcinoma 50 25 14 62 
Adenocarcinoma 67 19.8 9.1 73.8 
Others 18 24 6 121 
Degree of 
differentiation 
High 7 14.88 3.05 
21.8
8 
High to moderate 16 24.2 15.9 63.5 
Moderate 50 25 9 67 
Moderate to Low 23 26.9 12.2 96.7 
Low 14 17.9 7.5 42.5 
T Staging 
T-1 21 17.3 4.2 63 
T-2 57 21 9 65 
T-3 29 50 20 168 
T-4 16 18.3 6.1 65.3 
Nodal staging 
N-0 70 24.1 9 63.7 
N-1 22 31 11 82 
N-2 38 19 10 78 
TNM staging 
TNM1 39 17.3 6.9 59.7 
TNM2 31 52 20 189 
TNM3 51 19 12 63 
TNM4 1 
0.113
4 * * 
TNM substaging 
TNM1A 17 15.5 4.1 63 
TNM1B 22 21.9 8.2 60.3 
TNM2A 2 135 * * 
TNM2B 29 52 20 189 
TNM3A 37 20 14 63 
TNM3B 14 18.3 6.4 77.1 
Smoking history 
Non smokers 59 28.5 9.7 63.8 
Smokers 77 20 11 71 
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Table 3.1 B: Expression of SIPA1 transcripts in the clinical cohort of NSCLC 
lung cancers. SIPA1 transcript level was significant higher in lung tumour tissue, 
whether compared to normal tissue or paired normal tissue. *Mann-Whitney U test.   
 N Median (copy numbers/50ng 
RNA) 
p-value* 
All tissues    
Tumour 148 25  
0.0141 Normal 148 19 
Paired tissues    
Tumour 139 24.2  
0.0358 
Paired Normal 139 19 
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Statistic Tumour tissue Normal tissue 
median 25 19 
Q1-Q3 12-74 7-45 
Min-max 0-12482 0-8475 
Figure 3.1: Transcript level of SIPA1 between lung cancer and adjacent normal 
lung tissue. SIPA1 transcript level was significant higher in lung tumour tissue, 
whether compared to normal tissue. SIPA1 level was evaluated by copy 
numbers/50ng RNA. Statistical method: Mann-Whitney U test.  
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Statistic Tumour tissue Paired normal tissue 
Median 24.2 19 
Q1-Q3 10.3-68 7-46 
Min-Max 0.1-6104.6 0-84756 
Figure 3.2: Transcript level of SIPA1 between lung cancer and paired adjacent 
normal lung tissue. SIPA1 transcript level was significant higher in lung tumour 
tissue, whether compared to paired normal tissue. SIPA1 level was evaluated by copy 
numbers/50ng RNA. Statistical method: Mann-Whitney U test. 
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3.3.2 Protein level of SIPA1 in lung cancer 
To examine the protein expression level of SIPA1 in patients with lung cancer, 
immunohistochemical staining was performed using a commercial lung cancer tissue 
microarray (Figure 3.3). Samples included primary tumours of adenocarcinoma, 
squamous cell carcinoma, papillary adenocarcinoma, small cell carcinoma, atypical 
carcinoid, bronchioloalveolar carcinoma, giant cell carcinoma, large cell carcinoma, 
metastatic squamous cell carcinoma, metastatic adenocarcinoma and normal lung 
tissues. Summative pathological information of the TMA can be seen in Table 3.2 and 
Figure 3.4.  The IHC scoring did not show a significant difference of SIPA1 staining 
in lung tumours compared with all normal pneumonic tissue, neither did it show 
differences with normal tissue and adjacent normal tissue (Figures 3.4, 3.5, shows 
representative sections of the typical staining observed).  
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Figure 3.3: Overall look of the IHC staining of SIPA1 on lung cancer TMA 
(LC1201, Biomax, Maryland, US). The TMA slide contains lung tumours tissue, 
normal lung tissue and a positive control tissue. Image was scanned using a high 
resolution EVOS scanner after IHC stained using anti-SIPA1 antibody. Detailed 
information was seen in the appendix.  
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Table 3.2: Pathological information summary of lung cancer TMA (LC1201, 
Biomax, Maryland, US). Detailed information of each sample was seen in the 
appendix.  
Pathological characteristic Numbers of samples 
Normal tissue 12 
Normal pneumonic tissue 6 
Cancer adjacent normal pneumonic tissue 6 
Malignant tumour 108 
Adenocarcinoma 27 
Squamous cell carcinoma 27 
Papillary adenocarcinoma 8 
Small cell carcinoma 8 
Atypical carcinoid 8 
Bronchioloalveolar carcinoma 8 
Giant cell carcinoma 2 
Large cell carcinoma 8 
Metastatic squamous cell carcinoma 4 
Metastatic adenocarcinoma 8 
All 120 
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Score 0 2 3 4 5 6 all 
tumour 58 22 17 5 4 2 108 
normal 6 2 4 0 0 0 12 
all 64 24 21 5 4 2 120 
Figure 3.4: Frequency analysis of the each IHC score in lung cancer tumour 
and normal tissue samples by chi-square test. Table attached showed the exact 
frequency of each score sub-group in tumour and normal tissue group.  
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Figure 3.5: representative IHC SIPA1 staining images in the TMA. A-B are 
malignant tumour tissues, C-D are normal pneumonic tissues, E-F are cancer 
adjacent normal pneumonic tissues, G is the positive control from skin malignant 
melanoma. All the images were captured at 200× objective magnification.  
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Figure 3.6: Representative IHC SIPA1 staining images in the malignant tumour 
tissues. The expression of SIPA1 in tumour tissue under (A) 200× magnification. (B) 
400× magnification. Dark brown colour represents a higher SIPA1 expression level 
seen in the staining image.  
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3.3.3 SIPA1 transcript and protein expression and histological type of lung 
cancer  
Both transcript and protein levels of SIPA1 from different histology types of lung 
cancer were measured. In the clinical cohort, the main types of lung cancer were 
adenocarcinoma and squamous cell carcinomas. The levels of SIPA1 were then 
compared between these two types and the remaining patients which were small in 
number. As shown in Figure 3.7, the difference in transcript levels of SIPA1 among 
adenocarcinoma, squamous cell carcinoma and other types of lung cancer is not 
statistically significant (Figure 3.7). However, it was noted that adenocarcinoma 
tissues of the lung showed a trend towards higher levels of SIPA1 transcript than that 
in squamous cell carcinoma and other types of lung cancer (Figure 3.8).  
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Statistic Adenocarcinoma Squamous cell carcinoma others 
Sample numbers 67 50 15 
median 19.8 25 14.88 
Q1-Q3 9.1-73.8 0-62 3.05-
21.88 
Min-Max 1.4-1185.2 0-6023 1.37-
67.99 
Figure 3.7: Transcript level of SIPA1 in different histology of lung cancer. The 
transcript level of SIPA1 among the adenocarcinoma, squamous cell carcinoma and 
others are shown. (SIPA1 level was evaluated by copy numbers/50ng RNA). 
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Score 0 2 3 4 5 6 all 
Adenocarcinoma 12 9 7 3 3 1 35 
Squamous cell carcinoma 21 4 5 1 1 1 33 
Other 25 9 4 2 0 0 40 
Normal 6 2 4 0 0 0 12 
all 64 24 20 6 4 2 120 
Figure 3.8.1: Frequency analysis of the IHC scores in various histology of 
tumour samples and normal samples by chi-square test. The protein level of 
SIPA1 among the adenocarcinoma, squamous cell carcinoma and others are shown. 
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Score 0 2 3 4 5 6 all 
Adenocarcinoma 12 9 7 3 3 1 35 
Squamous cell carcinoma 21 4 5 1 1 1 33 
all 33 13 12 4 4 2 68 
Figure 3.8.2: Frequency analysis of each IHC score in adenocarcinoma and 
SCC samples by chi-square test. The protein level of SIPA1 between the 
adenocarcinoma and squamous cell carcinoma are shown. 
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Score 0 2 3 4 5 6 all 
Adenocarcinoma 12 9 7 3 3 1 35 
Other 25 9 4 2 0 0 40 
all 37 18 11 5 3 1 75 
Figure 3.8.3: Frequency analysis of each IHC score in adenocarcinoma samples 
and other lung cancer samples by chi-square test. The protein level of SIPA1 
between the adenocarcinoma and others are shown.  
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Score 0 2 3 4 5 6 all 
Squamous cell carcinoma 21 4 5 1 1 1 33 
Other 25 9 4 2 0 0 40 
all 46 13 9 3 1 1 73 
Figure 3.8.4: Frequency analysis of each IHC score in SCC samples and other 
lung cancer samples by chi-square test. The protein level of SIPA1 between the 
squamous cell carcinoma and others are shown. 
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Score 0 2 3 4 5 6 all 
Adenocarcinoma 12 9 7 3 3 1 35 
Normal 6 2 4 0 0 0 12 
all 18 11 11 3 3 1 47 
Figure 3.8.5: Frequency analysis of each IHC score in adenocarcinoma samples 
and normal samples by chi-square test. The protein level of SIPA1 between the 
adenocarcinoma and normal tissue are shown. 
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Score 0 2 3 4 5 6 all 
Squamous cell carcinoma 21 4 5 1 1 1 33 
Normal 6 2 4 0 0 0 12 
all 27 6 9 1 1 1 45 
Figure 3.8.6: Frequency analysis of each IHC score in SCC samples and normal 
samples by chi-square test. The protein level of SIPA1 between the squamous cell 
carcinoma and normal are shown. 
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3.3.4 SIPA1 in relation to the pathological tumour staging and clinical 
features of lung cancer 
The transcript level of SIPA1 in stage T-3 lung cancer was statistically significantly 
higher than that in stage T-1 and T-2 tumours (Figure 3.9). Comprehensive analysis 
of the TNM stage of the lung cancers, showed that TNM2 tumours had higher SIPA1 
transcript levels than for stage TNM1 tumours (Figure 3.10). SIPA1 transcript levels 
in TNM2-3-4 stage was comprehensively higher than in the TNM1 tumours, but the 
difference was not statistically significant. SIPA1 levels in Stage 1A and 1B tumours 
were lower than those in stage 2B which had increased metastasis; and the difference 
was statistically significant (Figure 3.11).  
To evaluate the protein level of SIPA1 in different stages of lung cancer, IHC was 
carried out and scored using a lung cancer TMA. Results showed that differences in 
SIPA1 levels did not reach statistical significance amongst T-1 to T-4 tumours (Figure 
3.12).  
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Stage T-1 T-2 T-3 
Sample numbers 21 57 29 
Median 17.3 21 50 
MIN-Max 2.9-260.6 2-6023 2-5151 
Q1-Q3 4.2-63 9-65 20-168 
p value to T-3 0.014 0.0381 NA 
Figure 3.9: Transcript level of SIPA1 in different T stage lung cancer. The 
transcript level of SIPA1 among the T-1, T-2 and T-3 stage of lung cancer are shown. 
(SIPA1 level was evaluated by copy numbers/50ng RNA). * p<0.05 by Mann-Whitney 
U test. 
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Stage TNM1 TNM2 TNM2-3-4 
Sample numbers 39 31 83 
Median 17.32 52.1 26.34 
MIN-Max 2.4-1185.2 4-5151 0-6023 
Q1-Q3 6.9-59.7 20-189 12-94 
p value to TNM1* NA 0.0053 0.0554 
Figure 3.10: Transcript level of SIPA1 in different TNM stage lung cancer. The 
transcript level of SIPA1 among the TNM1, TNM2 and TNM2-3-4 stage of lung cancer 
are shown. (SIPA1 level was evaluated by copy numbers/50ng RNA). * p<0.05 by 
Mann-Whitney U test. 
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Stage TNM1A TNM1B TNM2B 
Sample numbers 21 57 29 
Median 17.3 21 50 
Max 2.9-260.6 2-6023 2-5151 
Q3 4.2-63 9-65 20-168 
P value to TNM2B 0.0108 0.0356  
Figure 3.11: Transcript level of SIPA1 in different stage lung cancer. The 
transcript level of SIPA1 among the stage 1A, 1B and 2B of lung cancer are shown. 
(SIPA1 level was evaluated by copy numbers/50ng RNA). * p<0.05 by Mann-Whitney 
U test. 
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Score 0 2 3 4 5 6 all 
T1 4 4 2 1 1 0 12 
T2 27 7 6 2 0 1 43 
T3 11 9 6 1 1 1 29 
T4 4 0 0 1 1 0 6 
ALL 46 20 14 5 3 2 90 
Figure 3.12: Frequency analysis of the each IHC score various T stage samples 
by chi-square test. The protein level of SIPA1 among the stage T1, T2, T3 and T4 
of lung cancer are shown.  
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3.3.5 Correlation between SIPA1 expression and clinical outcome of the 
patients in the Peking cohorts  
Patients were divided into two groups according to the transcript expression level of 
SIPA1, with a cut-off at 25 copy numbers/50ng RNA, the median level of the tumour 
group. Overall survival was analysed using SPSS and the result is shown in Figure 
3.13. Kaplan-Meier survival analysis revealed that patients with a high expression 
level of SIPA1 had lower overall survival of 48.3 months (95%C.I. 40.7 – 55.9 months), 
compared to 55.9 months (95%C.I. 48.5 - 63.2 months) of patients with low 
expression level of SIPA1. However, the data did not reach statistical significance 
(p=0.204).  
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Total Events Censored Meana (months) 
N N N Percent Estimate 
Std. 
Error 
95% C.I. 
Lower 
Bound 
Upper 
Bound 
Low 
level 
55 19 48 76.2% 55.874 3.748 48.529 63.219 
High 
level 
118 34 36 65.5% 48.307 3.892 40.678 55.936 
Overall 118 34 84 71.2% 52.635 2.786 47.175 58.095 
Figure 3.13: The Kaplan-Meier survival model of correlation between SIPA1 
transcript levels and overall survival. Using 25, the median in the tumour group, 
as the cut-off to divide patients into two groups with high and low SIPA1 level.  
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Here, we carried out another analysis using a publicly available database, kmplot, 
that allows comparisons of tissue gene transcript information of patients from various 
cohorts available from (http://kmplot.com/analysis/index.php?p=background). In line 
with the analysis of our cohort, the analysis has also used the median as the cut-off 
to divide the patients into two groups. In all of the lung cancer patients, SIPA1 was 
statistically correlated with post-progression survival (PPS) (p=0.02) (Figure 3.14). 
Patients with higher SIPA1 levels correlated with poor prognosis in terms of post 
progression survival (PPS). There was no statistical correlation of SIPA1 expression 
level with overall survival (OS) (p=0.46) or progression-free survival (PFS) (p=0.071) 
(Figure 3.15).  
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Figure 3.14: The Kaplan-Meier survival model of correlation between SIPA1 
transcript levels and post-progression survival (PPS) in all lung cancer patients 
(available from http://kmplot.com/analysis/index.php?p=background ). The median 
was chosen as the cut-off to divide the patients into high and low groups.  
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Figure 3.15: The Kaplan-Meier survival model of correlation between SIPA1 
transcript levels and prognosis: overall survival (OS), progression-free survival 
(PFS) in all lung cancer patients (available from 
(http://kmplot.com/analysis/index.php?p=background ). (A) Overall survival (OS) (B) 
progression-free survival (PFS). The median was chosen as the cut-off to divide the 
patients into high and low groups. 
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Analysis was carried out to explore the correlation between SIPA1 levels and lung 
cancer patient prognosis in regards to the main histological types of lung cancer, 
namely adenocarcinoma and squamous cell carcinoma using the data from the 
Peking cohort. The result based on the Peking cohort showed that in patients with 
adenocarcinoma, those with a low level of SIPA1 tended to have longer survival, 
whilst in squamous cell carcinoma patients, those with a low level of SIPA1 tended 
toward a worse prognosis (Figure 3.16). However, due to the limitation of the sample 
size and the loss of follow-up data, neither of the subgroups showed statistical 
significance (p=0.115 and 0.292 in adenocarcinoma and squamous carcinoma 
respectively).  
To further explore the relationship between SIPA1 and lung cancer prognosis, survival 
data of patients with different histological lung cancers from the Kaplan Meier plotter 
website (http://kmplot.com/analysis/index.php?p=background) were analysed. In 
lung adenocarcinoma patients (Figures 3.17-3.19), high SIPA1 level was 
accompanied by a poor outcome of cancer in terms of both OS (p=0.0021) and PFS 
(p=0.0065). However, according to PPS, the trend was the same but the result was 
not statistically significant (p=0.17). In lung squamous cell carcinoma, the correlation 
between SIPA1 level and patients’ prognosis was established (Figure 3.20).  
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A Total Events Censored B Total Events Censored 
N N N Percent N N N Percent 
0 (low level) 31 5 26 83.90% 0 25 7 18 72.00% 
1 (high level) 27 13 14 51.90% 1 22 3 19 86.40% 
Overall 58 18 40 69.00% Overall 47 10 37 78.70% 
Figure 3.16: The Kaplan-Meier survival model of correlation between SIPA1 transcript levels and overall survival in various histology 
of lung cancer. (A) The correlation in adenocarcinoma. (B) The correlation in squamous cell carcinoma. a. Estimation is limited to the largest 
survival time if it is censored. Using 25, the median in the tumour group, as the cut-off to divide patients into two groups with high and low SIPA1 
level.  
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Figure 3.17: The Kaplan-Meier survival model of correlation between SIPA1 
transcript levels and overall survival (OS) in lung adenocarcinoma patients 
(available from http://kmplot.com/analysis/index.php?p=background ). The median 
was chosen as the cut-off to divide the patients into high and low groups. 
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Figure 3.18: The Kaplan-Meier survival model of correlation between SIPA1 
transcript levels and progression-free survival (PFS) in lung adenocarcinoma 
patients (available from http://kmplot.com/analysis/index.php?p=background ). The 
median was chosen as the cut-off to divide the patients into high and low groups. 
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Figure 3.19: The Kaplan-Meier survival model of correlation between SIPA1 
transcript levels and post-progression survival (PPS) in lung adenocarcinoma 
patients (available from http://kmplot.com/analysis/index.php?p=background ). The 
median was chosen as the cut-off to divide the patients into high and low groups. 
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Figure 3.20: The Kaplan-Meier survival model of correlation between SIPA1 
transcript levels and overall survival (OS), progression-free survival (PFS) and 
post-progression survival (PPS) in lung squamous cell carcinoma patients 
(available from http://kmplot.com/analysis/index.php?p=background ). (A) Overall 
survival (OS). (B) Progression-free survival (PFS). (C) Post-
progression survival (PPS). The median was chosen as the cut-off to divide the 
patients into high and low groups. 
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3.4 Discussion 
During the past decade, it was revealed, within the scope of limited literature, that 
SIPA1 may have a role to play in the progression of various cancers (Takahara et al., 
2017, Zhang et al., 2015, Brooks et al., 2010). A small number of studies investigated 
the expression level of SIPA1 in human tumours. Previous research by Takahara et 
al., demonstrated that SIPA1 level was upregulated in human oral squamous cell 
carcinoma compared with normal tissue by using IHC staining of the SIPA1 protein 
(Takahara et al., 2017). In prostate cancer, Gleason scores of IHC staining of SIPA1 
was found to be positively correlated with tumour progression and metastasis 
(Shimizu et al., 2011). Detecting the nuclear expression of SIPA1 in breast cancer 
tissue by IHC staining was also shown to predict lymph node metastasis (Zhang et 
al., 2015). These are very important indicators of a potential role for SIPA1 in human 
tumours.  
However, studies examining the role of SIPA1 in lung cancer are very few and the 
correlation between SIPA1 and clinical outcome in lung cancer is not at all clear. In 
this study we evaluated SIPA1 expression level in a clinical cohort consisting of 148 
lung tumour tissue samples with 148 adjacent normal tissue samples, of which 139 
tumour tissues were paired. SIPA1 transcript levels were higher in 148 tumour tissues 
compared with normal tissue (p=0.0141), and the same was seen in 139 tumour 
tissues compared with the paired normal tissue (p=0.0358). Thus, this dataset 
established that at the message RNA level, SIPA1 is more highly expressed in 
tumours compared with normal lung tissues.  
IHC staining and scoring of the lung tumour TMA was far less convincing. The protein 
level of SIPA1 in tumour tissue samples was higher than that in normal lung tissues 
and adjacent normal lung tissues, but the difference was not statistically significant. 
There are some possible reasons which can account for why the SIPA1 gene 
transcripts analysis result and the SIPA1 protein analysis result cannot be completely 
matched.  
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• Firstly, cohorts and composition of the cohort. Our clinical cohort is larger and 
most importantly has substantially more normal tissues than the TMA cohort (148 
vs 12, our cohorts vs TMA). This would undoubtedly contribute to the statistical 
power of the TMA cohorts, making it difficult to draw a solid conclusion.  
• Secondly, the nature of the samples. Whilst our cohort is fresh frozen and we 
were able to determine SIPA1 message quantitatively, the TMA however is an 
archival collection and only allows qualitative analysis. Of course, the size of the 
cohort and in particular that of the normal tissues in the cohort makes it less than 
ideal to appraise.  
• Thirdly, the present study cannot exclude the possibility of discrepancies 
between gene transcription and protein translation for SIPA1.  
• Fourthly, the evaluation of protein in this project is performed by IHC staining and 
scoring, which is more subjective whereas RNA extraction and analysis is a more 
specific, robust and reproducible laboratory technique. 
Nonetheless, in terms of tumorigenesis, clinical cohort data demonstrated that the 
transcript level of SIPA1 was higher in advanced T stage, TNM stage and stage 
grouping with statistical significance. Scoring of IHC staining showed a statistically 
significant result in T stage but there was not a clear trend between SIPA1 level and 
tumour development. It is very interesting to note that the present study and those 
from the independent cohort (KMplot) were able to establish a clear correlation 
between SIPA1 transcript expression and the clinical outcome of the patients with 
lung cancer. Kaplan-Meier survival model from the data of our clinical cohort showed 
that patients with highly expressed SIPA1 had a lower overall survival of 48.3 months 
compared to 55.9 months of patients with low level of SIPA1. While the result did not 
reach statistical significance, this is highly likely due to the size of the cohort. The 
data available from the KM-plotter website 
(http://kmplot.com/analysis/index.php?p=background), with a larger cohort, showed 
the same statistically significant trend between SIPA1 and the post-
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progression survival (PPS) of lung cancer statistically. Collectively, these data show 
that SIPA1 transcript levels are linked to the disease progression and clinical outcome 
of the patients with lung cancer. 
The role of SIPA1 in different histological types of lung cancer is of great interest. 
Overall, both cohorts have indicated that SIPA1 has a significant role to play in the 
progression of adenocarcinoma of the lung. In lung adenocarcinoma, a high level of 
SIPA1is associated with both shorter overall survival (OS) and shorter progression-
free survival (PFS) statistically significantly. The correlation of SIPA1 and patient 
prognosis in lung squamous cell carcinoma is not clear and lacked statistical 
significance.  
Taking all the data together, we found that in lung cancer, especially in 
adenocarcinoma, the expression of SIPA1 was increased and that high expression 
level of SIPA1 correlated with prognosis of lung cancer patients. Moreover, SIPA1 
levels were upregulated in advanced developed tumour compared with initially 
developed tumours, which demonstrated that SIPA1 may have an essential role in 
tumorigenesis.  
After analysing the data from the clinical cohorts, we are now left with a new set of 
questions:  
• Why SIPA1 was upregulated in lung cancer?  
• Why was SIPA1 correlated with the development of lung tumour?  
• What is the mechanism of SIPA1 involved in the tumorigenesis and metastasis?  
• How do SIPA1 and the HGF/MET connect in the intracellular signalling?  
The subsequent work in this thesis will aim to answer these questions.  
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expression on the cellular function 
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4.1 Introduction 
SIPA1 was first cloned from a murine lymphoid cell line (Hattori et al., 1995) and 
human peripheral blood lymphocytes (PBL) (Kurachi et al., 1997) and is highly 
expressed in lymphohematopoietic tissues (Hattori, 2011). In recent years, SIPA1 
was found to be abundantly expressed in solid tumours, although the levels of SIPA1 
expression level varies in different tumour cell lines. In breast cancer, expression of 
SIPA1 is highly expressed in MDA-MB-231 cells compared with MCF7 cells both at 
mRNA level and protein level (Zhang et al., 2015). The two human colorectal cancer 
cell line, HT115 and Caco-2, have high expression level of SIPA1 in terms of mRNA 
(Ji et al., 2012). Nine human oral squamous cell carcinoma (OCSS) HSC-2, HSC-3, 
HSC-4, Sa3, Ca9-22, SAS, KOSC-2, Ho-1-u-1 and Ho-1-N-1 all have a high 
expression level of SIPA1 compared to human normal oral keratinocytes HNOKs 
(Takahara et al., 2017). In prostate cancer, PC3 cells which have a high invasive 
potential showed highly upregulated expression of SIPA1 when compared with that 
in LNCaP cells which have a lower SIPA1 level and are less invasive (Shimizu et al., 
2011). SIPA1 knockdown or over-expression models in tumour cell lines have been 
established by distinct methods. In previous studies, shRNA was used to knockdown 
SIPA1 in human breast cancer MDA-MB-231 cells (Zhang et al., 2015), human 
prostate cancer PC-3 cells (Shimizu et al., 2011) and human OSCC HSC-3 and HSC-
4 cells (Takahara et al., 2017). SiRNA was used to suppress SIPA1 in the aggressive 
human melanoma cell line VM-1 (Mathieu et al., 2012) and ribozyme technology was 
used to target SIPA1 in the human colorectal cancer cell lines HT115 and Caco-2 (Ji 
et al., 2012).  
It has been shown that overexpression and knockdown of SIPA1 in cancer cell lines 
resulted in changes in the cellular function of these cancer cells. In vitro cell function 
experiments showed that knocking down of SIPA1 reduced adhesion, migration and 
invasion in the human breast cancer MDA-MB-231 cell line (Zhang et al., 2015). In 
vivo metastasis experiments revealed that SIPA1 was positively correlated with the 
invasion potential of prostate cancer cells (Shimizu et al., 2011). In the OSCC cell 
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line HSC-3 and HSC-4, knocking down SIPA1 reduced the invasion and migration 
ability of cells but increased the adhesion of cells, with no significant change on 
proliferation potential (Takahara et al., 2017).  
The number of studies on the mechanism of SIPA1 in cancer is insufficient to provide 
a categorical theory as to its role, with most studies being focused on the effect of 
SIPA1 on the invasion potential of cancer cells. In the host laboratory and at the 
preliminary phase of the present study, it was noted causal changes of barrier 
junction function following SIPA1 knock down in breast cancer cells, in that loss of 
SIPA1 in breast cancer cells resulted in a marked alteration of barrier electric 
resistance in these cells (Martin and Jiang 2013). Tight junctions have an essential 
role in cancer development and metastasis. In chapter 3, we found the intimate link 
between SIPA1 and its clinical relevance in lung cancer. In this present chapter we 
explore the influence of SIPA1 on cellular functions related to cancer cell metastasis 
as well as to the function of TJs, following the establishment of SIPA1 knock-down 
lung cancer cell models.  
 
4.2 Material and methods  
4.2.1 Cell lines  
A549, SKMES1 and CORL23 lung cancer cell lines were used in this study to set up 
the SIPA1 knockdown cell model. A549 and SKMES1 cell lines were cultured in 
DMEM medium with 10% FBS and antibiotics and CORL23 cell line was cultured in 
RPMI-1640 medium with 10% FBS and antibiotics. Detailed information of these cell 
lines is described in section 2.1.1. Cell culture, maintenance and storage is described 
in section 2.3.  
 
4.2.2 Knockdown of SIPA1 by using ribozyme transgene  
Anti-SIPA1 ribozyme transgenes were constructed as described in section 2.6. Briefly, 
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SIPA1 ribozymes were amplified using 2× GoTaq G2 Green PCR master mix 
(Promega, Southampton, UK). The ribozyme sequence was then cloned into the 
pEF6/V5-His TOPO TA plasmid to produce the SIPA1-KD plasmid utilising the 
pEF6/V5-His TOPO TA expression kit (Invitrogen, Life technologies, Paisley, UK). 
The plasmid was transferred into the TOP10 Chemically Competent Escherichia. coli.  
The colonies for amplification and purification were selected by ampicillin. Correct 
colonies of the plasmids detected by RT-PCR using T7F primer coupled either with 
RbBMR and RbTPF primers were extracted utilising the Promega Plasmid MidiPrep 
Kit. Anti-SIPA1 ribozyme knockdown (SIPA-KD) plasmid together with pEF6/V5-His 
TOPO TA control (pEF-CT) plasmid were transformed into lung cancer cell lines via 
electroporation. The transfected cells were selected in medium containing 5-10μg/ml 
blasticidin and maintained in medium containing 0.5μg/ml blasticidin for further 
experimentation.  
 
4.2.3 Primers and antibody 
All the primers used were synthesised and provided by Invitrogen (Paisley, UK). 
Primer sequences are shown in Table 2.3 and 2.4. Mouse anti-SIPA1 antibody 
(ab219085) was obtained from ABCAM (Cambridge, UK). The name, molecular 
weight, supplier, and the product code of the primary and secondary antibodies used 
in this chapter is shown in Table 2.5.  
 
4.2.4 RNA extraction, RT-PCR, and QPCR  
The RNA was extracted by using Tri Reagent as described in section 2.8.1. After the 
isolation of RNA was completed, the quantification of RNA was carried out as 
described in section 2.8.2, followed by RT-PCR to obtain the cDNA. The cDNA could 
then be used for PCR and QPCR as describes in section 2.4.3 to 2.4.6.  
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4.2.5 Potein extraction, SDS-PAGE, and western blot analysis  
The extraction of protein was carried out as the description in section 2.5.1. Proteins 
were extracted using lysis buffer and then quantified using the Bio-Rad DC Protein 
Assay kit (Bio-Rad Laboratories, Hemel-Hempstead, UK). After separation in the 
SDS-PAGE gel, proteins were transferred onto PVDF membranes as described in 
section 2.5.2. The membranes with protein were subsequently blocked and probed 
with various primary antibody and a corresponding peroxidise-conjugated secondary 
antibody. The antibodies’ information in this study is shewed in Table 2.5. Finally, the 
protein bands on the membrane were visualised using the chemiluminescence 
detection kit (Luminata, Millipore).  
 
4.2.6 In vitro cell growth assay  
Due to the difference growth speed between different cell lines, 3,000 - 5,000 cells 
were seeded into 200μl medium in three 96-well plates appropriately. After incubation 
for 1, 3, and 5 days respectively, the cells were fixed and stained by crystal violet. 
The absorbance was measured after dissolving the crystal violet with acetic acid (10% 
v/v) and the absorbance was determined at a wave length of 560nm using a 
spectrophotometer (BIO-TEK, Elx800, UK). 
 
4.2.7 In vitro cell invasion assay  
20,000-40,000 cells were seeded into transwell inserts (pore size, 8μm, Millicell, 
Merck KGaA, Darmstadt, Germany) coated with 50μg Matrigel. After the incubation 
of three days, cells that had invaded through the Matrigel and migrated on to the other 
side of the insert were fixed and stained with crystal violet and then counted. The 
absorbance was measured after dissolving the crystal violet with acetic acid (10% v/v) 
and the absorbance was determined at a wave length of 560nm using a 
spectrophotometer (BIO-TEK, Elx800, UK). 
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4.2.8 Transepithelial Resistance (TER) and Paracellular Permeability (PCP) 
assay  
The Transepithelial Resistance (TER) and Paracellular Permeability (PCP) assay 
were performed as described in section 2.7.9. Approximately 50,000 cells in 100μl 
medium were seeded into transwell inserts (pore size, 0.4μm, Millicell, Merck KGaA, 
Darmstadt, Germany) with 1ml medium in the well outside of the insert, following the 
incubation of three days. Resistance across the membrane was measured using the 
EVOM² Epithelial Voltohmmeter (World Precision Instruments, Hitchin, Hertfordshire, 
UK).  
 
4.2.9 Electric Cell-Substrate Impedance Sensing (ECIS)  
ECIS assay to detect the resistance of cells was performed as described in section 
2.7.8. 50,000 cells were seeded in the 96W1E+ electrode array plate after 
stabilization, following with measurement over different frequencies were to study 
different functional and structural cell properties. Resistance was measured between 
1,000-4000Hz. Increased resistance of confluent cell monolayers implies increased 
cell-cell adhesion and hence increased barrier function.  
 
4.2.10 Statistical Analysis  
In this session, t-tests and Mann-Whitney test were performed using the Graphpad 
Prism 6 software. Image J software was sued to analyse the PCR and western 
blotting bands. The results of the ECIS assay was analysed using the ECIS software. 
Differences were considered to be statistically significant when p<0.05.  
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4.3 Result 
4.3.1 Knockdown of SIPA1 in lung cancer cell lines 
Anti-SIPA1 ribozyme transgenes were used to knockdown SIPA1 in SKMES1, 
CORL23 and A549 lung cancer cell lines. PCR, QPCR and western blot were 
performed to detect the knockdown of SIPA1 in both mRNA level and protein level. 
As shown in Figures 4.1-4.3, SIPA1 was successfully knocked down at both 
message RNA (Figures 4.1 and 4.2) and protein levels (Figure 4.3) in all three cell 
lines.  
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Figure 4.1: Verification of the knockdown of SIPA1 in SKMES1, CORL23 and 
A549 cell lines in mRNA level using PCR. A. The mRNA level of SIPA1 knockdown 
in SKMES1, CORL23 and A549 lung cancer cell lines was examined using 
conventional PCR. B. Quantitative analysis of the PCR bands.  
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Figure 4.2: Verification of the knockdown of SIPA1 in SKMES1, CORL23 and 
A549 cell lines in mRNA level using QPCR. A. The mRNA level of SIPA1 
knockdown in SKMES1 cell lines was examined using QPCR. B. The mRNA level of 
SIPA1 knockdown in CORL23 cell lines was examined using QPCR. C. The mRNA 
level of SIPA1 knockdown in A549 cell lines was examined using QPCR. Error bars 
show SD.    
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Figure 4.3: Verification of the knockdown of SIPA1 in A549, SKMES1, and 
CORL23 cell lines in protein level using western blot. A. The protein level of 
SIPA1 knockdown in A549 cell lines was examined using western blot. B. The protein 
level of SIPA1 knockdown in SKMES1 cell lines was examined using western blot. C. 
The protein level of SIPA1 knockdown in CORL23 cell lines was examined using 
western blot. Image J software was used to analyse the bands quantitatively. Error 
bars show SD.  
 
  
169 
4.3.2 Impact of SIPA1 on proliferation potential of lung cancer cells 
The effect of SIPA1 knockdown on the proliferation of A549 cell lines was first 
evaluated by an in vitro growth assay (Figure 4.4). Results both after 3 days and 5 
days indicated that SIPA1 knockdown significantly decreased the proliferation 
potential of the A549 cells.  
 
 
Figure 4.4: Knockdown of SIPA1 decreased the growth of the A549 cells 
significantly. Cells were incubated for 1, 3, and 5 days respectively and eight-well 
repeats were included. Growth rate (%) = Absorbance (Day 1, 3, 5) / Absorbance 
(Day 0) × 100. Error bars show SD.  
 
4.3.3 Impact of SIPA1 on invasion potential of lung cancer cells 
In vitro trans-well invasion assay was performed to investigate the effect of SIPA1 on 
the invasion function of lung cancer cell lines. Result showed the invasion potential 
was markedly reduced after knockdown SIPA1 in A549 and SKMES1 lung cancer cell 
lines (Figure 4.5).  
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Figure 4.5: Knockdown of SIPA1 decreased the invasion of the A549 and SKMES1 cells significantly. Representative images of A549 
invaded cells after staining (upper) and the absorbance measured by dissolving the crystal violet from stained invaded cells. (B) Representative 
images of SKMES1 invaded cells after staining (upper), bar graph shows the measurement of numbers of invaded cells. Error bars show SD.  
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4.3.4 Impact of SIPA1 on tight junction of lung cancer cells 
To measure the change of barrier and TJ function on lung cancer cells after 
knockdown of SIPA1, two independent methods were employed, namely electric cell-
substrate impedance sensing (ECIS) assay and trans-epithelial electric resistance 
(TER). ECIS can provide data on barrier function of a confluent cell monolayer; TER 
is a well-known method for investigating resistance across cell layer that is directly 
related to TJ function. The data from the ECIS assay showed knockdown SIPA1 in 
A549 cells enhanced cell-cell barrier function significantly (Figure 4.6.A). 3D figure 
showed the impact of SIPA1 on TJ via various frequencies (Figure 4.6.B), and 
quantitative analysis of the resistance when cells formed the monolayer between time 
point 1.5 to 2.5 hours showed that SIPA1 knockdown effected statistically significant 
differences in the barrier function of these cells (Figure 4.6.C). The TER experiment 
results showed similar findings: knockdown of SIPA1 enhanced cell-cell TJ compared 
to WT-CT and pEF-CT group in the A549 cell line (Figure 4.7).  
 
 
Figure 4.6.A: Knockdown of SIPA1 increased the cell-cell tight junction of the 
A549 cells significantly. Measurement the change of the resistance during a period 
of 2.5 hours after cells seeded in the plate. 1000Hz frequency was chosen to analyse 
cell resistance referring to the function of tight junction. *** represents p<0.001, Error 
bars show SD.  
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Figure 4.6.B: 3D figure showed knockdown of SIPA1 increased the cell-cell tight junction in different frequencies. Left: A549 SIPA1-KD 
cells. Right: A549 pEF-CT cells. The change of normalised resistance of A549 SIPA1-KD cells was significantly higher than that in A549 pEF-CT 
cells.  
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Figure 4.6.C: The effect of SIPA1 in enhancing tight junction is statistically 
significant. Quantitative analysis of the change of resistance of the data from 4 time 
points between 1.5 and 2.5 hours showed the change of TJ was significant 
statistically (p<0.001).  
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Figure 4.7: The Effect of SIPA1 Knockdown on A549 cell line detected using 
Transepithelial Resistance (TER). Knockdown of SIPA1 enhanced cell-cell TJ 
significantly. Error bars show SD.  
  
175 
4.4 Discussion  
As mentioned above, expression of SIPA1 was higher in lung tumour tissue and the 
high level was correlated to the malignant phenotype of tumours and poor prognosis 
in lung cancer patients. We therefore determined to investigate the impact of SIPA1 
on the function of lung cancer cells, as well as on tight junction function and 
component expression. Similarly to the knockdown of SIPA1 in breast cancer (Zhang 
et al., 2015), prostate cancer (Shimizu et al., 2011) and OSCC (Takahara et al., 2017), 
knockdown SIPA1 in lung cancer cells decreased the invasive potential of cancer 
cells. Invasion is an essential part of tumour metastasis and is one of the main causes 
of secondary disease and poor prognosis (Hanahan and Weinberg, 2011, Valastyan 
and Weinberg, 2011). The correlation between the high expression level of SIPA1 in 
lung cancer and the malignancy of the tumour and poor prognosis may be related to 
the demonstration that SIPA1 promotes the invasion of lung cancer, resulting in a 
poor patient outcome. Meanwhile, SIPA1 increases the propensity of lung cancer 
cells to grow and tumour growth is another crucial feature of malignant disease. In 
breast cancer or OSCC, previous studies showed that the promotion of SIPA1 for 
tumour growth and invasion was correlated with ITGB1, Brd4 and MMP (Takahara et 
al., 2017, Zhang et al., 2015).  
Gradually, increasing studies demonstrated the essential role of TJs in cancer 
metastasis and the function of TJ proteins was not only pertinent in forming the 
structure of TJs but in various aspects such as extracellular signal transduction, cell 
morphology maintenance, participating intracellular signalling pathway, etc. (Martin, 
2014, Tracey A. Martin, 2013, Chiba et al., 2008). Previous studies showed that the 
expression patterns of Claudin1 and Claudin5 were highly disparate between lung 
squamous cell carcinomas and lung adenocarcinomas: Claudin1 was positive in lung 
squamous cell carcinomas and Claudin5 was negative, whereas adenocarcinomas 
were positive for Claudin5 and negative for Claudin1 (Paschoud et al., 2007). 
Claudin1 had confirmed expression in small cell lung cancer in more than 80% of 
tumour tissues assessed (Liu et al., 2007) . An early study of 68 lung cancers and 
  
176 
adjacent normal lung tissue showed that Occludin stained strongly in normal lung 
tissue (Tobioka et al., 2004).  
In this current study, barrier and TJ function of the cells was evaluated using ECIS 
and TER and PCP assays, with all the results from these assays showing that SIPA1 
knockdown enhanced the TJs of lung cancer cells both at total barrier function (ECIS) 
and at the transcellular and paracellular pathways. The TJ is the first barrier during 
cancer metastasis to overcome. The TJ provides the barrier to which cancer cells 
must overcome in order to (a) dissociate from the primary tumour; (b) intravasate; (c) 
extravasate at a secondary tumour site. If the TJ is either weak (so-called ‘leaky’ 
barriers) or dismantled (either by down regulation of vital TJ components, erroneous 
gene expression leading to truncated TJ proteins or changes in phosphorylation 
status) then cancer cells are able to undergo cancer spread. Conversely, 
strengthening of the TJ’s can lead to less cancer spread. The enhanced function of 
TJs in cancer cells after knockdown of SIPA1 indicates a decrease in cancer cell 
metastatic phenotype and was consistent with the correlation of SIPA1 with poor 
prognosis in patients with lung cancer. In essence, we can deduct from these data 
that SIPA1 is an essential driver in lung cancer development and metastasis, which 
can promote the proliferation, invasion of lung cancer and may accomplish this by 
mediating decreases in integrity of the TJs of lung cancer cells.  
Thus, the findings presented in this chapter strongly indicate that expression of SIPA1 
in lung cancer cells is closely related to the expression of TJ molecules and the barrier 
functions of the cells. This leads us to a new set of questions:  
• How does SIPA1 participate in the signalling events inside lung cancer cells and 
in particular to the events involved in the TJ signalling and indeed signalling that 
regulate cell migration and invasion?  
• Does SIPA1 form an integral part of the chain events of TJs/cell migration 
triggered by external factors, such as hepatocyte growth factor (HGF), a factor 
known to disrupt TJs and be one of the most powerful mitogens and indeed 
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indicated to have a role to play in SIPA1 related cell functions (Jiang, 2006, Jiang, 
2013).  
These further investigations will be presented in the following chapter. 
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Chapter-5 SIPA1 and its 
intracellular signalling pathways in 
human lung cancer cells 
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5.1 Introduction 
SIPA1 has been shown to play an important role in many kind tumours, like breast, 
gastric, cervical cancer, OSCC, colorectal cancer, and prostate cancer (Takahara et 
al., 2017, Li et al., 2017, Yi and Li, 2014, Pei et al., 2013, Ji et al., 2012, Shimizu et 
al., 2011). Our in vitro function research confirmed that knockdown of SIPA1 could 
inhibit the proliferation, invasion and increase the barrier function of lung cancer cells, 
which is consistent with the high expression of SIPA1 in tumour tissues compared to 
normal lung tissue in our clinical cohorts. Therefore, the specific mechanism of SIPA1 
knockdown on cell function is worthy of deeper investigation to help study the 
mechanism of tumour metastasis and guide future clinical solutions. Correlation of 
SIPA1 and HGF/MET signalling pathway in breast cancer and prostate cancer was 
demonstrated by the host lab. Based on the previous study we found that in breast 
cancer cells SIPA1 is involved in the regulation of HGF on tight junctions (Jiang, 2013, 
Jiang, 2006). Lacking SIPA1, the breast cancer cell line MDA-MB-231 showed low 
reaction to the stimulation of HGF compared to wide type control cells. Therefore, we 
hypothesized that in lung cancer, SIPA1 also regulates cell aggressive behaviours 
through the interaction with HGF/MET signalling pathway to cause lung cancer 
development and metastasis. 
HGF is known as a typical mitogen which could promote the motility, proliferation and 
invasion of the cells during the embryonic development, liver regeneration and cancer 
metastasis (Gherardi et al., 2012, Trusolino et al., 2010, Martin et al., 2004). Many 
studies have shown that the HGF/MET signalling pathway is constantly high 
expressed in primary cancer and  their metastases and this aberrant expression 
correlates with poor prognosis (Martin et al., 2001, Jiang et al., 1999). In cancer, MET 
signalling pathway activation most often occurs through the ligand-dependent binding 
mechanism of HGF. Many types of cancer often overexpress MET, but the ligand is 
not expressed by the tumour cells, but in the extracellular matrix. Therefore, 
HGF/MET signalling pathway is often paracrine activated (Birchmeier et al., 2003b, 
Martin et al., 2001). The binding of activated HGF to MET induces 
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autophosphorylation of the Tyr residues Y1234 and Y1235 on the MET protein, then 
the kinase domain of the dimerized receptor is activated as a consequence, resulting 
in increasing the catalytic activity. Subsequently, phosphorylation of the Tyr residues 
Y1349 and Y1356 at the C-terminal fragment produces a binding site for those 
proteins which contain a Src homology 2 (SH2) domain (Trusolino et al., 2010). Signal 
effector proteins such as phosphatidylinositol 3-kinase (PI3K), phospholipase C 
gamma (PLCγ), the non-receptor tyrosine kinase Src and signal transducer and 
activation of transcription 3 (STAT3) can attach to the binding domain of MET. 
Meanwhile, some scaffolding adapters such as growth factor-bound protein (GRB2), 
GRB2-associated binding protein 1 (GAB1), and SH2 domain-containing 
transforming protein (SHC) can also be recruited by MET and linked to the binding 
site, becoming the new binding sites for other molecules (Trusolino et al., 2010). The 
downstream of HGF/MET includes RAS-RAF-MEK-ERK/MAPK, PI3K-Akt, Rap, and 
Rac-Pak signalling pathways, resulting in changes of cancer cell proliferation, survival, 
with complex cell mitogenic and morphogenic features (Trusolino et al., 2010, 
Birchmeier et al., 2003b).   
Since SIPA1 can regulate the function of tumour cells and the response to HGF, 
HGF/MET signalling pathway may be the key point for SIPA1 regulation of tumour 
cells. HGF/MET signalling is an essential part of the control of tight junction function 
(Martin, 2014). HGF/MET signalling is also an important member of the receptor 
tyrosine kinase (RTK) signalling pathway, which also includes EGFR, VEGFR, IGFR, 
FGFR, etc. The RTKs family are a large and extremely complex family with similar 
functions, in which the interactions between family members, and the positive and 
negative feedback adjustments are particularly complicated (Trusolino et al., 2010). 
The complex interactions among the RTKs have been suggested to be potential 
causes of resistance to targeted therapy for lung cancer patients. The abnormal 
activity of MET is one of the most common causes of acquired resistance to EFGR-
TKI treatment, and MET amplification can be found in more than 5-22% EGFR 
targeted therapy secondary resistance cases (Wu et al., 2017). Therefore, the 
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regulation of HGF/MET signalling pathway by SIPA1 may be more than just a simple 
regulation but a complex process. Revealing more detail of the regulation of SIPA1 is 
particularly important for a better understanding of the process of cancer metastasis 
and then providing clear clinical applications.   
In this chapter, the markers known to be co-expressed with SIPA1 were investigated 
in both our Peking lung cancer cohort and TCGA database. Meanwhile, we analysed 
the intracellular signalling pathway regulated by SIPA1 and HGF/MET to find out the 
key markers and pathways involving in the interaction between SIPA1 and MET, 
aiming to find out the intracellular signalling pathways regulated by SIPA1 in human 
lung cancer cells.   
 
5.2 Methods 
5.2.1 Protein extraction  
The extraction of protein was carried out as the description in section 2.5.1. Proteins 
were extracted using lysis buffer and then quantified using the Bio-Rad DC Protein 
Assay kit (Bio-Rad Laboratories, Hemel-Hempstead, UK).  
 
5.2.2 KinexusTM protein microarray in SIPA1 knockdown A549 cancer cells 
treat with/without HGF  
Protein samples were collected from A549 lung cancer cells of PEF control and SIPA1 
knockdown using anti-SIPA1 ribozyme transgene, respectively. After protein 
extraction and subsequent quantification, 350μl lysis (4mg/ml) was prepared and 
being stored at -20°C before sending for an analysis using the KinexusTM antibody 
microarray (Kinexus Bioinformatics, Vancouver, British Columbia, Canada). 
 
5.2.3 TCGA database acquirement and statistical analysis  
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In this session, The TCGA-LUAD database was obtained from the website 
https://www.cancer.gov/about-nci/organization/ccg/research/structural-
genomics/tcga. T-tests, Mann-Whitney test and one-way ANOVA test were performed 
using the Graphpad Prism 6 software. Spearman correlation was calculated using 
SPSS software. Key signalling pathways were obtained from the Reactome website: 
www.reactome.org. Differences were considered to be statistically significant when 
p<0.05, *represents p<0.05, **represents p<0.01, *** represents p<0.001. Correlation 
was considered to be rather high when R2>0.3 or <-0.3.  
 
5.3 Results  
5.3.1 Potential connection among SIPA1, HGF signalling pathway and tight 
junctions’ components   
As discussed in the introduction, there is some evidence to indicate SIPA1 may be a 
potential downstream effector or interaction modulator of HGF and its receptor, MET 
signalling pathway (Kurachi et al., 1997, Birchmeier et al., 2003a). In this chapter, we 
delved deeper into HGF/MET-SIPA1 links and deciphered a potential link between 
SIPA1 and MET at the cellular level. Here we analysed the correlation between SIPA1, 
HGF, MET and PTK2 (Protein Tyrosine Kinase 2, or focal adhesion kinase, FAK), 
together with the MST1 (Macrophage Stimulating 1, or HGF-like Protein, HGFL, or 
Macrophage-Stimulating Protein, MSP) and its receptor, MST1R (or RON), in order 
to establish if a potential connection is present in the Peking lung cancer cohort. To 
investigate the regulation of HGF/MET-SIPA1 link on TJs, we also performed 
correlation analysis between SIPA1 and relevant TJ proteins. The dataset for HGF, 
MET, MST1, MST1R and PTK2 was only available in one of the two cohorts and the 
analysis was based on the Peking lung cancer cohort only (n=148). As shown in 
Figure 5.1, it was interesting to note that SIPA1 is highly correlated with transcript 
levels of the HGF, MET and PTK2, as well as with some TJ proteins such as JAM2, 
Marvel D2, Marvel D3, Nectin2 and some TJ regulating proteins such as RHOC, 
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ROCK1 and ROCK2. The correlation between SIPA1 and MST1/MST1R was not 
significant.  
 
 
Figure 5.1: Spearman's rank correlation coefficient between SIPA1, HGF 
related genes and tight junction component genes analysed from the lung 
cancer cohort (n=148). a. Correlation coefficients, by Spearman ranked correlation 
method. *represents p<0.05, **represents p<0.01 in 2-tailed significance test. High 
correlation was considered when R2>0.3 or <-0.3. All the detected genes were 
described using their official name from NCBI (https://www.ncbi.nlm.nih.gov/gene).  
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To further investigate the potential interaction between SIPA1 and the HGF-MET 
signalling pathway, RTK family, and their effect on TJs, we carried out the analysis 
based on the TCGA-LUAD database (Available from the website 
https://www.cancer.gov/about-nci/organization/ccg/research/structural-
genomics/tcga ). We selected HGF Activator (Hepatocyte Growth Factor Activator, 
HGFAC), HGF/MET, MST1/MST1R, ERF/EGFR, PKT2 and its antagonist PXN 
(Paxillin), together with PRKCA/PTEN, the regulator of PKT2, and SRC, the 
downstream protein of PKT2. We found all these genes were correlated with SIPA1 
in the transcriptional level with statistically significance (Figure 5.2).  
 
 
Figure 5.2: Spearman's rank correlation coefficient between SIPA1 and HGF 
related genes analysed from TCGA LUAD database (n=576). a. Correlation 
coefficients, by Spearman ranked correlation method. *represents p<0.05, 
**represents p<0.01 in 2-tailed significance test. High correlation was considered 
when R2>0.3 or <-0.3. All the detected genes were described using their official name 
from NCBI (https://www.ncbi.nlm.nih.gov/gene). 
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In another analysis on the correlation between SIPA1 and TJ components based on 
the TCGA-LUAD database (Available from the website: 
https://www.cancer.gov/about-nci/organization/ccg/research/structural-
genomics/tcga), we focused on the JAM family, Claudin family, ZO family, TAMP 
proteins, and some regulating markers such as MAGI family and ROCK, etc. The 
gene F11R (encoding JAM1 protein), the ZO family encoding genes, Claudin proteins 
encoding genes such as CLDN4, CLDN7, CLDN12, CLDN15, Marvel D3 and MAGIX 
were all highly correlated with SIPA1 in the transcriptional level (Figure 5.3).  
 
  
186 
 
Figure 5.3: Spearman's rank correlation coefficient between SIPA1 and tight 
junction component genes analysed from TCGA LUAD database (n=576). a. 
Correlation coefficients, by Spearman ranked correlation method. *represents p<0.05, 
**represents p<0.01 in 2-tailed significance test. High correlation was considered 
when R2>0.3 or <-0.3. All the detected genes were described using their official name 
from NCBI (https://www.ncbi.nlm.nih.gov/gene). 
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We collected protein samples from A549 pEF control cells and SIPA1 knockdown 
cells treated with/without HGF for the protein kinase array analysis KinexusTM 
platform. First, we obtained overall images of fluorescent-dye labelled antibody 
microarray slides, showing the overall phosphorylation intensity of the differently 
treated samples (Figure 5.4).  
 
 
Figure 5.4: Overall images of a direct fluorescent-dye labelled KAM-1325 
antibody microarray slide. A: detecting the protein sample from the A549 pEF 
control cells. B: detecting the protein sample from the A549 pEF control cells treat 
with HGF. C: detecting the protein sample from the A549 SIPA1 knockdown cells. D: 
detecting the protein sample from the A549 SIPA1 knockdown cells treat with HGF.  
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We then compared the phosphorylation status between A549 pEF control cells and 
the A549 SIPA1 knockdown cells. Table 5.1 shows the markers whose 
phosphorylation status were most decreased after SIPA1 knockdown in the A549 
cells, indicating the potential interaction markers with intercellular SIPA1. The website 
Reacome (www.reactome.org ) was used to conduct the key pathway analysis report. 
The most downregulated markers after SIPA1 knockdown could be integrated to 
numbers of centralized signalling pathways, in which the top 25 signalling pathways 
are listed in Table 5.2. Also, the genome-wide overview schematic diagram of the 
signalling pathways was generated (Figure 5.5) to show the overall review of the 
main area in which the pathways downregulated by SIPA1 are located.  
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Table 5.1: Key markers whose phosphor-status were down regulated after SIPA1 knock down on A549 cells.  
Target Name P-Site Full Target Protein Name 
Average Normalized Net Signal  
%CFC  Lead 
Control SIPA1 KD  
Rb1 T821 Retinoblastoma-associated protein 1 902 323  -64 Possible 
CRYAB S19 Crystallin aB 1307 545  -58 Possible 
GATA3 S369 
Trans-acting T-cell-specific transcription factor 
GATA-3 
1420 594 
 
-58 Possible 
GluR1 S849 Glutamate receptor 1 1261 536  -58 Possible 
GCK (MAP4K2) 
Pan-
specific 
Germinal centre protein-serine kinase 750 330 
 
-56 Possible 
PCTK2 
(PCTAIRE2, 
CDK17) 
Pan-
specific 
Cell division protein kinase 17; Protein-serine 
kinase PCTAIRE-2 
1844 861 
 
-53 Possible 
STAG2 Y433 Putative uncharacterized protein DKFZp781H1753 5391 2648  -51 Possible 
DYRK2 Y382 
Dual specificity tyrosine-phosphorylation-regulated 
kinase 2 
2816 1424 
 
-49 Possible 
ARRB1 S412 Arrestin beta 1 800 409  -49 Possible 
WNK2 
Pan-
specific 
Serine/threonine-protein kinase WNK2 1215 623 
 
-49 Possible 
SRF S224 Serum response factor 11435 5380  -53   
InsR (IR) 
Pan-
specific 
Insulin receptor 1131 635 
 
-44   
ASK1 
(MAP3K5) 
Pan-
specific 
Apoptosis signal regulating protein-serine kinase 1 2259 1414 
 
-37   
Jun (c-Jun) Y170 Jun proto-oncogene-encoded AP1 transcription 472 305  -35   
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factor 
JNK1 (MAPK8) Y185 
Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1 
5151 3362 
 
-35   
Jun (c-Jun) T91 
Jun proto-oncogene-encoded AP1 transcription 
factor 
937 639 
 
-32   
HDAC5 S498 Histone deacetylase 5 1727 1192  -31   
ITK 
Pan-
specific 
Tyrosine-protein kinase ITK/TSK 4223 2987 
 
-29   
WNK1 
Pan-
specific 
Serine/threonine-protein kinase WNK1 4291 3060 
 
-29   
IGF1R Y1280 
Insulin-like growth factor 1 receptor protein-
tyrosine kinase 
1722 1237 
 
-28   
IkBa 
Pan-
specific 
Inhibitor of NF-kappa-B alpha (MAD3) 1324 956 
 
-28   
STAT5 Y694 Signal transducer and activator of transcription 5 1745 1381  -21   
Yes 
Y222+Y22
3 
Yamaguchi sarcoma proto-oncogene-encoded 
tyrosine kinase 
10235 8126 
 
-21   
FAK (PTK2) 
Y576+Y57
7 
Focal adhesion protein-tyrosine kinase 404 324 
 
-20   
TARDBP 
S409+S41
0 
TAR DNA-binding protein 43 4900 3996 
 
-18   
AR S310 Androgen receptor 8398 6996  -17   
Fyn 
Pan-
specific 
Fyn proto-oncogene-encoded protein-tyrosine 
kinase 
903 765 
 
-15   
Vav Y174 Vav 1 guanine nucleotide exchange factor 1659 1414  -15   
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PKD1 (PRKCM, 
PKCm, PRKD1) 
S910 Protein-serine kinase C mu (Protein kinase D) 619 564 
 
-9   
MKK6 
(MAP2K6, 
MEK6) 
Pan-
specific 
MAPK/ERK protein-serine kinase 6 (MKK6); Dual 
specificity mitogen-activated protein kinase kinase 
6 
3719 3468 
 
-7   
HSP90AB1 
(HSP90; 
HSP84; 
HSP90B; 
HSPC2; 
HSPCB) 
Pan-
specific 
Heat shock 90 kDa protein beta 1056 993 
 
-6   
Lyn 
Pan-
specific 
Yes-related protein-tyrosine kinase; Tyrosine-
protein kinase Lyn 
973 927 
 
-5   
mTOR (FRAP) 
Pan-
specific 
Mammalian target of rapamycin (FRAP); FKBP12-
rapamycin complex-associated protein 
6718 6460 
 
-4   
CK2a1 
(CSNK2A1) 
T360+S36
2 
Casein protein-serine kinase 2 alpha/ alpha prime 893 874 
 
-2   
MLK1 
(MAP3K9) 
Pan-
specific 
Mixed-lineage protein-serine kinase 1; Mitogen-
activated protein kinase kinase kinase 9 
377 370 
 
-2   
Chk1 (CHEK1) S280 Checkpoint protein-serine kinase 1 10372 10176  -2   
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Table 5.2: Top signalling pathways which were downregulated by SIPA1 
knockdown on A549 cells. Generated from: www.reactome.org.  
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Figure 5.5: Genome-wide overview of the signalling pathway which were downregulated by SIPA1 knockdown on A549 cells. Pathways 
are arranged in a hierarchy. The centre of each of the circular represents the root of the top-level pathway. Each step away from the centre 
represents the next level lower in the pathway hierarchy. The light-yellow colour denotes over-representation of that pathway. Light grey signifies 
pathways which are not significantly over-represented. Generated from: www.reactome.org.    
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Similarly, Table 5.3 shows the markers whose phosphorylation status were most 
increased after SIPA1 knockdown in the A549 cells, indicating the potential interaction 
markers with intercellular SIPA1, as well. The website Reacome (www.reactome.org) 
was used to conduct the key pathway analysis report. The most upregulated markers 
after SIPA1 knockdown could be integrated to numbers of centralized signalling 
pathways, in which the top 25 signalling pathways are listed in Table 5.4. Also, the 
genome-wide overview schematic diagram of the signalling pathways was generated 
(Figure 5.6) to show the overall review of the main area in which the pathways 
upregulated by SIPA1 are located. 
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Table 5.3: Key markers whose phosphor-status were up regulated after SIPA1 knock down on A549 cells. 
Target Name P-Site Full Target Protein Name 
Average Normalized 
Net Signal 
%CF
C  
Lead 
Control SIPA1KD 
Plk1 (PLK) Pan-specific Polo-like protein-serine kinase 1 756 11286 1393 Priority 
EZH2 T487 Histone-lysine N-methyltransferase EZH2 1568 16728 967 Priority 
MEF2A T108 Myocyte-specific enhancer factor 2A 254 2636 939 Priority 
ERK1 (MAPK3) Y204+T207 
Extracellular regulated protein-serine kinase 1 (p44 
MAP kinase) 
767 5502 618 Priority 
Plk3 (CNK) Pan-specific 
Polo-like protein-serine kinase 3 (cytokine- inducible 
kinase (CNK)) 
417 2770 564 Priority 
MARK2 Pan-specific 
MAP/microtubule affinity-regulating protein-serine 
kinase 2 
861 5695 561 Priority 
RIPK2 (RICK; 
RIP2; CARD3) 
S176 
Receptor-interacting serine/threonine-protein kinase 2 
(RIPK2) 
3501 20283 479 Priority 
TTK T676 Dual specificity protein kinase TTK 561 3094 451 Priority 
HePTP (PTPN7) S44 Tyrosine-protein phosphatase non-receptor type 7 729 4009 450 Priority 
PP1/Cb (PPP1CB) T316 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit 
2106 10875 416 Priority 
mTOR (FRAP) S2478+S2481 
Mammalian target of rapamycin (FRAP); FKBP12-
rapamycin complex-associated protein 
399 1757 340 Priority 
Pim2 T195 Serine/threonine-protein kinase Pim-2 2129 8764 312 Priority 
TAK1 (MAP3K7) T184+T187 
TGF-beta-activated protein-serine kinase 1; Mitogen-
activated protein kinase kinase kinase 7 
733 2724 272 Priority 
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MPL Y591 Thrombopoietin receptor 1317 4864 269 Priority 
PKD2 (PRKD2) S197+S198 Serine/threonine-protein kinase D2 2428 8686 258 Priority 
PKD3 (PRKCN) Pan-specific 
Protein-serine kinase C nu; Serine/threonine-protein 
kinase D3 
538 1746 225 Priority 
MELK Y438 Maternal embryonic leucine zipper kinase 508 1595 214 Priority 
TBC1D7 Y14 TBC1 domain family member 7 499 1541 209 Priority 
AurKC (Aurora C, 
AIK3) 
Pan-specific Aurora Kinase C (serine/threonine-protein kinase 13) 567 1732 205 Priority 
RIOK1 Y466 Serine/threonine-protein kinase RIO1 1206 3527 192 Priority 
AAK1 S637 AP2-associated protein kinase 1 5683 16337 187 Priority 
RSK1 (RPS6KA1, 
p90RSK) 
Pan-specific 
Ribosomal S6 protein-serine kinase 1; Ribosomal 
protein S6 kinase alpha 2 
701 1913 173 Priority 
RIOK2 
S332+S335+S33
7 
Serine/threonine-protein kinase RIO2 3367 8853 163 Priority 
MSK2 (RPS6KA4) T687 Ribosomal protein S6 kinase alpha-4 4964 12958 161 Priority 
p38a MAPK 
(MAPK14) 
T180+Y182 
Mitogen-activated protein-serine kinase p38 alpha; 
Mitogen-activated protein kinase 14 
5219 12787 145 Priority 
MST1 (STK4, Krs2) T187 
Mammalian STE20-like protein-serine kinase 1 
(KRS2); Serine-threonine-protein kinase 4 
926 2254 143 Priority 
MST3 (STK24) T184 
Mammalian STE20-like protein-serine kinase 3; 
Serine-threonine-protein kinase 24 
2079 4894 135 Priority 
p38b MAPK 
(MAPK11) 
T180+Y182 
Mitogen-activated protein-serine kinase p38 beta; 
Mitogen-activated protein kinase 11 
5425 12466 130 Priority 
Met Y1234 
Hepatocyte growth factor (HGF) receptor-tyrosine 
kinase 
4427 10046 127 Priority 
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FAK (PTK2) Y397 Focal adhesion protein-tyrosine kinase 3460 7788 125 Priority 
Nek7 T191+S195 NIMA (never-in-mitosis)-related protein-serine kinase 7 2552 5530 117 Priority 
ErbB2 (HER2, Neu) Y877 ErbB2 (Neu) receptor-tyrosine kinase 1441 3121 117 Priority 
Fgr Pan-specific 
Gardner-Rasheed feline sarcoma viral (v-fgr) 
oncogene 
4823 9945 106 Priority 
BRSK1 T189 BR serine/threonine-protein kinase 1 21015 42125 100 Priority 
Bmx (Etk) Y40 Bone marrow X protein-tyrosine kinase 850 1669 96 Priority 
CDKL5 (STK9) Y171 
Cyclin-dependent kinase-like 5; Serine-threonine-
protein kinase 9 
7007 13300 90 Priority 
NDR1 (NDR, 
STK38) 
S281+T282 Serine/threonine-protein kinase 38 7340 13894 89 Priority 
MKK3 (MAP2K3, 
MEK3) 
S218 
MAPK/ERK protein-serine kinase 3 beta isoform 
(MKK3 beta); Dual specificity mitogen-activated protein 
kinase kinase 3 
23383 43796 87 Priority 
FOXO1A (FKHR) S256 Forkhead box protein O1 3148 5840 86 Priority 
PKCa (PRKCA) Y195 Protein-serine kinase C alpha 1028 1885 83 Priority 
NFAT5 T135 Nuclear factor of activated T-cells 5 6169 10954 78 Priority 
Akt1 (PKBa) Y326 RAC-alpha serine/threonine-protein kinase 269 1250 364 Possible 
Btk Y223+Y225 Bruton's agammaglobulinemia tyrosine kinase 192 765 298 Possible 
NFkB p50 (NFKB1) S337 Nuclear factor NF-kappa-B p105 subunit 192 762 296 Possible 
STAT4 S721 Signal transducer and activator of transcription 4 289 1094 278 Possible 
MEK1 (MKK1, 
MAP2K1) 
S222 
MAPK/ERK protein-serine kinase 1 (MKK1); Dual 
specificity mitogen-activated protein kinase kinase 1 
321 1017 216 Possible 
p38a MAPK Pan-specific Mitogen-activated protein-serine kinase p38 alpha; 241 749 211 Possible 
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(MAPK14) Mitogen-activated protein kinase 14 
BCKD (BCKDK) Pan-specific 
[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] 
kinase, mitochondrial 
300 920 207 Possible 
ERK3 (MAPK6) Pan-specific Extracellular regulated protein-serine kinase 3 460 1221 165 Possible 
GOLGA2 (GM130) S25 Golgin subfamily A member 2 367 971 165 Possible 
Abl2 (Arg) Y439 Abelson murine leukemia viral oncogene homologue 2 462 1133 145 Possible 
ATR Pan-specific 
Ataxia telangiectasia and Rad3 related protein-serine 
kinase 
455 1050 131 Possible 
TAO1 (TAOK1) S181 Serine/threonine-protein kinase TAO1 365 823 125 Possible 
Plk1 (PLK) T210 Polo-like protein-serine kinase 1 1007 2236 122 Possible 
MEK1 (MKK1, 
MAP2K1) 
T286 
MAPK/ERK protein-serine kinase 1 (MKK1); Dual 
specificity mitogen-activated protein kinase kinase 1 
526 1126 114 Possible 
Raf1 (RafC) S296 Raf1 proto-oncogene-encoded protein-serine kinase 3787 8055 113 Possible 
Bcr Pan-specific Breakpoint cluster region protein 373 770 107 Possible 
SLK S189 
STE20-like serine/threonine-protein kinase; CTCL 
tumour antigen se20-9 
631 1286 104 Possible 
Rb1 S249+T252 Retinoblastoma-associated protein 1 407 827 103 Possible 
GRK2 (BARK1, 
ADRBK1) 
S670 Beta-adrenergic receptor kinase 1 1296 2245 73 Possible 
mTOR (FRAP) Pan-specific 
Mammalian target of rapamycin (FRAP); FKBP12-
rapamycin complex-associated protein 
11143 19239 73 Possible 
Rb1 T826 Retinoblastoma-associated protein 1 1264 2170 72 Possible 
PAK1 (PAKa) Pan-specific 
p21-activated kinase 1 (alpha) (Protein-
serine/threonine kinase PAK 1) 
2786 4782 72 Possible 
HIPK1 Y352 Homeodomain-interacting protein-serine kinase 1 4848 8286 71 Possible 
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PFTAIRE2 
(ALS2CR7, 
CDK15) 
Pan-specific 
Amyotrophic lateral sclerosis 2 chromosomal region 
candidate gene 7 protein 
1197 2035 70 Possible 
NFKB p65 (Rel A) Pan-specific NF-kappa-B p65 nuclear transcription factor 955 1619 70 Possible 
RSK2 (RPS6KA3) T577 
Ribosomal S6 protein-serine kinase 2; Ribosomal 
protein S6 kinase alpha-3 
799 1341 68 Possible 
p53 (TP53) Pan-specific Cellular tumor antigen p53 2880 4772 66 Possible 
Raf1 (RafC) S301+T303 Raf1 proto-oncogene-encoded protein-serine kinase 775 1274 64 Possible 
ANXA2 Y238 Annexin A2 5030 8231 64 Possible 
ULK1 Pan-specific 
Unc-51-like kinase 1; Serine-threonine-protein kinase 
ULK1 
466 762 63 Possible 
PIK3R2 Y464 Phosphatidylinositol 3-kinase regulatory subunit beta 2688 4316 61 Possible 
Raf1 (RafC) S259 Raf1 proto-oncogene-encoded protein-serine kinase 3456 5512 59 Possible 
Tyro3 Y685+Y686 Tyrosine-protein kinase receptor TYRO3 1851 2951 59 Possible 
CTNNB1 Y489 Catenin (cadherin-associated protein) beta 1 14391 22502 56 Possible 
CLK1 S337 Dual specificity protein kinase CLK1 1786 2791 56 Possible 
CaMK2a Pan-specific 
Calcium/calmodulin-dependent protein kinase type II 
subunit alpha 
3192 4957 55 Possible 
IGF1R Y1161+T1163 
Insulin-like growth factor 1 receptor protein-tyrosine 
kinase 
1844 2814 53 Possible 
Plk1 (PLK) Y217 Polo-like protein-serine kinase 1 3743 5672 52 Possible 
CDK5 Y15 Cyclin-dependent protein-serine kinase 5 5122 7761 52 Possible 
Abl2 (Arg) Pan-specific Abelson murine leukemia viral oncogene homologue 2 5641 8509 51 Possible 
Chk1 (CHEK1) Pan-specific Checkpoint protein-serine kinase 1 1047 1550 48 Possible 
GR(NR3C1) S226 Glucocorticoid receptor 7219 10664 48 Possible 
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RPS6 
S235+S236+S24
0 
40S Ribosomal S6 3516 5172 47 Possible 
SHIP2 (INPPL1) Y886 
Phosphatidylinositol-3,4,5-trisphosphate 5-
phosphatase 2 
19347 28267 46 Possible 
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Table 5.4: Top signalling pathways which were up regulated by SIPA1 
knockdown on A549 cells. Generated from: www.reactome.org.  
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Figure 5.6: Genome-wide overview of the signalling pathway which were upregulated by SIPA1 knockdown on A549 cells. Pathways are 
arranged in a hierarchy. The centre of each of the circular represents the root of the top-level pathway. Each step away from the centre represents 
the next level lower in the pathway hierarchy. The light-yellow colour denotes over-representation of that pathway. Light grey signifies pathways 
which are not significantly over-represented. Generated from: www.reactome.org.  
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Besides the analysis of SIPA1 knockdown in A549 cells, we compared the 
phosphorylation status after the treatment of HGF on A549 pEF control cells. Table 
5.5 shows the markers whose phosphorylation status were most decreased after 
HGF treatment in the A549 pEF control cells, indicating the downstream markers of 
HGF/MET signalling. The website Reacome (www.reactome.org ) was used to 
conduct the key pathway analysis report. The most downregulated markers after HGF 
treatment could be integrated to numbers of centralized signalling pathways, in which 
the top 25 signalling pathways are listed in Table 5.6. Also, the genome-wide 
overview schematic diagram of the signalling pathways was generated (Figure 5.7) 
to show the overall review of the main area in which the pathways downregulated by 
SIPA1 are located.  
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 Table 5.5: Key markers whose phosphor-status were down regulated in A549 pEF control cells with treatment of HGF.  
Target Name P-Site Full Target Protein Name 
Average Normalized Net Signal 
%CFC  Lead 
Control Control+HGF 
SRF S224 Serum response factor 11435 1214 -89 Priority 
ITK Pan-specific Tyrosine-protein kinase ITK/TSK 4223 471 -89 Priority 
STAT5A Y694 
Signal transducer and activator of transcription 
5A 
2786 217 -92 Possible 
InsR (IR) Pan-specific Insulin receptor 1131 318 -72 Possible 
TARDBP S409+S410 TAR DNA-binding protein 43 4900 1470 -70 Possible 
GCK (MAP4K2) Pan-specific Germinal centre protein-serine kinase 750 228 -70 Possible 
HDAC5 S498 Histone deacetylase 5 1727 533 -69 Possible 
Vav Y174 Vav 1 guanine nucleotide exchange factor 1659 514 -69 Possible 
ACTB Y53 Actin, cytoplasmic 1; Beta-actin 1099 344 -69 Possible 
PCTK2 
(PCTAIRE2, 
CDK17) 
Pan-specific 
Cell division protein kinase 17; Protein-serine 
kinase PCTAIRE-2 
1844 659 -64 Possible 
CRYAB S19 Crystallin aB 1307 508 -61 Possible 
AAK1 S637 AP2-associated protein kinase 1 5683 2342 -59 Possible 
RPS6 S235+S236 40S Ribosomal S6 3861 1693 -56 Possible 
Lyn Pan-specific 
Yes-related protein-tyrosine kinase; Tyrosine-
protein kinase Lyn 
973 467 -52 Possible 
p70S6K (S6Ka, 
RPS6KB1) 
Pan-specific 
Ribosomal protein S6 kinase beta-1; Ribosomal 
protein S6 kinase 1 
3889 1882 -52 Possible 
Fyn Y213+Y214 
Fyn proto-oncogene-encoded protein-tyrosine 
kinase 
1065 520 -51 Possible 
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CDKL1 Pan-specific 
Cyclin-dependent kinase-like 1; 
Serine/threonine protein kinase KKIALRE 
3147 1538 -51 Possible 
Fyn Pan-specific 
Fyn proto-oncogene-encoded protein-tyrosine 
kinase 
903 447 -50 Possible 
ASK1 (MAP3K5) Pan-specific 
Apoptosis signal regulating protein-serine 
kinase 1 
2259 1186 -47 Possible 
MEF2A T108 Myocyte-specific enhancer factor 2A 254 47 -82   
p38b MAPK 
(MAPK11) 
T180+Y182 
Mitogen-activated protein-serine kinase p38 
beta; Mitogen-activated protein kinase 11 
5425 1807 -67   
ANXA2 Y238 Annexin A2 5030 1900 -62   
GATA3 S369 
Trans-acting T-cell-specific transcription factor 
GATA-3 
1420 659 -54   
PAK1 (PAKa) Pan-specific 
p21-activated kinase 1 (alpha) (Protein-
serine/threonine kinase PAK 1) 
2786 1299 -53   
MEK1 (MKK1, 
MAP2K1) 
T286 
MAPK/ERK protein-serine kinase 1 (MKK1); 
Dual specificity mitogen-activated protein 
kinase kinase 1 
526 260 -51   
Plk3 (CNK) Pan-specific 
Polo-like protein-serine kinase 3 (cytokine- 
inducible kinase (CNK)) 
417 212 -49   
MEK1 (MKK1, 
MAP2K1) 
S222 
MAPK/ERK protein-serine kinase 1 (MKK1); 
Dual specificity mitogen-activated protein 
kinase kinase 1 
321 166 -48   
Raf1 (RafC) S301+T303 
Raf1 proto-oncogene-encoded protein-serine 
kinase 
775 412 -47   
PIK3R2 Y464 Phosphatidylinositol 3-kinase regulatory subunit 2688 1486 -45   
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beta 
IGF1R 
Y1161+T11
63 
Insulin-like growth factor 1 receptor protein-
tyrosine kinase 
1844 1058 -43   
CDK5 Y15 Cyclin-dependent protein-serine kinase 5 5122 3045 -41   
Abl2 (Arg) Y439 
Abelson murine leukemia viral oncogene 
homologue 2 
462 276 -40   
BRSK1 T189 BR serine/threonine-protein kinase 1 21015 13148 -37   
p38a MAPK 
(MAPK14) 
Pan-specific 
Mitogen-activated protein-serine kinase p38 
alpha; Mitogen-activated protein kinase 14 
241 151 -37   
PFTAIRE2 
(ALS2CR7) 
Pan-specific 
Amyotrophic lateral sclerosis 2 chromosomal 
region candidate gene 7 protein 
1197 761 -36   
PKCa (PRKCA) Y195 Protein-serine kinase C alpha 1028 666 -35   
ErbB2 (HER2, 
Neu) 
Y877 ErbB2 (Neu) receptor-tyrosine kinase 1441 951 -34   
Plk1 (PLK) T210 Polo-like protein-serine kinase 1 1007 676 -33   
RSK2 (RPS6KA3) T577 
Ribosomal S6 protein-serine kinase 2; 
Ribosomal protein S6 kinase alpha-3 
799 546 -32   
Chk1 (CHEK1) Pan-specific Checkpoint protein-serine kinase 1 1047 722 -31   
ULK1 Pan-specific 
Unc-51-like kinase 1; Serine-threonine-protein 
kinase ULK1 
466 329 -29   
MSK2 
(RPS6KA4) 
T687 Ribosomal protein S6 kinase alpha-4 4964 3539 -29   
DYRK2 Y382 
Dual specificity tyrosine-phosphorylation-
regulated kinase 2 
2816 2026 -28   
GRK2 (BARK1, S670 Beta-adrenergic receptor kinase 1 1296 957 -26   
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ADRBK1) 
CLK1 S337 Dual specificity protein kinase CLK1 1786 1336 -25   
Abl2 (Arg) Pan-specific 
Abelson murine leukemia viral oncogene 
homologue 2 
5641 4301 -24   
Bmx (Etk) Y40 Bone marrow X protein-tyrosine kinase 850 650 -23   
RSK1 (RPS6KA1, 
p90RSK) 
Pan-specific 
Ribosomal S6 protein-serine kinase 1; 
Ribosomal protein S6 kinase alpha 2 
701 540 -23   
CDKL5 (STK9) Y171 
Cyclin-dependent kinase-like 5; Serine-
threonine-protein kinase 9 
7007 5451 -22   
SLK S189 
STE20-like serine/threonine-protein kinase; 
CTCL tumour antigen se20-9 
631 500 -21   
Raf1 (RafC) S259 
Raf1 proto-oncogene-encoded protein-serine 
kinase 
3456 2784 -19   
Rb T821 Retinoblastoma-associated protein 1 902 777 -14   
ERK3 (MAPK6) Pan-specific Extracellular regulated protein-serine kinase 3 460 402 -13   
WNK2 Pan-specific Serine/threonine-protein kinase WNK2 1215 1069 -12   
TAO1 (TAOK1) S181 Serine/threonine-protein kinase TAO1 365 334 -8   
MST1 (STK4, 
Krs2) 
T187 
Mammalian STE20-like protein-serine kinase 1 
(KRS2); Serine-threonine-protein kinase 4 
926 858 -7   
GR S226 Glucocorticoid receptor 7219 6801 -6   
NFAT5 T135 Nuclear factor of activated T-cells 5 6169 5913 -4   
HIPK1 Y352 
Homeodomain-interacting protein-serine kinase 
1 
4848 4689 -3   
yro3 Y685+Y686 Tyrosine-protein kinase receptor TYRO3 1851 1798 -3   
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Table 5.6: Top signalling pathways which were downregulated by treatment 
with HGF on A549 pEF control cells. Generated from: www.reactome.org.  
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Figure 5.7: Genome-wide overview of the signalling pathway which were downregulated by treatment with HGF on A549 pEF control 
cells. Pathways are arranged in a hierarchy. The centre of each of the circular represents the root of the top-level pathway. Each step away from 
the centre represents the next level lower in the pathway hierarchy. The light-yellow colour denotes over-representation of that pathway. Light 
grey signifies pathways which are not significantly over-represented. Generated from: www.reactome.org. 
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We also compared the phosphorylation status after the treatment of HGF on A549 
pEF control cells. Table 5.7 shows the markers whose phosphorylation status were 
most increased after HGF treatment in the A549 pEF control cells, indicating the 
downstream markers of HGF/MET signalling. The website Reacome 
(www.reactome.org) was used to conduct the key pathway analysis report. The most 
upregulated markers after HGF treatment could be integrated to numbers of 
centralized signalling pathways, in which the top 25 signalling pathways are listed in 
Table 5.8. Also, the genome-wide overview schematic diagram of the signalling 
pathways was generated (Figure 5.8) to show the overall review of the main area in 
which the pathways upregulated by SIPA1 are located.
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Table 5.7: Key markers whose phosphor-status were upregulated in A549 pEF control cells with treatment of HGF.  
Target Name P-Site Full Target Protein Name 
Average Normalized Net 
Signal %CF
C  
Lead 
Control 
Control+HG
F 
NMDAR1 S896 Glutamate [NMDA] receptor subunit zeta-1 151 1918 1168 Priority 
Plk1 (PLK) Pan-specific Polo-like protein-serine kinase 1 756 6631 777 Priority 
FAK (PTK2) Y576+Y577 Focal adhesion protein-tyrosine kinase 404 1846 357 Priority 
PP1/Cb 
(PPP1CB) 
T316 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit 
2106 9557 354 Priority 
ERK1 
(MAPK3) 
Y204+T207 
Extracellular regulated protein-serine kinase 1 (p44 
MAP kinase) 
767 3355 338 Priority 
RIPK2 (RICK; 
RIP2; CARD3) 
S176 
Receptor-interacting serine/threonine-protein kinase 
2 (RIPK2) 
3501 12641 261 Priority 
ACTB Pan-specific Actin, cytoplasmic 1; Beta-actin 828 2912 252 Priority 
Cbl Y700 E3 ubiquitin-protein ligase CBL 458 1565 242 Priority 
RIOK1 Y466 Serine/threonine-protein kinase RIO1 1206 3247 169 Priority 
HePTP 
(PTPN7) 
S44 Tyrosine-protein phosphatase non-receptor type 7 729 1870 157 Priority 
CK2a1 
(CSNK2A1) 
T360+S362 Casein protein-serine kinase 2 alpha/ alpha prime 893 2248 152 Priority 
EGFR (ErbB1) Pan-specific Epidermal growth factor receptor-tyrosine kinase 8596 19023 121 Priority 
PKD2 
(PRKD2) 
S197+S198 Serine/threonine-protein kinase D2 2428 5322 119 Priority 
STAT5 Y694 Signal transducer and activator of transcription 5 1745 3799 118 Priority 
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Akt1 (PKBa) S473 RAC-alpha serine/threonine-protein kinase 1781 3851 116 Priority 
IkBa Pan-specific Inhibitor of NF-kappa-B alpha (MAD3) 1324 2670 102 Priority 
DLK (ZPK) S269 Mitogen-activated protein kinase kinase kinase 12 3777 7431 97 Priority 
Fgr Pan-specific 
Gardner-Rasheed feline sarcoma viral (v-fgr) 
oncogene 
4823 8878 84 Priority 
Met T1241 
Hepatocyte growth factor (HGF) receptor-
tyrosine kinase 
5492 9699 77 Priority 
Myc S373 Myc proto-oncogene protein 94 1092 1062 Possible 
BRCA1 S1423 Breast cancer type 1 susceptibility protein 110 922 739 Possible 
CDK1 (CDC2) T161 
Cyclin-dependent protein-serine kinase 1; Cell 
division control protein 2 homologue 
445 1403 215 Possible 
Jun (c-Jun) Y170 
Jun proto-oncogene-encoded AP1 transcription 
factor 
472 1042 121 Possible 
mTOR (FRAP) S2478+S2481 
Mammalian target of rapamycin (FRAP); FKBP12-
rapamycin complex-associated protein 
399 799 100 Possible 
MLK1 
(MAP3K9) 
Pan-specific 
Mixed-lineage protein-serine kinase 1; Mitogen-
activated protein kinase kinase kinase 9 
377 754 100 Possible 
PKD1 
(PRKCM, 
PKCm, 
PRKD1) 
S910 Protein-serine kinase C mu (Protein kinase D) 619 1229 98 Possible 
Met Y1230 
Hepatocyte growth factor (HGF) receptor-
tyrosine kinase 
6448 10846 68 Possible 
IGF1R Y1280 
Insulin-like growth factor 1 receptor protein-tyrosine 
kinase 
1722 2877 67 Possible 
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AR S310 Androgen receptor 8398 14030 67 Possible 
WNK1 Pan-specific Serine/threonine-protein kinase WNK1 4291 7166 67 Possible 
CTNNB1 Y489 Catenin (cadherin-associated protein) beta 1 14391 23704 65 Possible 
MAT1A T341 S-adenosylmethionine synthase isoform type-1 10216 16693 63 Possible 
Caveolin 2 
(CAV2)  
Pan-specific Caveolin 2 761 1228 61 Possible 
Chk1 (CHEK1) S280 Checkpoint protein-serine kinase 1 10372 16632 60 Possible 
Ksr2 S490 Kinase suppressor of Ras 2 6444 10325 60 Possible 
MARK1 T215 
MAP/microtubule affinity-regulating protein-serine 
kinase 1 
13737 21972 60 Possible 
JNK1 (MAPK8) Y185 
Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1 
5151 8200 59 Possible 
MELK Y438 Maternal embryonic leucine zipper kinase 508 800 58 Possible 
RPS6 
S235+S236+S24
0 
40S Ribosomal S6 3516 5513 57 Possible 
MKK3 
(MAP2K3, 
MEK3) 
S218 
MAPK/ERK protein-serine kinase 3 beta isoform 
(MKK3 beta); Dual specificity mitogen-activated 
protein kinase kinase 3 
23383 36429 56 Possible 
MYPT1 (MBS) T696 Protein phosphatase 1 regulatory subunit 12A 963 1480 54 Possible 
ENO2 Y25 Gamma-enolase 5672 8715 54 Possible 
mTOR (FRAP) Pan-specific 
Mammalian target of rapamycin (FRAP); FKBP12-
rapamycin complex-associated protein 
6718 10267 53 Possible 
EIF2AK3 
(PERK) 
T982 
Eukaryotic translation initiation factor 2-alpha kinase 
3 
10245 15647 53 Possible 
JNK1 (MAPK8) Pan-specific Jun N-terminus protein-serine kinase 2 (Stress- 656 998 52 Possible 
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activated protein kinase-alpha) 
CK1 epsilon 
(CSNK1E) 
Pan-specific Casein protein-serine kinase 1 epsilon 3392 5122 51 Possible 
HSP90AB1 
(HSP90; 
HSP84; 
HSP90B; 
HSPC2; 
HSPCB) 
Pan-specific Heat shock 90 kDa protein beta 1056 1572 49 Possible 
Jun (c-Jun) T91 
Jun proto-oncogene-encoded AP1 transcription 
factor 
937 1386 48 Possible 
Yes Y222+Y223 
Yamaguchi sarcoma proto-oncogene-encoded 
tyrosine kinase 
10235 15101 48 Possible 
MKK6 
(MAP2K6, 
MEK6) 
Pan-specific 
MAPK/ERK protein-serine kinase 6 (MKK6); Dual 
specificity mitogen-activated protein kinase kinase 6 
3719 5474 47 Possible 
STAG2 Y433 Putative uncharacterized protein DKFZp781H1753 5391 7798 45 Possible 
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Table 5.8: Top signalling pathways which were upregulated by treatment with 
HGF on A549 pEF control cells. Generated from: www.reactome.org  
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Figure 5.8: Genome-wide overview of the signalling pathway which were upregulated by treatment with HGF on A549 pEF control cells. 
Pathways are arranged in a hierarchy. The centre of each of the circular represents the root of the top-level pathway. Each step away from the 
centre represents the next level lower in the pathway hierarchy. The light-yellow colour denotes over-representation of that pathway. Light grey 
signifies pathways which are not significantly over-represented. Generated from: www.reactome.org.  
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Comparison the phosphorylation status between the A549 pEF control cells and 
SIPA1 knockdown cells treated with HGF was carried out. Table 5.9 shows the 
markers whose phosphorylation status were most decreased after HGF treatment in 
the SIPA1 knockdown cells compared to pEF control cells, indicating the downstream 
markers which can be activated in pEF control cells but not in SIPA1 knockdown cells. 
The website Reacome (www.reactome.org) was used to conduct the key pathway 
analysis report. The most downregulated markers after HGF treatment in SIPA1 
knockdown cells could be integrated to numbers of centralized signalling pathways, 
in which the top 25 signalling pathways are listed in Table 5.10. Also, the genome-
wide overview schematic diagram of the signalling pathways was generated (Figure 
5.9) to show the overall review of the main area in which the pathways downregulated 
by HGF treatment in SIPA1 knockdown cells are located. 
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Table 5.9: Key markers whose phosphor-status were down regulated in SIPA1 knock down cells compared to pEF control cells with 
treatment of HGF. 
Target Name P-Site Full Target Protein Name 
Average Normalized 
Net Signal 
%
CF
C  
Lead 
pEF+HGF 
SIPA1KD 
+HGF 
PRKACA (PKA) Pan-specific cAMP-dependent protein kinase catalytic subunit alpha 771 98 -87 Possible 
NFKB p65 (Rel A) S529 NF-kappa-B p65 nuclear transcription factor 1141 384 -66 Possible 
BCKD (BCKDK) Pan-specific 
[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] 
kinase, mitochondrial 
10933 5447 -50 Possible 
CK2a1 
(CSNK2A1) 
T360+S362 Casein protein-serine kinase 2 alpha/ alpha prime 2248 632 -72   
Jun (c-Jun) T91 Jun proto-oncogene-encoded AP1 transcription factor 1386 619 -55   
IkBa Pan-specific Inhibitor of NF-kappa-B alpha (MAD3) 2670 1266 -53   
BCKD (BCKDK) Pan-specific 
[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] 
kinase, mitochondrial 
360 178 -51   
MKK6 (MAP2K6, 
MEK6) 
Pan-specific 
MAPK/ERK protein-serine kinase 6 (MKK6); Dual specificity 
mitogen-activated protein kinase kinase 6 
8157 4716 -42   
A6 (Twinfilin-1, 
TWF1) 
Y309 Twinfilin, actin-binding protein, 1; Protein tyrosine kinase 9; 3958 2350 -41   
AurKC (Aurora C, 
AIK3) 
Pan-specific Aurora Kinase C (serine/threonine-protein kinase 13) 17085 10211 -40   
Myc S373 Myc proto-oncogene protein 1092 692 -37   
JNK1 (MAPK8) Y185 
Jun N-terminus protein-serine kinase (stress-activated 
protein kinase (SAPK)) 1 
8200 5353 -35   
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MLK1 (MAP3K9) Pan-specific 
Mixed-lineage protein-serine kinase 1; Mitogen-activated 
protein kinase kinase kinase 9 
754 497 -34   
AurKC (Aurora C, 
AIK3) 
Pan-specific Aurora Kinase C (serine/threonine-protein kinase 13) 721 487 -33   
IGF1R Y1346 Insulin-like growth factor 1 receptor 4476 3083 -31   
WNK1 Pan-specific Serine/threonine-protein kinase WNK1 7166 4937 -31   
ACTB Pan-specific Actin, cytoplasmic 1; Beta-actin 2912 2011 -31   
ALK Pan-specific Anaplastic lymphoma receptor-tyrosine kinase 669 463 -31   
GRK2 (BARK1, 
ADRBK1) 
S670 Beta-adrenergic receptor kinase 1 957 663 -31   
Plk1 (PLK) Pan-specific Polo-like protein-serine kinase 1 6631 4660 -30   
p53 (TP53) Pan-specific Cellular tumor antigen p53 3201 2261 -29   
DNAPK (PRKDC) T2609 DNA-dependent protein kinase catalytic subunit 5854 
 
4258 
 
-27   
KHS1 (MAP4K5; 
KHS) 
S174 
Kinase homologous to SPS1/STE20 (MAP kinase kinase 
kinase protein-serine kinase 5 (MEKKK5) 
15746 11635 -26   
Rb T821 Retinoblastoma-associated protein 1 777 578 -26   
Jun (c-Jun) Y170 Jun proto-oncogene-encoded AP1 transcription factor 1042 779 -25   
LTK Y672 Leukocyte tyrosine kinase receptor 10453 7816 -25   
STAG2 Y433 Putative uncharacterized protein DKFZp781H1753 7798 6190 -21   
JAK2 Pan-specific Janus protein-tyrosine kinase 2 12322 10011 -19   
CaMK1d T180 
Calcium/calmodulin-dependent protein-serine kinase 1 
delta 
4052 3364 -17   
STAT5 Y694 Signal transducer and activator of transcription 5 3799 3156 -17   
AR S310 Androgen receptor 14030 11845 -16   
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Bcr Y177 Breakpoint cluster region protein 3101 2654 -14   
YAP1 T119 Yorkie homologue 17998 15464 -14   
ACLY Y682 ATP-citrate synthase 8803 7622 -13   
MPL Y591 Thrombopoietin receptor 2303 2017 -12   
Btk Y551 Bruton's agammaglobulinemia tyrosine kinase 3182 2819 -11   
Yes Y222+Y223 
Yamaguchi sarcoma proto-oncogene-encoded tyrosine 
kinase 
15101 13816 -9   
ACS1 (ACSL1) Y567 Long-chain-fatty-acid--CoA ligase 1 3898 3731 -4   
PAK5 (PAK7) Pan-specific 
p21-activated kinase 5; Protein-serine/threonine kinase 
PAK 7 
11348 11014 -3   
ERK2 (MAPK1) Pan-specific 
Extracellular regulated protein-serine kinase 2 (p42 MAP 
kinase) 
25815 25143 -3   
MEK1 (MKK1, 
MAP2K1) 
T292 
MAPK/ERK protein-serine kinase 1 (MKK1); Dual specificity 
mitogen-activated protein kinase kinase 1 
1813 1784 -2   
HIPK1 Y352 Homeodomain-interacting protein-serine kinase 1 4689 4661 -1   
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Table 5.10: Top signalling pathways which were down regulated in SIPA1 knock 
down cells compared to pEF control cells after the treatment of HGF. Generated 
from: www.reactome.org.  
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Figure 5.9: Genome-wide overview of the signalling pathway which were down regulated in SIPA1 knock down cells compared to pEF 
control cells after the treatment of HGF. Pathways are arranged in a hierarchy. The centre of each of the circular represents the root of the 
top-level pathway. Each step away from the centre represents the next level lower in the pathway hierarchy. The light-yellow colour denotes over-
representation of that pathway. Light grey signifies pathways which are not significantly over-represented. Generated from: www.reactome.org.   
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Comparison the phosphorylation status between the A549 pEF control cells and 
SIPA1 knockdown cells treated with HGF was carried out. Table 5.11 shows the 
markers whose phosphorylation status were most increased after HGF treatment in 
the SIPA1 knockdown cells compared to pEF control cells, indicating the downstream 
markers which can be activated in SIPA1 knockdown cells but not in pEF control cells. 
The website Reacome (www.reactome.org) was used to conduct the key pathway 
analysis report. The most upregulated markers after HGF treatment in SIPA1 
knockdown cells could be integrated to numbers of centralized signalling pathways, 
in which the top 25 signalling pathways are listed in Table 5.12. Also, the genome-
wide overview schematic diagram of the signalling pathways was generated (Figure 
5.10) to show the overall review of the main area in which the pathways upregulated 
by HGF treatment in SIPA1 knockdown cells are located. 
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Table 5.11: Key markers whose phosphor-status were up regulated in SIPA1 knock down cells compared to pEF control cells with 
treatment of HGF.  
Target Name P-Site Full Target Protein Name 
Average Normalized 
Net Signal %CF
C  
Lead 
pEF+HGF 
SIPA1KD 
+HGF 
MEF2A T108 Myocyte-specific enhancer factor 2A 47 2057 4304 Priority 
STAT5A Y694 Signal transducer and activator of transcription 5A 217 3135 1342 Priority 
PFN1 Y129 Profilin 1 134 1728 1192 Priority 
Plk3 (CNK) Pan-specific 
Polo-like protein-serine kinase 3 (cytokine- inducible 
kinase (CNK)) 
212 2324 997 Priority 
CDK12 (Cdc2L7) T893 
Cell division protein kinase 12; Cell division cycle 2-
related protein kinase 7 
1070 11291 955 Priority 
SRF S224 Serum response factor 1214 11154 819 Priority 
Syk Y323 Spleen protein-tyrosine kinase 380 2190 477 Priority 
ERK3 (MAPK6) Pan-specific Extracellular regulated protein-serine kinase 3 402 2110 425 Priority 
TTK T676 Dual specificity protein kinase TTK 674 3460 414 Priority 
CrkL Pan-specific Crk-like protein 381 1835 381 Priority 
PLCB3 S1105 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase beta-3 
487 2170 346 Priority 
PFTAIRE1 (CDK14) Pan-specific Serine/threonine protein kinase PFTAIRE-1 1560 6737 332 Priority 
p38b MAPK 
(MAPK11) 
T180+Y182 
Mitogen-activated protein-serine kinase p38 beta; 
Mitogen-activated protein kinase 11 
1807 7405 310 Priority 
EphB1 Y594 Ephrin type-B receptor 1 protein-tyrosine kinase 1952 7854 302 Priority 
Plk1 (PLK) T210 Polo-like protein-serine kinase 1 676 2708 301 Priority 
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SIK3 (QSK) T411 Salt-inducible serine/threonine-protein kinase SIK3 918 3636 296 Priority 
TEC Y519 Tyrosine-protein kinase Tec 812 3161 289 Priority 
Raf1 (RafC) S301+T303 Raf1 proto-oncogene-encoded protein-serine kinase 412 1596 287 Priority 
SIT Y95 Signaling threshold-regulating transmembrane adapter 1 7861 28073 257 Priority 
STAT6 Pan-specific Signal transducer and activator of transcription 6 513 1807 253 Priority 
ITK Pan-specific Tyrosine-protein kinase ITK/TSK 471 1655 252 Priority 
PTPN21 S637 Tyrosine-protein phosphatase non-receptor type 21 437 1506 245 Priority 
SPT5 T791 Transcription elongation factor SPT5 2966 10014 238 Priority 
PFTAIRE2 
(ALS2CR7) 
Pan-specific 
Amyotrophic lateral sclerosis 2 chromosomal region 
candidate gene 7 protein 
1642 5476 233 Priority 
PFKFB3 S461 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 717 2363 229 Priority 
RSK1 (RPS6KA1, 
p90RSK) 
Pan-specific 
Ribosomal S6 protein-serine kinase 1; Ribosomal 
protein S6 kinase alpha 2 
540 1762 226 Priority 
PAK1 (PAKa) Pan-specific 
p21-activated kinase 1 (alpha) (Protein-serine/threonine 
kinase PAK 1) 
1299 4182 222 Priority 
PYK2 (PTK2B) Y402 Protein tyrosine kinase 2 beta 1947 6270 222 Priority 
TARDBP S409+S410 TAR DNA-binding protein 43 1470 4667 218 Priority 
EZH2 T487 Histone-lysine N-methyltransferase EZH2 3983 12549 215 Priority 
Raf-B (BRaf) S446+S447 
B-Raf proto-oncogene serine-threonine-protein kinase; 
RafB proto-oncogene-encoded protein-serine kinase 
1985 6178 211 Priority 
MARK2 Pan-specific 
MAP/microtubule affinity-regulating protein-serine 
kinase 2 
1205 3742 210 Priority 
AAK1 S637 AP2-associated protein kinase 1 2342 7239 209 Priority 
p53 (TP53) S392 Cellular tumor antigen p53 2522 7782 209 Priority 
HDAC5 S498 Histone deacetylase 5 533 1591 198 Priority 
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TAK1 (MAP3K7) T184+T187 
TGF-beta-activated protein-serine kinase 1; Mitogen-
activated protein kinase kinase kinase 7 
1169 3405 191 Priority 
RSK2 (RPS6KA3) T577 
Ribosomal S6 protein-serine kinase 2; Ribosomal 
protein S6 kinase alpha-3 
546 1549 184 Priority 
PKR1 (PRKR; 
EIF2AK2) 
T446 
Double-stranded RNA-dependent protein-serine kinase; 
Interferon-induced, double-stranded RNA-activated 
protein kinase 
1991 5577 180 Priority 
Shc1 (Shc) Y349+Y350 SH2 domain-containing transforming protein 1 586 1604 174 Priority 
p38b MAPK 
(MAPK11) 
Pan-specific 
Mitogen-activated protein-serine kinase p38 beta; 
Mitogen-activated protein kinase 11 
1014 2692 166 Priority 
SHIP1 (INPP5D) Y187 
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 
1 
2746 7226 163 Priority 
MSK2 (RPS6KA4) T687 Ribosomal protein S6 kinase alpha-4 3539 9299 163 Priority 
PKD3 (PRKCN) Pan-specific 
Protein-serine kinase C nu; Serine/threonine-protein 
kinase D3 
598 1558 161 Priority 
CDKL1 Pan-specific 
Cyclin-dependent kinase-like 1; Serine/threonine protein 
kinase KKIALRE 
1538 3994 160 Priority 
RPS6 S235+S236 40S Ribosomal S6 1693 4373 158 Priority 
ERK1 (MAPK3) Y204+T207 
Extracellular regulated protein-serine kinase 1 (p44 MAP 
kinase) 
3355 8658 158 Priority 
SIN3A S832 Paired amphipathic helix protein Sin3a 9009 22656 151 Priority 
Pim2 T195 Serine/threonine-protein kinase Pim-2 4044 9982 147 Priority 
Raf1 (RafC) S259 Raf1 proto-oncogene-encoded protein-serine kinase 2784 6782 144 Priority 
STAT3 Y705 Signal transducer and activator of transcription 3 837 2019 141 Priority 
PIK3R2 Y464 Phosphatidylinositol 3-kinase regulatory subunit beta 1486 3582 141 Priority 
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SIK2 (QIK) Pan-specific 
Salt-inducible serine/threonine-protein kinase SIK2; 
Serine-threonine-protein kinase SNF1-like kinase 2 
933 2236 140 Priority 
Frk Pan-specific Fyn-related kinase; Tyrosine-protein kinase FRK 1108 2579 133 Priority 
ITK Y512 Tyrosine-protein kinase ITK/TSK 8353 19336 131 Priority 
TTK Y833+Y836 Dual specificity protein kinase TTK 3934 9070 131 Priority 
PFTAIRE2 
(ALS2CR7) 
Pan-specific 
Amyotrophic lateral sclerosis 2 chromosomal region 
candidate gene 7 protein 
761 1739 128 Priority 
TGM2 Y369 Protein-glutamine gamma-glutamyltransferase 2 6091 13873 128 Priority 
Chk1 (CHEK1) Pan-specific Checkpoint protein-serine kinase 1 722 1636 127 Priority 
PLCG1 Y977 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-2 
3511 7827 123 Priority 
JAK2 
Y1007+Y10
08 
Janus protein-tyrosine kinase 2 1930 4298 123 Priority 
PRKACB (PKA) Y69 
cAMP-dependent protein-serine kinase catalytic subunit 
beta 
1475 3250 120 Priority 
CDK5 Y15 Cyclin-dependent protein-serine kinase 5 3045 6669 119 Priority 
CLK1 S337 Dual specificity protein kinase CLK1 1336 2908 118 Priority 
CSF1R (Fms) Y699 Macrophage colony-stimulating factor 1 receptor 734 1595 117 Priority 
NFAT5 T135 Nuclear factor of activated T-cells 5 5913 12704 115 Priority 
IKKe (IkBKE) S172 Inhibitor of nuclear factor kappa-B kinase subunit epsilon 6799 14531 114 Priority 
ICK (LCK2) Y159 Intestinal cell (MAK-like) kinase 3252 6890 112 Priority 
Rb S608 Retinoblastoma-associated protein 1 1006 2080 107 Priority 
Vav Y826 Vav 1 guanine nucleotide exchange factor 818 1654 102 Priority 
LATS1 S464 
Large tumour suppressor 1 protein-serine kinase 
(WARTS) 
1273 2530 99 Priority 
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HSF1 S303+S307 Heat shock factor protein 1 7173 13886 94 Priority 
Fes Y713 Fes/Fps protein-tyrosine kinase 1752 3368 92 Priority 
SRPK2 Pan-specific 
Serine/arginine-rich protein-specific kinase 2; Serine 
kinase SRPK2 
4222 8088 92 Priority 
CDKL5 (STK9) Y171 
Cyclin-dependent kinase-like 5; Serine-threonine-protein 
kinase 9 
5451 10391 91 Priority 
p70S6K (S6Ka, 
RPS6KB1) 
Pan-specific 
Ribosomal protein S6 kinase beta-1; Ribosomal protein 
S6 kinase 1 
1882 3519 87 Priority 
VEGFR1 (Flt1) Y1053 Vascular endothelial growth factor receptor 1 2378 4421 86 Priority 
CDK7 Pan-specific Cyclin-dependent protein-serine kinase 7 865 1598 85 Priority 
Cbl Y674 E3 ubiquitin-protein ligase CBL 2544 4654 83 Priority 
Kit Y703 Mast/stem cell growth factor receptor protein-tyrosine Kit 4461 8114 82 Priority 
Kit Y730 Mast/stem cell growth factor receptor protein-tyrosine Kit 949 1712 80 Priority 
SIK (SNF1LK) T182 
Salt-inducible serine/threonine-protein kinase SIK1; 
Serine-threonine-protein kinase SNF1-like kinase 1 
3321 5980 80 Priority 
RIOK2 
S332+S335
+S337 
Serine/threonine-protein kinase RIO2 3828 6825 78 Priority 
SIT Y90 Signaling threshold-regulating transmembrane adapter 1 4721 8410 78 Priority 
ROCK2 (ROKa) Y722 Rho-associated protein kinase 2 1511 2683 78 Priority 
Raf1 (RafC) S296 Raf1 proto-oncogene-encoded protein-serine kinase 4903 8601 75 Priority 
RIPK2 (RICK; RIP2; 
CARD3) 
S176 
Receptor-interacting serine/threonine-protein kinase 2 
(RIPK2) 
12641 22124 75 Priority 
PLCE1 
S1096+T11
00 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase epsilon-1 
79 892 1035 Possible 
CLK3 Pan-specific Dual specificity protein kinase CLK3 146 1240 752 Possible 
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PLCD1 S460 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase delta-1 
153 1139 646 Possible 
Myc T58 Myc proto-oncogene protein 109 789 627 Possible 
CBS S227 Cystathionine beta-synthase 171 1085 533 Possible 
PLCG1 Pan-specific 
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase gamma-1 
255 1373 438 Possible 
Plk4 (SAK; STK18) Pan-specific Polo-like kinase-serine 4 (SAK) 225 1041 363 Possible 
NFkB p50 S337 Nuclear factor NF-kappa-B p105 subunit 272 1100 305 Possible 
TAO1 (TAOK1) S181 Serine/threonine-protein kinase TAO1 334 1351 304 Possible 
InsR (IR) Pan-specific Insulin receptor 318 1235 288 Possible 
GSK3a Pan-specific Glycogen synthase-serine kinase 3 alpha/beta 257 909 254 Possible 
PRKACA (PKA) Pan-specific cAMP-dependent protein kinase catalytic subunit alpha 344 1193 247 Possible 
LKB1 (STK11) S428 Serine/threonine-protein kinase 11 287 928 223 Possible 
CRYAB S19 Crystallin aB 508 1440 184 Possible 
LATS1 Pan-specific 
Large tumour suppressor 1 protein-serine kinase 
(WARTS) 
554 1490 169 Possible 
Rb S249+T252 Retinoblastoma-associated protein 1 449 1199 167 Possible 
GRK2 (BARK1, 
ADRBK1) 
Pan-specific G protein-coupled receptor-serine kinase 2 490 1300 165 Possible 
PKD1 (PRKCM, 
PKCm, PRKD1) 
Pan-specific Protein-serine kinase C mu (Protein kinase D) 300 792 164 Possible 
JAK2 
Y1007+Y10
08 
Janus protein-tyrosine kinase 2 360 929 158 Possible 
PTEN S380 
Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
and protein phosphatase and tensin homolog deleted on 
317 807 155 Possible 
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chromosome 10 
PCYT1A (CTPCT; 
CCTA) 
T342+S343 CTP: phosphocholine cytidylyltransferase isoform A 298 752 152 Possible 
SLK S189 
STE20-like serine/threonine-protein kinase; CTCL 
tumour antigen se20-9 
500 1236 147 Possible 
Vav Y174 Vav 1 guanine nucleotide exchange factor 514 1237 141 Possible 
GRK2 (BARK1, 
ADRBK1) 
S670 G protein-coupled receptor-serine kinase 2 615 1422 131 Possible 
Raf1 (RafC) S621 Raf1 proto-oncogene-encoded protein-serine kinase 382 859 125 Possible 
JNK1 (MAPK8) Pan-specific 
Jun N-terminus protein-serine kinase (stress-activated 
protein kinase (SAPK)) 1 
7090 15476 118 Possible 
PTPN11 (PTP1D; 
PTP2C; SHP2; 
SHPTP2; Syp) 
Pan-specific Tyrosine-protein phosphatase non-receptor type 11 517 1121 117 Possible 
PKCa (PRKCA) Y195 Protein-serine kinase C alpha 666 1422 113 Possible 
PKCg (PRKCG) Pan-specific Protein-serine kinase C gamma 533 1134 113 Possible 
Rb T356 Retinoblastoma-associated protein 1 410 864 111 Possible 
CDC2L5 (CHED, 
CDK13) 
Pan-specific CDC2-related protein kinase 5 542 1135 109 Possible 
Fos Pan-specific 
Fos-c FBJ murine osteosarcoma oncoprotein-related 
transcription factor 
547 1125 106 Possible 
FGFR3 Y647+Y648 Fibroblast growth factor receptor 3 3749 7643 104 Possible 
eIF4B Pan-specific Eukaryotic translation initiation factor 4B 482 980 103 Possible 
NFKB1 (NFkB-p105) S932 Nuclear factor NF-kappa-B p105 subunit 378 765 102 Possible 
IGF1R Y1161+T11 Insulin-like growth factor 1 receptor protein-tyrosine 1058 2056 94 Possible 
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63 kinase 
Pim3 Pan-specific Serine/threonine-protein kinase Pim-3 418 786 88 Possible 
TAO1 (TAOK1) Y309 Serine/threonine-protein kinase TAO1 1814 3348 85 Possible 
ZC2 (TNIK) Pan-specific TRAF2 and NCK-interacting kinase 419 767 83 Possible 
Lyn Pan-specific 
Yes-related protein-tyrosine kinase; Tyrosine-protein 
kinase Lyn 
467 849 82 Possible 
MELK Y438 Maternal embryonic leucine zipper kinase 800 1416 77 Possible 
LEDGF S273+S275 PC4 and SFRS1-interacting protein 680 1194 76 Possible 
Tyro3 Y685+Y686 Tyrosine-protein kinase receptor TYRO3 1798 3121 74 Possible 
SOCS7 Y561 Suppressor of cytokine signaling 7 6744 11599 72 Possible 
PTPN1 (PTP1B) Y66 Tyrosine-protein phosphatase non-receptor type 1 1498 2545 70 Possible 
MARK4 Pan-specific 
MAP/microtubule affinity-regulating protein-serine 
kinase 4 
492 827 68 Possible 
PU.1 (SPI1) S146 Transcription factor PU.1 758 1264 67 Possible 
ILK1 (ILK) S343 Integrin-linked protein-serine kinase-1 698 1158 66 Possible 
Rb T826 Retinoblastoma-associated protein 1 1524 2522 65 Possible 
PIK3R1 Y467 Phosphatidylinositol 3-kinase regulatory subunit alpha 7791 12760 64 Possible 
SIK3 (QSK) T163 Salt-inducible serine/threonine-protein kinase SIK3 8840 14444 63 Possible 
JNK2 (MAPK9) Pan-specific 
Jun N-terminus protein-serine kinase (stress-activated 
protein kinase (SAPK)) 2 
5195 8391 62 Possible 
LATS2 (KPM) Pan-specific Large tumour suppressor 2 protein-serine kinase 4051 6453 59 Possible 
Ron (RONa) Y1238 Macrophage-stimulating protein receptor alpha chain 10756 16801 56 Possible 
Raf-B (BRaf) S729 
B-Raf proto-oncogene serine-threonine-protein kinase; 
RafB proto-oncogene-encoded protein-serine kinase 
2486 3827 54 Possible 
CDK6 Y24 Cyclin-dependent protein-serine kinase 6 4531 6941 53 Possible 
  
232 
NDR1 (NDR, STK38) S281+T282 Serine/threonine-protein kinase 38 10051 15336 53 Possible 
ErbB2 (HER2, Neu) Y735 ErbB2 (Neu) receptor-tyrosine kinase 5339 8084 51 Possible 
Met Y1234 Hepatocyte growth factor (HGF) receptor-tyrosine kinase 5777 8705 51 Possible 
VIM Y117 Vimentin 3333 4965 49 Possible 
mTOR (FRAP) Pan-specific 
Mammalian target of rapamycin (FRAP); FKBP12-
rapamycin complex-associated protein 
12239 18124 48 Possible 
TBK1 S172 
TANK binding kinase TBK1; Serine/threonine-protein 
kinase TBK1 
3455 5111 48 Possible 
MSK1 (RPS6KA5) S212 
Mitogen & stress-activated protein-serine kinase 1; 
Ribosomal protein S6 kinase alpha 5 
8139 12015 48 Possible 
CSF1R (Fms) Y809 Macrophage colony-stimulating factor 1 receptor 2365 3447 46 Possible 
PKD2 (PRKD2) S197+S198 Serine/threonine-protein kinase D2 5322 7741 45 Possible 
CDKL2 Pan-specific 
Cyclin-dependent kinase-like 2; Serine/threonine protein 
kinase KKIAMRE 
3657 5312 45 Possible 
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Table 5.12: Top signalling pathways which were upregulated in SIPA1 knock 
down cells compared to pEF control cells after the treatment of HGF. Generated 
from: www.reactome.org.  
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Figure 5.10: Genome-wide overview of the signalling pathway which were up regulated in SIPA1 knock down cells compared to pEF 
control cells after the treatment of HGF. Pathways are arranged in a hierarchy. The centre of each of the circular represents the root of the 
top-level pathway. Each step away from the centre represents the next level lower in the pathway hierarchy. The light-yellow colour denotes over-
representation of that pathway. Light grey signifies pathways which are not significantly over-represented. Generated from: www.reactome.org.  
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Different comparison methods can obtain many signalling pathways that regulate 
SIPA1 and/or HGF/MET. Among those we selected some high-frequency, 
representative signalling pathways for further discussion (Figure 5.11-5.12), and 
more figures of the selected signalling pathways can be found in the appendix.   
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Figure 5.11: Schematic diagram of signalling transduction process. Generated from: www.reactome.org.  
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Figure 5.12: Schematic diagram of signalling by receptor tyrosine kinases. Generated from: www.reactome.org.  
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5.4 Discussion 
The results of the gene expression correlation analysis with SIPA1 both in our lung 
cancer cohorts and the TCGA database demonstrate that SIPA1 is highly correlated 
with the key markers within the HGF/MET signalling pathway and TJs. Focus on the 
HGF/MET signalling pathway related markers, HGF, MET, HGFAC are found high 
corelated with SIPA1 in our lung cancer cohort, and in TCGA cohort besides MET, 
downstream markers of HGF/MET signalling pathway such as MST1, MST1R, PTK2, 
PXN, PRKCA, PTEN, and SRC are all highly corelated with SIPA1. Moreover, another 
major RTK family member EGFR have highly expression correlation with SIPA1 as 
well. The corelated expressions of these molecules have been tested and confirmed 
by two cohorts and all these results indicate that SIPA1 is more likely to synergize 
with these molecules in lung cancer cells.  
The gene expression correlation analysis also shows us the potential regulation role 
of SIPA1 on TJs. In our Peking lung cancer cohort, transcript level of some TJs 
markers such as JAM2, OCLD, MARVEL D2, and NECTIN2 are highly corelated with 
SIPA1, and JAM1 protein encoding gene F11R, ZO family encoding genes, Claudin 
proteins encoding genes such as CLDN4, CLDN7, CLDN12, CLDN15, and PDZ 
domain containing protein encoding gene Marvel D3 were found highly expressed 
with SIPA1. Correlation analysis of gene expression can confirm our previous 
hypothesis to a certain extent. The results reveal that SIPA1 not only interacts with 
the HGF/MET pathway, but their interaction can regulate tight junctions. However, the 
correlation at the transcript level cannot fully explain the specific mechanism of SIPA1 
interacting with HGF/MET in tumours. We performed the protein array analysis, 
aiming to find out the difference on the protein level, investigating the effect of SIPA1 
on the phosphorylation status of intercellular protein.   
Firstly, all the genome-wide figures of the signalling pathway (Figure 5.5-5.10) 
indicate that regulation of the interaction between SIPA1 and HGF/MET focus on the 
area of signal transduction, immune system, disease, cell cycle, developmental 
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biology, and cellular responses to external stimuli (the yellow colour is more 
pronounced in these areas). These are very consistent with our previous assumptions. 
As described in the introduction, HGF/MET signalling pathway belongs to the RTK 
family, and the RTKs are major cell surface proteins involved in Signal Transduction. 
The interaction of SIPA1 with HG/MET regulates cell signal transduction, further 
confirming our previous experimental hypothesis. Meanwhile, in chapter 4, we 
confirmed knockdown SIPA1 could decrease the lung cancer cells’ proliferation and 
invasion potential, which was also further proved by the protein array results, since 
the cell cycle pathway is deeply adjusted.  
It was very interesting indeed to find that signal transduction pathway and receptor 
tyrosine kinases (RTK) pathway were both upregulated and downregulated with the 
collective effect of SIPA1 and HGF/MET. This demonstrated that the combined effect 
of SIPA1 and HGF/MET is not a simple one-way regulation, there are extremely 
complicated regulation mechanisms involved. Inhibition of one key molecule or one 
critical pathway may lead to feedback activation of other pathways. For instance, 
Knockdown SIPA1 inhibits the signalling by the signal transduction and RTK 
significantly (Table 5.2), while in Table 5.4, signal transduction and RTK related 
pathways were activated by SIPA1 knockdown, which looks rather contradictory and  
confusing. However as discussed in Chapter 1, the signal transduction and RTKs are 
extremely complex, knockdown SIPA1 inhibits some members of RTKs such as SCF-
KIT signalling pathway, ESR-mediated signalling pathway, and regulation of KIT 
signalling (Table 5.2, Figure 5.13-5.15), but the Interleukin-17 (IL-17) signalling 
pathway was increased (Table 5.4, Figure 5.16) which could also stimulate the signal 
transduction. Knockdown of SIPA1 decreased the RTKs downstream Akt signalling 
pathway (Table 5.2, Figure 5.13-5.15), and increased MAP kinase activation 
signalling pathway (Table 5.4, Figure 5.17) at the same time. In terms of HGF 
treatment and the synergy of SIPA1 and HGF, the MET downstream pathways MAP 
kinases activation signalling and MAPK family signalling cascades signalling were 
both activated by treatment of HGF, which was consistent with general understanding. 
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ESR signalling was activated with MET synergistically (Table 5.8), further enhanced 
RTK signalling and signal transduction. Treatment with HGF inhibits SCF-KIT 
signalling, VEGFA-VEGFR2 signalling, and VGEF signalling, indicating that they may 
be competitive with MET. Downstream of RTKs such as MAPK target, ERK/MAPK 
targets, and MAP kinase activation signalling pathway were all downregulated by HGF 
(Table 5.6). Compared to its role in control cells, knocking down SIPA1 can reduce 
the active effect of HGF on cell cycle signalling, indicating that the regulation of SIPA1 
on proliferation of lung cancer A549 cells was mediated by interacting with HGF/MET 
(Table 5.10). Interaction between SIPA1 and HGF/MET enhanced RTKs signalling by 
activating the SCF-KIT, FGFR3 signalling pathway, further strengthening intracellular 
downstream PI3K/Akt and PIP3 actives Akt signalling (Table 5.12).  
Extremely complex interaction between SIPA1 and HGF/MET is consistent with the 
clinical status of lung cancer. As stated previously, 5-22% lung cancer patients with 
acquired resistance to EFGR-TKI have MET amplification and oncogenic mutation. 
The amplification and oncogenic mutation at Exon 14 of MET are the second most 
common cause for acquired resistance to EFGR-TKI after EGFR T790M resistance 
mutation (Wu et al., 2017). This all proves the complexity of the positive/negative 
regulation within the RTKs family from distinct perspectives. Certain treatment may 
inhibit one or more RTKs, but at the same time it will cause other RTKs members to 
rise in a feedback manner. Therefore, the specific interaction mechanism between 
SIPA1 and HGF/MET signalling pathway requires further investigation. The regulation 
of interaction between SIPA1 and HGF/MET in lung cancer cells and lung cancer 
metastasis is worthy of more detail explanation in order to have a better understanding 
for clinical application.  
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Chapter-6 SIPA1 is a modulator of 
the regulation of HGF on cellular 
function behaviour of human lung 
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6.1 Introduction  
As discussed in Chapter 1 and Chapter 5, intracellular signalling pathways regulated 
by the interaction of SIPA1 and HGF/MET in human lung cancer cells are complicated, 
with various positive and/or negative feedback adjustments which are still unclear. 
SIAP1 can interact with many Intracellular molecules to play an essential role in the 
regulation of cancer cell aggressive behaviours. In the nucleus, SIPA1 can bind to the 
promoter region of ITGB1 gene and enhance ITGB transcription, increase the 
expression of Integrin β 1, which accordingly activates the integrin-mediated FAK/Akt 
signalling pathway (Takahara et al., 2017, Zhang et al., 2015). SIPA1 directly binds to 
AQP2 and participates in the regulation of AQP2 transportation (Noda et al., 2004). It 
was found that Brd4 could bind to the SIPA1 GRD domain, and SIPA1 reduces the 
expression of BRD4 in the nucleus. This interaction further enhances the expression 
of MMP7, leading to tumour invasion and metastasis, and tumour growth (Takahara 
et al., 2017, Alsarraj et al., 2013). The regulatory mechanism of the MET pathway is 
multi-dimensional. The regulation may be directly on the MET receptor or the key 
molecules of the downstream signalling (Zhang and Babic, 2016). Moreover, the 
regulation of the MET receptor is also multifaceted, which includes MET oncogene 
mutations, methylation of the MET oncogene, regulation by transcription factors, 
alternative splicing of mRNA, mRNA regulated by microRNAs, regulation of 
translation of the MET receptor, proteolysis of MET, modifications of the MET receptor 
such as glycosylation and phosphorylation, MET internalization and degradation, 
nuclear localization of MET, and MET autoregulation. Furthermore, other membrane 
molecules such as RTKs EGFR, and other oncogenes such as p53 are all involved in 
the regulation of MET (Zhang and Babic, 2016).  
Since the regulation of MET is extremely complicated, which regulatory process 
involving SIPA1 and the specific mechanisms involved require clarification. At the 
same time, we see that the effect of HGF on cells requires the presence of SIPA1. 
How the interaction of SIPA1 and HGF/MET affects cell aggressive behaviour and 
barrier function requires further investigation.  
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One of the limited numbers of molecules known to be the target of SIPA1 signalling is 
Rap1/MEK/ERK. It is a target of SIPA1 and is also located downstream of the HGF 
signalling pathway, responding to the action of HGF (Kurachi et al., 1997, Birchmeier 
et al., 2003b). Meanwhile, SIPA1 and AF6 have been shown to be able to interact with 
each other (Su et al., 2003). AF6 is one member of the membrane integral protein at 
the TJ in the cell. It directly or indirectly interacts with other TJ proteins including ZO1, 
Occludin and JAMs (Singh et al., 2003, Martin, 2014, Tracey A. Martin, 2013, Martin 
et al., 2013). Collectively, these studies suggest that SIPA1 may have the potential to 
regulate TJs under the induction of HGF, which in turn may play a role in the 
development and metastasis of the tumour. In this chapter, we aim to find out the 
mechanism of the interaction of SIPA1 and HGF/MET. We perfumed a series of 
experiment to examine the effect of SIPA1 knockdown on MET and tight junction 
components.  
In this chapter, we aim to find out the mechanism of the interaction of SIPA1 and 
HGF/MET. We performed a series of experiment to examine the effect of SIPA1 
knockdown on MET and tight junction components.  
 
6.2 Materials and methods  
6.2.1 RNA extraction, RT-PCR, and QPCR  
The RNA was extracted by using Tri Reagent as described in section 2.8.1. After the 
isolation of RNA was completed, the quantification of RNA was carried out as 
described in section 2.8.2, followed by RT-PCR to obtain the cDNA. The cDNA could 
then be used for PCR and QPCR as describes in section 2.4.3 to 2.4.6.  
 
6.2.2 Primers and antibody 
All the primers used were synthesised and provided by Invitrogen (Paisley, UK). 
Primer sequences are shown in Table 2.3, 2.4. The name, molecular weight, supplier, 
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and the product code of the primary and secondary antibodies used in this chapter is 
shown in Table 2.5. 
 
6.2.3 Protein extraction, SDS-PAGE, and western blot analysis  
The extraction of protein was carried out as the description in section 2.5.1. Proteins 
were extracted using lysis buffer and then quantified using the Bio-Rad DC Protein 
Assay kit (Bio-Rad Laboratories, Hemel-Hempstead, UK). After separation in the 
SDS-PAGE gel, proteins were transferred onto PVDF membranes as described in 
section 2.5.2. The membranes with protein were subsequently blocked and probed 
with various primary antibody and a corresponding peroxidise-conjugated secondary 
antibody. The antibodies’ information in this study is shewed in Table 2.5. Finally, the 
protein bands on the membrane were visualised using the chemiluminescence 
detection kit (Luminata, Millipore).  
 
6.2.4 In vitro cell growth assay  
Due to the difference growth speed between different cell lines, 3,000 - 5,000 cells 
were seeded into 200μl medium in three 96-well plates appropriately. After incubation 
for 1, 3, and 5 days respectively, the cells were fixed and stained by crystal violet. The 
absorbance was measured after dissolving the crystal violet with acetic acid (10% v/v) 
and the absorbance was determined at a wave length of 560nm using a 
spectrophotometer (BIO-TEK, Elx800, UK). 
 
6.2.5 In vitro cell invasion assay  
20,000-40,000 cells were seeded into transwell inserts (pore size, 8μm, Millicell, 
Merck KGaA, Darmstadt, Germany) coated with 50μg Matrigel. After the incubation 
of three days, cells that had invaded through the Matrigel and migrated on to the other 
side of the insert were fixed and stained with crystal violet and then counted. The 
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absorbance was measured after dissolving the crystal violet with acetic acid (10% v/v) 
and the absorbance was determined at a wave length of 560nm using a 
spectrophotometer (BIO-TEK, Elx800, UK). 
 
6.2.6 Electric Cell-Substrate Impedance Sensing (ECIS)  
ECIS assay to detect the resistance of cells was performed as described in section 
2.7.8. 50,000 cells were seeded in the 96W1E+ electrode array plate after stabilization, 
following with measurement over different frequencies were to study different 
functional and structural cell properties. In this study, resistance measured under 
1,000-4000Hz frequencies were chosen to analyse cell resistance referring to the 
function of tight junction.  
 
6.2.7 Immunofluorescence staining 
Immunofluorescence staining to detect the cell location and the target molecules’ 
location of cells was performed as described in section 2.4.9. Cells were seeded into 
8 or 16 well glass chamber slides to reach about 90% confluency. Cells were fixed 
and washed, then treated with a permeabilisation buffer before additional washing. 
Block the cells and add primary antibody and secondary antibodies. Secondary 
antibodies tagged with either FITC or TRITC, and DAPI for nuclear staining. laid over 
the slides, examined under a fluorescent microscope.  
 
6.2.8 Statistical Analysis  
In this chapter, t-tests, Mann-Whitney test, and one-way ANOVA test were performed 
using the Graphpad Prism 6 software. Image J software was sued to analyse the PCR 
and western blotting bands. The results of the ECIS assay was analysed using the 
ECIS software. Differences were considered to be statistically significant when p<0.05.  
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6.3 Results 
6.3.1 The impact of HGF on the cellular behaviour of lung cancer cells 
We carried out a series of in vitro function assay to determine the effect of HGF in the 
A549 and SKMES1 cells and whether the effect was regulated after knockdown of 
SIPA1 on the A549 and SKMES1 cells.  
In vitro trans-well invasion assay was performed to investigate the effect of HGF on 
the invasion function of pEF-CT and SIPA1-knockdown A549 and SKMES1 lung 
cancer cell lines. Results showed that invasion potential was markedly increased after 
the treatment with HGF on the pEF-CT A549 and SKMES1 cells. After knockdown of 
SIPA1 in A549 and SKMES1 cells, the reaction of the invasion potential to HGF was 
reduced (Figure 6.1). 
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Figure 6.1: HGF increased the invasion potential of pEF-CT A549 cells, and 
knockdown of SIPA1 decreased invasion both in A549 pEF control and SIPA1 
knockdown cells. Representative images of A549 invaded cells after staining (upper) 
and the absorbance measured by dissolving the crystal violet from stained invaded 
cells, bar graph shows the absorbance measured by dissolving the crystal violet from 
stained invaded cells. Error bars show Sd.  
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6.3.2 The impact of HGF on the barrier function of lung cancer cells 
Electric cell-substrate impedance sensing (ECIS) assay was performed to measure 
the change of TJ function on lung cancer cells after treatment of HGF. The data from 
the ECIS assay showed HGF reduced the barrier function of the pEF-CT A549 cells, 
and the inhibitor of MET could counteract the effect of HGF on pEF-CT cells, and HGF 
did not reduce tight junction barrier function after knockdown of SIPA1 on A549 cells 
(Figure 6.2).  
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Figure 6.2 A: HGF decreases cell-cell tight junction function of A549 pEF-CT 
cells significantly, but did not decrease tight junction function of A549 SIPA1 
knockdown cells. Graph indicates measurement of the change of resistance at the 
1000Hz frequency to analyse cell resistance which can be used to assess to the 
function of tight junctions. First time point = wounding, second time point = treatment 
with HGF.   
 
 
  
250 
 
Figure 6.2 B: HGF decreases cell-cell tight junction function of A549 pEF-CT 
cells significantly, but did not decrease tight junction function of A549 SIPA1 
knockdown cells and this effect produced a similar result as that achieved when 
using the MET inhibitor. The combination of SIPA1 knockdown and MET 
inhibitor could further prevent regulation of HGF on A549 cells. Graph indicates 
measurement the change of the resistance using 1000Hz frequency to analyse cell 
resistance resistance which can be used to assess to the function of tight junctions. 
First time point = wounding, second time point = treatment with HGF.  
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6.3.3 The interaction of SIPA1 and MET  
To determine the role of SIPA1 in the HGF/MET signalling pathway, we first detected 
the expression level of MET in the control and SIPA1 knockdown A549 and SKMES1 
cells. Both the results from the normal PCR and QPCR showed the transcript level of 
MET was not influenced by the knockdown of SIPA1 in A549 lung cancer cell lines, 
and in SK-MES1 lung cancer cell lines, QPCR showed the transcript level of MET was 
even higher in SIPA1-KD cells compared to pEF-CT cells (Figure 6.3, 6.4). Western 
blotting result showed that the protein level of MET was reduced in SIPA1 knockdown 
A549 and SKMES1 cells (Figure 6.5, 6.6). And the phosphorylation of MET was also 
reduced in SIPA1 knockdown cells (Figure 6.7).  
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Figure 6.3: The mRNA level of MET was not regulated by the knockdown of 
SIPA1 in A549 lung cancer cell lines examined using conventional PCR. A. PCR 
bands of MET and GAPDH in the wide type control, pEF-control and SIPA1 
knockdown cells. B. Quantitative analysis of the PCR bands.  
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Figure 6.4 A: The mRNA level of MET was not regulated by the knockdown of 
SIPA1 in A549 lung cancer cell lines examined using QPCR. A. SIPA1 transcript 
level was reduced in SIPA1 knockdown cells significantly. B. MET transcript level was 
not changed in SIPA1 knockdown cells.  
 
 
Figure 6.4 B: The mRNA level of MET was not regulated by the knockdown of 
SIPA1 in SK MES1 lung cancer cell lines examined using QPCR. MET transcript 
level was even improved in SIPA1 knockdown cells. 
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Figure 6.5: The protein level of MET was down regulated by the knockdown of 
SIPA1 in A549 lung cancer cell lines examined using western blotting. Figure 
showed the bands of SIPA1, MET and GAPDH in three repeated protein samples from 
SIPA1 knockdown A549 cells and one A549 pEF-CT sample.  
 
 
Figure 6.6: The protein level of MET was down regulated by the knockdown of 
SIPA1 in A549 and SKMES1 lung cancer cell lines examined using western 
blotting. The column shows ratio of MET to GAPDH as loading control in SIPA1-KD 
cells compared to pEF-CT cells in (A) A549 cell line and (B) SKMES1 cell line. Image 
J software was used to analyse the bands quantitatively. Error bars show SD.  
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Figure 6.7: The phosphorylation level of MET was down regulated by the knockdown of SIPA1 in A549 lung cancer cell lines examined 
using western blotting. Figure showed the bands of MET, phosphor-MET and GAPDH in three repeated protein samples from SIPA1 knockdown 
A549 cells and one A549 pEF-CT sample. Three phosphorylation sites of MET were detected using different antibodies.  
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6.3.4 Impact of SIPA1 on the expression of TJ components 
To begin exploring the potential relationship between SIPA1 and TJ components in 
A549 cells, QPCR aiming to investigate gene expression of the major TJ proteins 
was performed (Figure 6.8). Claudin1, Claudin2, Claudin7, Claudin8, Claudin10, 
Claudin11, Claudin14, Claudin17 from the Claudin family, constituting an important 
transmembrane TJ protein family, were statistically downregulated and Claudin5 was 
statistically upregulated in SIPA1 knockdown A549 cells. The effects of knockdown 
of SIPA1 on the JAM family or ZO family were not significantly significant. Whilst AF6 
was upregulated, MUPP1 was downregulated significantly; both of these two proteins 
contain a PDZ domain. Marvel D3, binding protein belonging to TAMP family was 
statistically downregulated by knockdown of SIPA1, while the Occludin, another 
TAMP protein was upregulated by knockdown of SIPA1 in terms of transcript level. 
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Figure 6.8 A: The effect of SIPA1 knockdown on gene expression of Claudin family in A549 cells. Gene expression was assessed using 
QPCR, expression was normalised to GAPDH and is shown as fold change relative to pEF control. Error bars show SD.  
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Figure 6.8 B: The effect of SIPA1 knockdown on gene expression of JAM family in A549 cells. Gene expression was assessed using QPCR, 
expression was normalised to GAPDH and is shown as fold change relative to pEF control. Error bars show SD.  
 
  
260 
 
Figure 6.8 C: The effect of SIPA1 knockdown on gene expression of TJ proteins containing a PDZ domain in A549 cells. Gene expression 
was assessed using QPCR, expression was normalised to GAPDH and is shown as fold change relative to pEF control. Error bars show SD. 
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Figure 6.8 D: The effect of SIPA1 knockdown on gene expression of TAMP proteins in A549 cells. Gene expression was assessed using 
QPCR, expression was normalised to GAPDH and is shown as fold change relative to pEF6 control. Error bars show SD.  
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in SK MES1 cells, potential relationship between SIPA1 and TJ components was 
investigated using QPCR in transcript level (Figure 6.9). The knockdown of SIPA1 
upregulated the transcript level of ZO family significantly with the same trend we 
found in A549 cells (Figure 6.8 C) (while the trend in A549 cells were not significantly). 
Whilst AF6 was downregulated with significantly significant, MUPP1 was upregulated; 
the trend of these two were not same with A549 cells. Both Marvel D3 and Occludin, 
binding protein belonging to TAMP family, were statistically upregulated by 
knockdown of SIPA1 in transcript level.  
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Figure 6.9 A: The effect of SIPA1 knockdown on gene expression of TJ proteins containing a PDZ domain in SK MES1 cells. Gene 
expression was assessed using QPCR, expression was normalised to GAPDH and is shown as fold change relative to pEF control. Error bars 
show SD.
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Figure 6.9 B: The effect of SIPA1 knockdown on gene expression of TAMP proteins in SK MES1 cells. Gene expression was assessed 
using QPCR, expression was normalised to GAPDH and is shown as fold change relative to pEF control. Error bars show SD.
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Western blotting was performed to further investigate the potential relationship 
between SIPA1 and TJ components in A549 cells (Figure 6.10, 6.11). Claudin7, 
Claudin10 and Claudin15 protein levels were decreased by knockdown of SIPA1 in 
A549 cells, with the trend supporting the results of assessment at the mRNA level. 
The effect of knockdown of SIPA1 on the JAM family, Occludin and PDZ domain 
containing proteins was not significant. In CORL23 cells the effect of knockdown of 
SIPA1 on AF6 or ZO1 was not significant.
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Figure 6.10: The effect of SIPA1 knockdown on expression TJ proteins in protein level in A549 cell line. Protein level of TJ proteins was 
assessed using western blotting, protein expression in SIPA1-KD cells was compared to pEF-CT cells. (A) The effect of SIPA1 knockdown on 
JAM family components. (B) The effect of SIPA1 knockdown on Claudin family components. (C) The effect of SIPA1 knockdown on AF6 and ZO 
family components.   
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Figure 6.11: The effect of SIPA1 knockdown on expression of AF6 and ZO1 in 
protein level in CORL23 cell line. Protein level of TJ proteins was assessed using 
western blotting, protein expression in SIPA1-KD cells was compared to pEF-CT and 
WT-CT cells.  
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6.3.5 The impact of SIPA1 on the morphology of the cells and TJs  
As we described, knockdown SIPA1 downregulated the tight junction based cell to 
cell barrier function, and numerous tight junction molecules were affected by 
knockdown of SIPA1 at the transcript level and/or protein level. Following this, we 
carried out immunofluorescence staining to further investigate the visible impact of 
SIPA1 on the cell morphology and tight junctions. ZO1 was chosen to stain in the 
A549 pEF-CT cells and SIPA1-KD cells. The immunofluorescence staining 
demonstrated that the intensity of ZO1 was strong in the pEF control cells but weak 
in the SIPA1 knockdown cells, and the tight junctions between cells were rather loose 
and spotty. In the control group, the cells were spread on the surface of the slides 
with strong and tight binding, but the SIPA1 knockdown cells were separated from 
each other with rather more isolated cells due to cell to cell association after tight 
junction disassembly (Figure 6.12, 6.13).  
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Figure 6.12: Immunofluorescence staining for ZO1 in A549 pEF-CT cells and SIPA1-KD cells. The pEF-CT cells have good ZO1 staining 
and tight junction integrity compared to the SIPA1-KD cells. The staining for ZO-1 in knockdown cells much reduced. Red arrows indicate the 
ZO1 staining indicating intact to tight junctions between cells. DAPI was used to show the nuclear staining. The bars correspond to 10μm.   
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Figure 6.13: Typical images displaying the immunofluorescence staining of ZO1 in the A549 pEF-CT cells and SIPA1-KD cells. The pEF-
CT cells have stronger ZO1 staining and tight junctions compared to the SIPA1-KD cells where the staining is much reduced of spotty. Red arrows 
indicate ZO1 staining indicating intact tight junctions between cells. The bars correspond to 10μm.  
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6.4 Discussion 
In the previous chapters, an unanticipated finding from the present study was the 
highly significant correlation between SIPA1, HGF and MET in lung cancer tissues. 
This provides evidence at a tissue level of this important link, and to some degree is 
indicated in previous studies (Kurachi et al., 1997, Birchmeier et al., 2003b). It was 
also interesting to note that SIPA1 did not correlate with HGFL and its receptor, RON, 
which to a good degree argue the close link between HGF/MET. Similarly, to the 
results found in breast cancer, the promotion of invasion and the reduction of tight 
junctions by HGF in lung cancer cells also require the participation of SIPA1 (Figure 
6.1-6.2). We also found that knockdown of SIPA1 decreased the reaction of lung 
cancer cells to HGF, which was similar to the MET targeted inhibitor Crizotinib. These 
results indicate that targeting SIPA1 could be a potential treatment for lung cancer 
patients with abnormal MET activity, amplification or mutation. However, as described 
earlier, the mechanism by which SIPA1 participates in the complex regulation of 
HGF/MET pathways is indefinite, and at which level SIPA1 is involved in the 
regulation of HGF/MET undefined explicitly. There exist dozens of approaches to the 
regulation of MET, such as transcriptional regulation, translational regulation, and 
phosphorylation, etc(Zhang and Babic, 2016). Previous research revealed SIPA1 
could either bind to the promoter region and regulate the transcription in the nucleus, 
or directly act on the protein molecule to regulate its biological function (Zhang et al., 
2015, Alsarraj et al., 2013). Here we found in lung cancer cells, transcription of MET 
was not regulated by SIPA1, the regulation of SIPA1 on MET was actually at the 
protein level, and both expression and phosphorylation level of MET are reduced after 
SIPA1 knockdown (Figure 6.3-6.7). This shows that in the regulation of MET, SIPA1 
is not working as a transcription factor, but a regulator of MET at the protein levels, 
which includes two aspects. Firstly, the decreasing MET receptor reduces the number 
of targeted sites on the cell surface for HGF, which inhibits the HGF/MET signalling 
in the ligand/receptor binding level. Secondly, the downregulated phosphorylation of 
Tyr1349 and Tyr1356 makes MET lose its ability to provide a binding site for 
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downstream molecules, which silences the HGF/MET signalling by blocking 
downstream activation. These data largely explain how SIPA1 regulates the 
HGF/MET signalling pathway.  
Simultaneously, SIPA1 decreased TJ function in lung cancer, so QPCR and western 
blotting were performed to detect the effect of SIPA1 on gene transcription and protein 
expression of TJ components. At the mRNA level, Claudin1, Claudin2, Claudin7, 
Claudin8, Claudin10, Claudin11, Claudin14 and Claudin17 from the Claudin family 
were downregulated after knockdown of SIPA1, as well as MUPP1 which contains a 
PDZ domain. Claudin5 and another PDZ domain containing protein, AF6 were 
upregulated. Previous studies showed that SIPA1 also contains a PDZ domain 
(Hattori, 2011) and several TJ markers such as ZO1, ZO2, AF6 MAGI1, MAGI2, 
MAGI3, PAR3, PAR6 and MUPP1 all contain a PDZ domain (Martin and Jiang, 2009). 
These proteins all constitute the plaque or anchoring function for TJs and link the 
transmembrane components with the signalling mechanism of the cell. The IF 
staining result showed that ZO1 was strong in the pEF control cells but weak in the 
SIPA1 knockdown cells, and knockdown of SIPA1 loose the tight junctions between 
cells. These all suggest that SIPA1 could be a potential regulator of TJs. Previous 
studies also showed that SIPA1 co-localised with AF6 in Hela cells (Su et al., 2003) 
and that AF6 could bind to ZO1 in MDCK2, Rat1 and PC12 cells (Yamamoto et al., 
1997). Thus, we may have a conclusion indicating that the mechanism of SIPA1 
regulating TJs in lung cancer may be via the interaction between SIPA1 and AF6 or 
ZO1.  
Therefore, we can conclude that in lung cancer cells, HGF binds to the MET receptors 
on the cell surface, reducing the cell to cell tight junctions via acting on the regulating 
components of TJs such as AF6 and ZO family. This process requires the presence 
of SIPA1 to maintain the MET expression at a rather high level, which make sure that 
there exist sufficient MET receptors on the surface of lung cancer cell membrane to 
acquire adequate respond to the stimulation of HGF.  
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7.1 Introduction  
In the previous chapter 5 and 6, we summarized the interaction mechanism of SIPA1 
and HGF/MET signalling pathway: the high expression of SIPA1 in lung cancer cells 
maintains a high level of MET. As a result, the cells obtain a higher response to HGF 
stimulation, which enhances the ability to invade and proliferate, and reduces the tight 
junction-dependent barrier function through the regulation on AF6 and ZO families. 
Focusing on the regulation of SIPA1 on the protein level of MET, we further 
investigated the changes of other key molecules brought by the interaction of SIPA1 
with HGF/MET signalling pathway.  
Growth factor receptor bound protein 2 (Grb2) is a 25 kDa adaptor protein, which is 
a 217 amino acid sequence with a Src homology 2 (SH2) domain and two Src 
homology 3 (SH3) domains. Grb2 works as an intermediate linker between the 
activated receptors on the cell membrane surface and downstream targets through 
the SH2 and SH3 domains. Downstream of the MET signalling, activated MET has 
phosphorylated tyrosine residues Tyr1234 and Tyr1235 in the catalytic region, which 
could phosphorylate the Tyr1349 and Tyr1356 tyrosine residues in the C-terminal 
docking site, providing the docking site for the SH2 domain of Grb2. Meanwhile the 
SH3 domain of SH3 could recruit other key molecules such as SOS, leading the 
activation of Ras mediated PI3K/PDK/Akt signalling pathway and RAF/MEK/ERK 
signalling pathway (Ijaz et al., 2018).  
Suppressor of cytokine signalling (SOCS) protein family includes SOCS1-7 and CIS 
(cytokine-inducible SH2-containing protein), which are the essential components that 
regulate RTK signalling. All the SOCS proteins contain a SH2 domain which could 
also be recruited by the phosphorylated Tyr1349 and Tyr 1356 tyrosine residues in 
the docking site of MET.  Expression of the SOCS family is enhanced by RTKs 
signalling. Nevertheless once SOCS proteins bind to the RTKs, the RTKs are 
silenced by the interaction (Yoshimura et al., 2007, Kile and Alexander, 2001). The 
RTKs downstream JAK/STAT signalling was confirmed to be suppressed by SOCS 
family (Kazi et al., 2014).  
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The protein kinase C (PKC) family consists of a series of serine/threonine kinases 
with conserved structures. PKC family are involved in a group of metabolic processes 
and implicated in multiple signal transduction networks (Isakov, 2018).  
Although knockdown SIPA1 decreased MET at the protein level, the mechanism by 
which SIPA1 is involved during the procedure of the generation and degradation of 
MET receptor protein needs to be explained. As stated previously, Grb2, SOCS family 
proteins and PKC are involved in the internalization and recycling of MET (Viticchiè 
and Muller, 2015). In the initial stages of internalization and recycling, docking 
tyrosine Tyr1349 and Tyr 1356 are activated to recruit related molecules, in which 
Grb2 is involved to enhance the recruitment effect. A crucial molecule in 
internalization is Cbl (Castias B-lineage lymphoma), which is an E3 ubiquitin ligase 
responsible for MET ubiquitination, and Grb2 is confirmed to be required for Cbl-
dependent MET internalization and endocytosis (Hausser et al., 2002, Zhang and 
Babic, 2016). The SH2 domain of SOCS binds to the Met protein while its SOCS box 
recruits the E3 ubiquitin, leading to MET ubiquitination and internalization (Gui et al., 
2011). PKC is a major molecule in the progress from MET internalization to the 
formation of endosomes (Viticchiè and Muller, 2015). Therefore, in this chapter we 
further examined the expression of Grb2, SOCS family, and PKC proteins after SIPA1 
knockdown in lung cancer cells, and further investigated whether MET internalization 
and recycling were regulated by SIPA1.  
 
7.2 Materials and methods  
7.2.1 Primary and secondary antibody 
The name, molecular weight, supplier, and the product code of the primary and 
secondary antibodies used in this chapter is shown in Table 2.5. 
 
7.2.2 Protein extraction, SDS-PAGE, and western blot analysis  
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The extraction of protein was carried out as the description in section 2.5.1. Proteins 
were extracted using lysis buffer and then quantified using the Bio-Rad DC Protein 
Assay kit (Bio-Rad Laboratories, Hemel-Hempstead, UK). After separation in the 
SDS-PAGE gel, proteins were transferred onto PVDF membranes as described in 
section 2.5.2. The membranes with protein were subsequently blocked and probed 
with various primary antibody and a corresponding peroxidise-conjugated secondary 
antibody. The antibodies’ information in this study is shewed in Table 2.5. Finally, the 
protein bands on the membrane were visualised using the chemiluminescence 
detection kit (Luminata, Millipore).  
 
7.2.3 Statistical Analysis  
In this chapter, t-tests, Mann-Whitney test, and one-way ANOVA test were performed 
using the Graphpad Prism 6 software. Image J software was sued to analyse the 
PCR and western blotting bands. Differences were considered to be statistically 
significant when p<0.05.  
 
7.3 Results  
In order to investigate whether the internalization and recycling of MET is regulated 
by SIPA1, we have selected a series of molecules that have been shown by previous 
studies to regulate the internalization and recycling of MET. Grb2, suppressor of 
cytokine signalling (SOCS) protein family, and protein kinase C Mu (PKCμ) were 
examined in A549 and SKMES1 SIPA1-KD cells using western blotting compared to 
pEF-CT cells. Figure 7.1 shows the expression of Grb2 was downregulated by SIPA1 
knockdown in A549 and SKMES1 cells. Figure 7.2 shows the expression of most 
SOCS family was inhibited by SIPA1 knockdown in A549 and SKMES1 cells. Figure 
7.3 shows PKCμ was down regulated by SIPA1 knockdown in A549 and SKMES1 
cells.  
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Figure 7.1: The protein level of PKCμ is down regulated by the knockdown of 
SIPA1 in A549 and SKMES1 lung cancer cell lines examined using western 
blotting. The column shows ratio of PKCμ to GAPDH as loading control in SIPA1-
KD cells compared to pEF-CT cells in (A) A549 cell line and (B) SKMES1 cell line. 
Image J software was used to analyse the bands quantitatively. Error bars show SD. 
 
 
Figure 7.2: The protein level of Grb2 is down regulated by the knockdown of 
SIPA1 in A549 and SKMES1 lung cancer cell lines examined using western 
blotting. The column shows ratio of Grb2 to GAPDH as loading control in SIPA1-KD 
cells compared to pEF-CT cells in (A) A549 cell line and (B) SKMES1 cell line. Image 
J software was used to analyse the bands quantitatively. Error bars show SD.  
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Figure 7.3: The protein level of SOCS family in A549 and SKMES1 lung cancer 
cell lines examined using western blotting. The overall level of SOCS family is 
down regulated by the knockdown of SIPA1 in (A) A549 and (B) SKMES1 lung cancer 
cell lines.  
 
  
279 
7.4 Discussion  
As stated in the introduction, Grb2, PKCμ, and the SOCS 1-7 have all been shown to 
play key roles in MET internalization and recycling. Grb2, as the most direct 
recruitment factor of MET, can recruit Cbl to bind with MET and promote ubiquitination 
of MET, which could be regarded as one of the initial factors of MET internalization. 
The SOCS family together with MET form the SOCS box, with the ability to recruit E3 
ubiquitin to promote MET internalization. PKC ensures that internalized METs form 
internal endosomes, which can then be recycled to the surface of the cell membrane 
instead of being degraded. In this chapter, we found Grb2, PKCμ, and some of the 
SOCS family members (SOCS1, 3, 4, 7) are all down regulated in SIPA1 knockdown 
lung cancer A549 and SKMES1 cells compared to pEF control cells. These results 
indicate that in lung cancer cells, SIPA1 works as a promoting factor for MET 
internalization and recycling. Without the participation of SIPA1, the recycling of MET 
will be suppressed. This could be the potential approach by which SIPA1 regulates 
the MET receptor at the protein level.  
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Chapter-8 General discussion  
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8.1 The aims of the thesis  
Independently of region, lung cancer is the leading cause of malignant tumour death. 
Although in the past decades, basic research and clinical trial on lung cancer have 
developed rapidly, the prognosis of lung cancer is still not ideal and metastatic lung 
cancer which has a poor prognosis and limited treatment options. This is largely due 
to the inadequate understanding of the mechanisms of development and metastasis 
of lung cancer. Extensive evidence has suggested that the HGF/MET signalling 
pathway is essential in lung cancer tumorigenesis and progression via the alteration 
of cell apoptosis, growth, migration, morphology and motivation. MET can be 
regarded as one of the driving oncogenes in lung cancer and the cause of drug 
resistance to EGFR TKIs (Trusolino et al., 2010). Based on previous research results 
in the host lab, we selected SIPA1 as a potential modulator of the HGF/MET signalling 
pathway. Therefore, this thesis aimed to evaluate the interaction mechanism of SIPA1 
and HGF/MET, as well as their influence on lung cancer in terms of molecular 
activation, cellular behaviour and clinical relevance.  
 
8.2 Influence of SIPA1 on the function of lung cancer cells  
Gradually, more and more studies indicate the importance of the TJ in cancer 
metastasis. The function of the TJ is not only maintaining the formation of basic 
structure of local tissue, but also to extracellular signal transduction, maintenance of 
cell morphology, and participation in intracellular signalling pathways (Martin, 2014). 
SIPA1 has been shown to work as a driving factor in a variety of tumours, such as 
breast, gastric, cervical, OSCC, colorectal, and prostate cancer (Takahara et al., 2017, 
Li et al., 2017, Yi and Li, 2014, Pei et al., 2013, Ji et al., 2012, Shimizu et al., 2011). 
The potential of SIPA1 in regulating TJs was also confirmed in breast cancer and 
prostate cancer in the host lab (Jiang, 2013, Jiang, 2006). Aiming to find out the 
regulation of SIPA1 on the function of lung cancer cells, we performed a series of 
functional assay in this project. In this current study, the TJ function of the cells was 
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assessed using ECIS analysis, and TER analysis, all of which demonstrated that TJs 
of lung cancer cells were enhanced by SIPA1 knockdown. TJ is seen as the first 
obstacle to overcome in the process of cancer metastasis. More than this, after 
overcoming the barrier function, SIPA1 also enhanced the ability of lung cancer cells 
to invade and proliferate, providing necessary conditions for further spread and 
metastasis of lung tumour cells after breaking through the barrier into adjacent 
stromal tissues. Therefore, we can consider that SIPA1 is a crucial driving force for 
the development and metastasis of lung cancer with the potential to promote 
proliferation and invasion, as well as reduce the TJs of lung cancer cells.   
 
8.3 Influence of SIPA1 interaction with HGF/MET on the function of lung cancer 
cells 
The effect of the HGF/MET signalling pathway on breast cancer cells requires the 
presence of SIPA1 (Jiang, 2013, Jiang, 2006). Likewise, in our current study, we 
found that knockdown of SIPA1 reduced the response of lung cancer cells to HGF in 
terms of invasion and barrier function. HGF enhanced the invasion of pEF control 
cells, while the enhancement could be blocked by SIPA1 knockdown. HGF decreased 
the barrier function of lung cancer cells, which was counteraction of SIPA1 
knockdown was similar to the small molecule MET targeted inhibitor. Since 
knockdown of SIPA1 has a similar outcome to pharmacological MET inhibition on 
blocking the regulation of HGF signalling on tight junctions, we assume that SIPA1 
could have some potential interaction with MET. 
 
8.4 Intracellular interaction between SIPA1 and MET signalling pathway 
The mechanism of interaction between SIPA1 and MET is an important issue to be 
determined in this thesis. We analysed SIPA1 gene expression correlation in the 
Peking lung cancer cohort and the TCGA database, and the results showed that 
SIPA1 is highly correlated with key markers in HGF/MET signalling pathways and TJ 
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components. At the same time, protein phosphorylation array revealed that SIPA1 is 
involved in the regulation of complex signal transduction and RTK activation. This 
confirms what we have described previously - that SIPA1 and MET interact to affect 
changes in cell barrier function. It is known that the regulation of RTKs is an extremely 
complicated process involving multiple signalling pathways. Although protein array 
analysis has shown us that there exists a co-relationship between SIPA1 and RTKs 
family to which MET belongs, the specific mechanism of interaction requires to be 
further demonstrated. However, the protein expression level of MET was suppressed 
by SIPA1 knockdown detected by western blotting, which made the cell surface lack 
sufficient MET receptors to transmit extracellular HGF signals. At the same time, the 
level of MET phosphorylation is also affected by the knockdown of SIPA1. The 
phosphorylation status of key sites of the MET receptor's domain used to anchor 
downstream molecules is inhibited, limiting the function of MET to down-stream 
transmission signals. 
 
8.5 Influence of SIPA1 on the regulation of MET receptor  
As mentioned in Chapter 1 and Chapter 5, MET regulation involves more than a 
dozen different processes from transcription to degradation, which include MET 
oncogene mutations, MET gene methylation, transcription factors regulation, 
alternative splicing, microRNAs regulation, MET translational regulation, proteolysis 
of MET, glycosylation and phosphorylation on MET, internalization, degradation and 
recycling of MET, nuclear localization of MET, and autoregulation of MET. We have 
proved that SIPA1 can regulate the expression of MET, but the specific process (or 
processes) by which SIPA1 acts is still one an area for future study. We selected 
some key regulatory molecules during the MET recycling process such as Grb2, 
SCOS, and PKCμ for further analysis. WB results for these molecules showed that 
the protein expression of these molecules decreased after SIPA1 knockdown. In 
previous publications, Grb2, SCOS, and PKCμ all promoted internalization of MET, 
leading the process towards recycling to the membrane rather than degradation 
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(Viticchiè and Muller, 2015). Knockdown of SIPA1 decreased the expression of these 
molecules which could be the potential approach to regulate MET receptors. 
Therefore, we can conclude that in lung cancer cells, the presence of SIPA1 promotes 
the recycling of MET via Grb2, SCOS, and PKCμ, maintaining the MET receptor at a 
rather high level, thereby further transmitting the HGF signal into the cells.  
 
8.6 Influence of SIPA1 interaction with HGF/MET on tight junction components  
Therefore, the findings in Chapter 4 and Chapter 7 strongly suggest that the 
expression of SIPA1 in lung cancer cells is closely related to the expression of TJ 
molecules and the cell's barrier function. Gene expression correlation analysis 
showed us the potential regulatory effect of SIPA1 on TJs. We analysed data from 
our Peking cohort and the TGCA database. The components of tight junction proteins 
that are highly correlated with expression SIPA1 include JAM1, JAM2, ZO family, 
OCLD, Marvel D2, Marvel D3, NECTIN2, and CLDN4, CLDN7, CLDN12, and 
CLDN15, which are proven in at least one database. QPCR and/or western blotting 
demonstrated that Claudin1, Claudin2, Claudin7, Claudin8, Claudin10, Claudin11, 
Claudin14 and Claudin17 from the Claudin family, and MUPP1 which contains a PDZ 
domain were downregulated after knockdown of SIPA1. Claudin5, and PDZ domain 
containing protein AF6 and ZO family proteins were upregulated in SIPA1 knockdown 
cells compared to pEF control cells. Previous studies showed that SIPA1 contains a 
PDZ domain (Hattori, 2011), and other TJ markers such as the ZO family, AF6, MAGI1, 
MAGI2, MAGI3, PAR3, PAR6 and MUPP1 all contain a PDZ domain (Martin, 2014, 
Martin and Jiang, 2009). PDZ domain is the binding site for those molecules. SIPA1, 
AF6, and ZO family all contain the PDZ domain, which could be the potential 
regulation site at the molecular level. And AF6 and ZO family should be the regulation 
point for SIPA1 to regulate the tight junction  
 
8.7 Clinical relevance of SIPA1  
  
285 
Firstly, the transcriptional expression level of SIPA1 is higher in cancer than adjacent 
normal tissue or normal tissue. In this thesis we examined SIPA1 expression 
transcriptional level in the Peking clinical cohort, which consists of 148 lung tumour 
tissue samples with 148 adjacent normal tissue samples, and 139 tumour tissues 
which were paired to the cancer tissue. SIPA1 transcript levels were high in 148 
tumour tissues compared with both normal tissue (p=0.0141) and paired normal 
tissue (p=0.0358). The IHC staining score of the lung tumour TMA lacks statistical 
significance. The protein level of SIPA1 in tumour tissue samples was higher than 
that in normal lung tissue and adjacent normal lung tissue, but the difference was not 
statistically significant. There may be inconsistencies between SIPA1 gene 
transcripts and SIPA1 protein analysis. As previously discussed, there is a possibility 
that difference exists between the transcription level of SIPA1 gene and the protein 
level of translation, but our Peking clinical cohort is larger than the TMA cohort, and 
most importantly, it has much more normal tissue. The clinical cohort samples are 
fresh frozen from surgery and capable of quantifying the expression of SIPA1 whilst 
the TMA samples are blocked collection only used for qualitative or semi-quantitative 
analysis. In terms of tumorigenesis, the Peking clinical cohort data showed that the 
transcription level of SIPA1 was significantly higher in the advanced T stage and TNM 
stage tumours. From the prognostic analysis of lung cancer database, the median 
survival time of patients with high SIPA1 expression was significantly shorter than 
that of patients with low SIPA1 expression, and the difference is particularly 
pronounced in patients with adenocarcinoma with statistically significance. 
Transcription of SIPA1 was high in lung cancer tumour and more advanced TNM 
stages of lung cancer, and the high level of SIPA1 correlated with the worst prognosis 
of lung cancer patients, which all indicate that SIPA1 can be used as a potential 
independent clinical biomarker to detect the occurrence of lung cancer, measure the 
staging of lung cancer progression, and evaluate the prognosis.  
Secondly, MET is the driving factor and therapeutic target for NSCLC. Crizotinib 
(Xalkori) is approved by the FDA as a MET targeted inhibitor used in NSCLC patients 
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with MET amplification and/or exon 14 skipping mutation. Since SIPA1 can interact 
with MET, and SIPA1 can regulate the MET receptor protein, and the inhibition of 
SIPA1 has similar effects on the TJs of lung cancer cells as MET inhibitors- Crizotinib, 
we believe that SIPA1 may be a potential therapeutic target in NSCLC and a potential 
substitute target for MET targeted therapy resistance in NSCLC.  
The clinical relevance of SIPA1 in NSCLC is reflected in several aspects. SIPA1 could 
be a biomarker of diagnosis, staging and assessment of lung cancer development, 
and prediction of NSCLC patients’ prognosis. In terms of the treatment, SIPA1 could 
be utilised to evaluate the curative effect of MET targeted therapy, and targeted 
inhibition of SIPA1 may be synergistic with MET inhibitors for NSCLC.   
 
8.8 Final conclusion and perspectives  
In concluding this work, SIPA1 plays an essential role in NSCLC tumorigenesis and 
metastasis, by enhancing invasion and proliferation and suppressing the barrier 
function of lung cancer cells. This is achieved via promoting Grb2, SOCS and PKCμ, 
ensuring the recycling of MET, and further ensuring normal transmission of the 
HGF/MET signalling pathway (Figure 8.1). This summarises the findings of this 
thesis: SIPA1 and HGF form an axis that is able to regulate the function of TJ’s in 
human lung cancer cells. This novel discovery offers a pathway that may be explored 
both biologically and clinically. Biologically, this of interest as there has previously 
been little information regarding the exact pathway involved in HGF effected changes 
of TJ function. Clinically, this pathway may provide possible routes of therapeutic 
intervention. How this can be achieved is beyond the scope of the current work and 
remains an important area of future research.   
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Figure 8.1: Diagram of the overview of the thesis outline. Schematic indicating the possible regulatory pathway for of SIPA1 in lung 
cancer cells and the control of tight junction function and assembly by HGF.  
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8.9 Future directions:  
• In addition to affecting the recirculation of MET, in what other ways can SIPA1 
regulate the expression of the MET receptor? 
• Since SIPA1 can interact with MET, can it also interact with other RKTs family 
members, especially the crucial EGF/EGFR signalling pathway in non-small cell 
lung cancer? 
• Besides HGF/MET, does SIPA1 interact with other key intercellular signalling 
pathways to regulate lung cancer metastasis?   
• What are the other mechanisms by which SIPA1 regulates the tight junctions of 
lung cancer cells?  
• A targeted inhibitor of SIPA1 protein needs to be developed, and examining its 
effect at different levels of molecules, cells, and further study the possibility for 
clinical use.  
• The role and mechanism of SIPA1 in other types of tumours require further 
exploration and investigation.  
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Appendix 1: Peking University Cancer Hospital Patients in Consent Information 
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Appendix 2: figures of the selected representative signalling pathways.  
 
Schematic diagram of ESR-mediated signalling. Generated from: 
https://reactome.org/content/detail/R-HSA-8939211. 
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Schematic diagram of Interleukin-17 signalling. Generated from: https://reactome.org/content/detail/R-HSA-448424.  
  
311 
 
 
 
 
Schematic diagram of MAP kinase activation. Generated from: https://reactome.org/content/detail/R-HSA-450294.   
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Schematic diagram of PIP3 activates Akt signalling. Generated from: https://reactome.org/content/detail/R-HSA-1257604.  
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Schematic diagram of regulation of KIT signalling. Generated from: https://reactome.org/content/detail/R-HSA-1433559.    
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Schematic diagram of signalling by SCF-KIT. Generated from: https://reactome.org/content/detail/R-HSA-1433557.   
